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Abstract
Radiation therapy is an important component in the treatment and management of cancer patients.
Despite current advances in imaging technologies and treatment planning strategies, a major limitation
persists in accurately delineating tumor from normal tissue resulting in radiation–induced damage to
healthy structures. Therefore, the frequency and dose of radiation exposure is limited by the generated
toxicity in healthy tissues. The use of nanoparticles for contrast–enhanced imaging could improve the
accuracy of therapeutic delivery and guide radiation treatments to maximize delivery to disease target
tissues while sparing adjacent normal structures. Further, advancements in radiation therapy focus on the
use of radiosensitizers that are intended to enhance tumor cell killing while minimizing effects on normal
tissue. We have developed multifunctional nanoplatforms, containing sub–nanometer gold and iron
nanoparticles that can provide contrast enhancement using computed tomography and magnetic
resonance imaging, while also serving as radiosensitizers for X–ray therapy. The effectiveness of these
nanoparticles was evaluated in vivo demonstrating an improvement in both tumor margin visualization for
image-guided radiation therapy and overall survival in tumor bearing mice. Importantly, we found that
measurements of contrast enhancement in imaging correlated strongly with tumor response after
radiation therapy. Furthermore, we have found that by encapsulating sub–nanometer gold particles within
micelles we are able achieve improved excretion profiles compared to larger gold particles, with gold
detected in both urine and feces suggesting that particles within this size range are more efficiently
removed by the kidneys and liver. Finally, the use of an actively targeted nanoplatform can achieve higher
tumor retention, facilitate nanoparticle internalization, and improve tumor specificity. To facilitate the
introduction of targeting molecules onto micelle formulations, a naturally occurring surfactant protein
oleosin was used to stabilize superparamagnetic iron oxide clusters. Functionalization with targeting
ligands (e.g. Her2/neu affibody) was achieved by fusing the biologically relevant motifs to oleosin using
standard cloning techniques, and cell specific targeting was confirmed using magnetic relaxation
techniques. In the future, we envision that strategies like this will minimize the off–target effects of
radiation, reduce tumor burden, provide information on the likelihood of tumor regression in response to
therapy and reduce long–term nanoparticle retention.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Bioengineering

First Advisor
Andrew Tsourkas

Keywords
Cancer, Gold Nanoparticles, Imaging, Nanoparticle clearance, Radiation therapy, Radiosensitizer

Subject Categories
Engineering | Oncology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1188

GOLD AND IRON LOADED MICELLES: A MULTIFUNCTIONAL
APPROACH FOR COMBINED IMAGING AND THERAPY, WITH
IMPROVED PHARMACOKINETICS
Ajlan Al Zaki

A DISSERTATION
in
Bioengineering

Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2014

____________________________________________
Andrew Tsourkas, Ph.D., Associate Professor of Bioengineering Supervisor of Dissertation
__________________________________________________
Jason Burdick, Ph.D., Professor of Bioengineering - Graduate Group
Chairperson
Dissertation Committee
Jim Delikatny, Ph.D., Associate Professor of Radiology
Andrew Maidment, Ph.D., Associate Professor of Radiology
Jay Dorsey, M.D., Ph.D., Assistant Professor of Radiation Oncology
David Cormode, Ph.D., Assistant Professor of Radiology

This thesis is dedicated to my parents, Waheed Al Zaki and Madonna Irvin

Thank you for supporting me in everything that I aspire to become and everything that I
choose to do.
Without their love, guidance, and support this thesis would not have been possible…

ii

AKNOWLEDGEMENTS
I would like to thank my advisor Andrew Tsourkas for always taking the time out of the
day to sit down and formulate alternative strategies, for teaching me that failed
experiments are often more valuable than successful ones, for giving me the flexibility to
pursue new ideas and expand my imagination, for allowing me to reach my full potential,
for encouraging me to collaborate with people from various disciplines, and for being an
extremely patient. But most of all I would like to thank him for exemplifiying an
outstanding teacher, mentor, and scientist. It truly has been a privelage to graduate from
his lab.

I would also like to thank all the members of my committee including Jim Delikatny,
Andrew Maidment, Jay Dorsey, and David Cormode for their continuous support during
my journey to become an independent thinker. Without their guidance, support, and
mentorship this would not have been possible.

I would like to thank the Scholarship Coordination Office in The United Arab Emirates
for their continuous support and providing me with a fellowship throughout my grauduate
school education. It is an honor to be among the selected few to receive this prestigious
support.

iii

ABSTRACT

GOLD AND IRON LOADED MICELLES: A MULTIFUNCTIONAL
APPROACH FOR COMBINED IMAGING AND THERAPY, WITH
IMPROVED PHARMACOKINETICS

Ajlan Al Zaki

Andrew Tsourkas, Ph.D.

Radiation therapy is an important component in the treatment and management of cancer
patients. Despite current advances in imaging technologies and treatment planning
strategies, a major limitation persists in accurately delineating tumor from normal tissue
resulting in radiation-induced damage to healthy structures. Therefore, the frequency and
dose of radiation exposure is limited by the generated toxicity in healthy tissues. The use
of nanoparticles for contrast-enhanced imaging could improve the accuracy of therapeutic
delivery and guide radiation treatments to maximize delivery to disease target tissues
while sparing adjacent normal structures. Further, advancements in radiation therapy
focus on the use of radiosensitizers that are intended to enhance tumor cell killing while
minimizing effects on normal tissue. We have developed multifunctional nanoplatforms,
containing sub-nanometer gold and iron nanoparticles that can provide contrast
enhancement using computed tomography and magnetic resonance imaging, while also
serving as radiosensitizers for X-ray therapy. The effectiveness of these nanoparticles
iv

was evaluated in vivo demonstrating an improvement in both tumor margin visualization
for image-guided radiation therapy and overall survival in tumor bearing mice.
Importantly, we found that measurements of contrast enhancement in imaging correlated
strongly with tumor response after radiation therapy. Furthermore, we have found that by
encapsulating sub-nanometer gold particles within micelles we are able achieve improved
excretion profiles compared to larger gold particles, with gold detected in both urine and
feces suggesting that particles within this size range are more efficiently removed by the
kidneys and liver. Finally, the use of an actively targeted nanoplatform can achieve
higher tumor retention, facilitate nanoparticle internalization, and improve tumor
specificity. To facilitate the introduction of targeting molecules onto micelle
formulations, a naturally occurring surfactant protein oleosin was used to stabilize
superparamagnetic iron oxide clusters. Functionalization with targeting ligands (e.g.
Her2/neu affibody) was achieved by fusing the biologically relevant motifs to oleosin
using standard cloning techniques, and cell specific targeting was confirmed using
magnetic relaxation techniques. In the future, we envision that strategies like this will
minimize the off-target effects of radiation, reduce tumor burden, provide information on
the likelihood of tumor regression in response to therapy and reduce long-term
nanoparticle retention.
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Chapter

1:

Introduction

to

Radiation

therapy,

Nanotechnology, and Radiosensitizers
1.1 X – Ray Radiation Therapy
The discovery of X-rays in 1895 by Wilhelm Rontgen has paved the way for
many advancements in medical imaging. In 1896, Emil Grubbe was one of the first
physicians to administer X-rays for the treatment of cancer. Since then there have been
many parallels in X-ray imaging and therapy that continues to be an integral component
in healthcare. Radiation therapy, an important cornerstone in cancer therapy, is one of
the most common and efficient treatments for many types of cancer. It is estimated that
approximately 50% of patients diagnosed with cancer will undergo radiation therapy
during the course of their treatment.1 In particular radiation therapy with ionizing
radiation (IR) such as X-rays, gamma rays and charged particles are used to cause lethal
damage to cancer cells.
For diagnostic imaging, X-rays are generated by accelerating electrons across a
potential difference. These electrons leave the negative cathode and strike a positively
charged metal target. At the anode, X-rays are created as the electrons strike the metal
target losing their kinetic energy either through inelastic scattering with nuclei resulting
in the production of bremsstrahlung radiation, or by scattering inner electrons resulting in
Auger electrons and characteristic radiation. The energy range of diagnostic X-rays are
typically in the range of 10 – 150 kV.2 X-rays with an energy range of 150-500 kV are
called ortho-voltage and occasionally used for the treatment of tissues with depths
between 4-6 cm.3 Megavoltage X-rays, produced by linear accelerators (linacs), contain
the highest energies ranging from 1-25 MV and are the most commonly used in
1

radiotherapy as they have a higher penetration depth (in cm). As a rule of thumb, 80% of
the maximum dose lies at a depth (cm) that is roughly one third of the electron energy
(MV).

1.1.1 Conventional External Beam Radiation Therapy
A Conventional or two-dimensional radiotherapy arrangement, also known as box
radiotherapy, typically consists of one or more beams of radiation delivered to the patient
from various directions. Two-dimensional treatment planning is performed using
radiation simulators in conjunction with diagnostic X-ray tubes. Using these simulators,
the dose distribution is calculated and the treatment fields necessary to encompass the
target tissue while sparing normal tissue are determined.4
Unfortunately, conventional therapy lacks accurate tissue localization,5 especially
with tissues of complex contours making it difficult to spare radiation doses to
uninvolved healthy tissues. As a result, high dose therapies are limited by the radiation
tolerability of healthy tissues adjacent to target tumor regions.6 Furthermore, treatment
planning is limited to estimating dose distributions in one or few planes of the patients
target volume.

1.1.2 Stereotactic Radiation
Stereotactic radiation is a specialized technique of external beam radiotherapy. In
this procedure beams of ionizing radiation coming from various directions converge at a
target that is spatially localized in a three-dimensional coordinate system. This is
achieved using state of the art computer and imaging systems to guide ablative radiation
beams with precision to tumors previously not achievable using conventional external
beam therapy.7
2

Stereotactic radiation can be categorized into two different types. The first is
stereotactic radiosurgery (SRS), first introduced by a Swedish neurosurgeon named Lars
Leksell,8 which involves the use a single or multiple stereotactic radiation treatments for
ailments of the central nervous system. Typically a head frame is fixed to the skull to
provide an external three-dimensional frame of reference for precise localization of
intracranial radiotherapies.7 The second is called stereotactic body radiation therapy
(SBRT) and is an extension of SRS used to treat extra-cranial diseases.
However there are limitations to stereotactic radiation. About one-third of patients
experience potential side-effects immediately post SRS.9 Furthermore, even with the
improved precision of beam delivery, there is the potential for long term side effects
ranging from neurological toxicity to death.10-13 There have also been reported cases of
the long-term neuropsychological effects of SRS with patients exhibiting cognitive
decline and memory impairment.14 Another concern of using high-energy ionizing
radiation in SRS is the potential risk of radiation-induced malignancies such as
glioblastomas.15-20
For SBRT applications, immobilization is one critical factor that must be taken
into consideration when administering radiotherapy. Tumor motion during respiration can
pose challenges exposing surrounding tissues to radiation as the tumor changes position.
As a result, several immobilization and positioning strategies are employed such as body
frames,21-23 real time tracking of fiducial makers,24 and respiratory holding and gating.25

1.1.3 3-Dimensional and Intensity-Modulated Radiation
Therapy
3

As the name suggests 3-dimensional conformal radiotherapy (3DCRT) is
performed such that the profile of the radiation beams is molded to match that of the
shape of the tumor. This can be achieved through the use of specialized planning
software and imaging systems such as computed tomography (CT), and magnetic
resonance imaging (MRI) enabling physicians to take into account axial anatomy, and
complexities in tumor morphology. As this type of treatment conforms to the gross tumor
volume (GTV), radiation doses to the tumor can be increased with relatively lower
increases in radiation toxicity of surrounding tissue structures. While 3DCRT enabled the
planning and delivery of radiation to irregular structures, it is limited in modulating the
intensity of radiation within a single field(i.e single uniform intensity).26-28

Figure 1.1. (A) Schematic of 2-dimensional radiotherapy showing two beams with single
intensities and (B) intensity modulated radiation therapy showing multiple beams with varying intensities
applied from any angle.(adapted from Bucci et al.)5

Intensity-modulated radiation therapy (IMRT) is an advanced high precision
radiation modality that builds on 3DCRT with the ability to customize radiation doses
within a single field.29 Treatment plans are generated using inverse planning software
4

and computer controlled intensity modulation to produce non-uniform radiation beam
intensities throughout the tumor during treatment.30 Therefore, the radiation dose is
elevated within the GTV and minimized or negligible among the neighboring healthy
tissue. Therefore IMRT can provide more selective tumor targeting with reduced
radiation toxicity as compared to 3DCRT.31

1.1.4 Other forms of Radiation Therapy
Gamma rays are also commonly used as a radiation source in the clinic. They are
generally produced through decay of radioactive substances (e.g. radium, technetium99m, cobalt-60). Particle therapy is another emerging technique in the field of
radiotherapy and is increasing in popularity worldwide. With X-rays the dose absorbed
decreases exponentially as the tissue depth increases. On the other hand, for heavier ions,
the dose increases as the particle travels through tissue and loses energy continuously as
it starts to slow down (Figure 1.2).

Figure 1.2. Comparison of physical dose as a function of tissue depth for X-rays and high energy
particles.(adapted from Durante et al.)32

5

External beam radiation therapy can be carried out using a variety of charged
particles including electrons, protons, neutrons, and other heavy ions (carbon, helium,
neon).32,

33

One distinction of this type of therapy from X-rays is the linear energy

transfer (LET), which is a measure of the number of ionizations generated per unit
distance, and is a function of both charge and velocity. Fast moving light particles have a
low LET compared to slow moving heavy particles resulting in reduced biological
effectiveness. Compared to X-rays, charged particles have a high linear energy transfer
(LET) radiation, that is they deposit larger amounts of energy as they move across a
tissue section. Electrons have a finite range after which the dose drops off rapidly and are
generally reserved for the treatment of superficial tumors (lymphomas, melanomas) since
they poorly penetrate into deep sites within the body.33 Protons beams produce
characteristic dose-tissue absorption profiles called the Bragg peak. Hence the radiation
dose increases with increasing tissue thickness up to the Bragg peak occurring near the
end of the particle trajectory (Figure 1.2). Beyond the Bragg Peak, the dose drops to zero
and can be finely tuned to coincide with target tissues such that the radiation payload is
released almost entirely within the tumor while sparing normal healthy tissues. Proton
therapy is already used for the treatment of pediatric tumors located adjacent to critical
structures where radiation exposure could be detrimental.34 Neutrons are classified as
indirectly ionizing radiation exerting their biological effect almost entirely due to the
generation of secondary electrons within tissues. However, they have not gained
widespread use due to the difficulty in generating neutrons, and the associated costs.

6

1.2 Mechanism of Radiotherapy
The primary objective of radiation therapy is to deprive cancer cells of their
mitotic potential and ultimately promote cancer cell death. The main interaction of Xrays in cells is by Compton scattering, producing secondary high-energy electrons that
exert their effects on biological structures. In the cell, DNA is the desired biological
target of ionizing radiation. There are two mechanisms by which radiation can interact
with DNA. The first is known as direct action where ionizing radiation interacts directly
with DNA to cause damage. The second is known as indirect action where ionizing
radiation interacts with the surrounding water molecules, generating free radicals, notably
hydroxyl radicals,35 which cause lethal damage to cellular DNA. Hydroxyl radicals are
generated either directly by the oxidation of water by ionizing radiation, or indirectly by
the formation of secondary partially reactive oxygen species (ROS). ROS include
superoxide (O2-), hydrogen peroxide (H2O2), and hydroxyl radicals (OH-). The damage
incited can include DNA strand breaks that are initiated by the removal of a deoxyribose
hydrogen atom by the activated hydroxyl radical.36
Excessive damage to cells exposed to radiation can lead to either double strand
breaks (DSB) or single strand breaks (SSB). DSBs are the not the most common type of
radiation induced damage but are regarded as the most serious and potentially lethal. At
this stage, some cells will arrest their cell cycle to repair the damage. If the damage is
beyond repair then the cell will undergo apoptosis. Alternatively, some cancer cells with
mutations in cell cycle checkpoints can continue to proliferate following radiation
exposure. However, the majority of these cells will undergo cell death during mitosis as a
result of sustained DNA damage and chromosomal defects. The post mitotic or
7

reproductive mode of cell death is considered to be the most prevalent mechanism in cells
exposed to ionizing radiation.37-39 The apoptotic signaling pathway can be initiated in
various cellular compartments that include the plasma membrane, cytoplasm and
nucleus.40 In the plasma membrane, ionizing radiation can promote lipid oxidative
damage through interactions with radiation induced free radicals resulting in altered ion
channels, a build up in arachidonic acid, and the production of ceramide which is
involved in mediating cellular death. Cell death occurs via free radical molecules eliciting
cumulative un-repairable lipid oxidative damage.41

8

1.3 Types of Cell Death – Cell Response to Radiation
Therapy
1.3.1 Apoptosis
Apoptosis, derived from ancient Greek implying “leaves falling from a tree”,42-44
also known as programmed cell death is a regulatory cellular mechanism that eliminates
unwanted cells occurring during embryonic development, cellular regeneration, growth
and differentiation.42 It is characterized by specific morphological events such as cell
shrinkage as the cytoskeleton is broken down, chromatin condensation, DNA
fragmentation, membrane blebbing and the formation of apoptotic bodies as the cell
breaks apart.45 Apoptosis can also be characterized by biochemical events (elevated TNF
cytokines, activated caspases, mitochondrial release of apoptosis-inducing factor).46-48
Physiological or pathological stress factors such as receptor mediated processes,
oxidative stress, chemotherapeutic drugs and radiation can trigger apoptotic signaling
pathways.49, 50

9

Figure 1.3. Three Pathways of Cell Death. Among the three major pathways of cell death —
apoptosis, autophagy, and necrosis — a particular mode of cell death may predominate, depending on the
injury and the type of cell. Cross-talk among the different types of cell-death pathways exists at multiple
levels and is not shown.(adapted from Hotchkiss et al. 51)

Radiation induced apoptosis is regarded as a significant component in the
mechanism of cell death after exposure to ionizing radiation.49 Further findings suggest
that plasma membrane damage may activate intracellular transduction pathways that are
responsible for the regulation of the apoptotic pathway.52, 53 In the cytoplasm, ionizing
radiation can generate cytosolic stimuli such as reactive oxygen intermediates, and Bcl-2associated X protein that can induce mitochondrial damage that activates mitochondrial
release of caspase-activating factors promoting apoptosis.54 In response to radiationinduced nuclear DNA damage, tumor suppressor protein p53 is activated which halts cell
cycle progression allowing DNA repair to take place prior to replication and cell
10

division.55, 56 However, if DNA repair is unsuccessful, p53 may trigger cell death through
apoptosis. In vivo, apoptosis is generally seen as individual cells that are subsequently
phagocytosed by macrophages or neighboring cells.57

1.3.2 Mitotic-Linked Death
Numerous studies quantitatively comparing apoptotic death with mitotic-linked
death in irradiated cells have shown that the primary mechanism of cell death is
associated with mitotic catastrophe.50 Specifically, this type of cell death occurs during or
after abnormal mitosis, characterized by various morphological changes such as
missegregated chromosomes, multinucleated giant cells and resulting in cell death.58
Combined apoptosis and mitotic-linked cell death account for most of the ionizing
radiation induced cell death.33

1.3.3 Senescence
Another mechanism of cell death in response to radiotherapy is known as
senescence which is a cellular processes that results in an irreversible cell cycle growth
arrest.59 These cells are viable and primarily characterized by a reduction in proliferative
capacity, no longer synthesize DNA, acquire distinct changes in shape by flattening out
with an increase in cytoplasmic vacuolization, and can be identified biochemically by an
increase in senescence associated β-galactosidase (SA-β-gal) activity.60

1.3.4 Necrosis
Necrosis, originating from Greek “necros” for corpse, differs from apoptosis in
cells exposed to ionizing radiation by the loss of plasma membrane integrity prior to
randomized DNA degradation.57 In necrosis, there is a characteristic swelling of cells and
their organelles, which is a consequence of an early disruption in membrane intactness
11

allowing the influx of extracellular ions and fluid.51 Ultimately, plasma and organelle
membranes swell so much that they rupture allowing lyososomal proteolytic enzymes to
escape into and out of the cytosol causing cellular damage.61,

62

Generally, necrosis is

initiated in events associated with metabolic stress such as the rapid depletion of ATP
that can occur in ischemic scenarios.63,

64

Although not as frequent, necrosis can also

occur in irradiated cells mediated by the generation of reactive oxygen species.33 In vivo,
necrosis usually presents as clumps of cells surrounded by an infiltrating inflammatory
response resulting from intracellular release of compromised cells.65

1.3.5 Autophagy
Autophagy, originating from Greek self “auto” and eating “phagy”, is another
type of programmed cell death in which the cell eats itself. It is characterized by the
presence of autophagosomes,61,

66

double membrane vacuoles that engulf cytosolic

proteins and organelles, which are delivered to and fused with lysosomes for
degradation.67,

68

The autophagic response in cells receiving ionizing radiation is

controversial.69 Recently, this mechanism of cell death has been reported in irradiated
cancer cells lacking various apoptotic regulators.70, 71 However, autophagy may also elicit
a protective mechanism against radiation-induced injury by sequestering damaged
proteins and organelles.72
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1.4 Radioresistant Cancer Cells
Although ionizing radiation is an integral component in antineoplastic management and
control, malignancies resistant to radiation often relapse and continue to pose major
challenges and limitations to this type of therapy. During the early 20th century, Bergonié
and Tribondeau proposed radioresistant cells are characterized by a high mitotic rate,
evade normal cellular senescence, and have an undifferentiated phenotype.3 More
recently, this has been attributed to cells in metabolic statuses associated with high levels
of free radical scavengers, low proteosome activation and activated DNA checkpoints.73
Originally described by Withers, the fundamental principles of radiobiology, also
known as the “four R’s”, help to explain some mechanisms for cells that are resistant to
radiation damage. These are: repair, redistribution, repopulation and reoxygenation.73

1.4.1 Repair
Chromatin is the molecular complex that contains nuclear DNA within the cell
and is composed of nucleosomes that play an important role in providing structure and
function in DNA packaging. The nucleosome is made up of a base pair strand of DNA
that is wound around eight histone protein cores (a pair of H4, H3, H2B, and H2A).
Evidence suggests that the nucleosome is not only involved in the essential packaging of
DNA, but also in the regulation of information transfer from DNA including
transcription, meiosis and mitosis, and the maintenance of genomic integrity.74-76
Specifically, these functions are carried out through the modification of specific amino
acid residues on histones.74
The H2A histone family member X (H2AX) is involved in the localization and
repair of DNA DSBs. One of the hallmarks in radiobiology for DNA DSB, occurring
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within three minutes after irradiation,77 is the phosphorylation on serine 139 of H2AX,
primarily by the kinases ataxia telangiectasia mutated (ATM), ataxia telangiectasia and
Rad3-related protein (ATR).78 This phosphorylation at the specific serine site is called γH2AX and it is believed that phosphorylation decondenses DNA providing repair
proteins space during recruitment. γ-H2AX nuclear foci can be quantitatively determined
immunohistochemically using an antibody to the phosphorylated serine of γ-H2AX.
Furthermore, the extent of DSBs is proportional to the number of γ-H2AX foci with each
foci corresponding to a single DSB.79, 80 Several groups have shown that resistant cancer
cell lines tend to have lower γ-H2AX foci and appear to resolve faster after radiation.81, 82
In this thesis, I use the γ-H2AX assay to quantify the amount of DSBs in cells lines the
presence or absence of X-ray radiation therapy.
A considerable amount of cell death is based on the ability of ionizing radiation to
inflict sufficient damage to induce un-repairable DSBs. However, at low doses the
majority of radiation induced DNA damage is sublethal enabling cells to repair the breaks
and proliferate. The interaction of ionizing radiation with water molecules generates
reactive oxygen species (ROS) that rapidly interact with molecules in cells. These ROS
generated are more efficient in causing DNA damage than the direct interaction of DNA
with ionizing radiation.73 Therefore the presence of free radical scavengers within the cell
is a major determining factor on the fate of irradiated cells. A study on CD24-/low/CD44+,
a breast cancer cell line with low levels of ROS and high free radical scavengers, was
found to have low levels of DSBs with increased tumorigenicity.83 Further studies verify
this hypothesis by reversing radiation resistances after the depletion of glutathione, an
important intracellular free radical scavenger.84 Thus, the level of radiation generated
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ROS within a cancer cell may help in determining the responsiveness to radiation. In
glioblastomas, Bao et al. showed that CD133+ cancer stem cells can become
radioresistant by activating DNA damage checkpoints that increase their ability to repair
DNA.85 Other groups have proposed alternative mechanisms of radioresistance, such as
increased autophagy related proteins in CD133+ cells after irradiation as alternative
explanations for their radioprotective mechanisms.86

1.4.2 Redistribution
The resistance to radiation damage is determined largely by what phase of the cell
cycle a cell is experiencing, with cells in mitosis being the most sensitive to DSBs and
cells in the S phase being the least sensitive.87 This is modulated by the activation of cell
cycle checkpoints, which can be induced in the G1, S, and G2 phases of the cell cycle, to
allow the cell to repair possible defects. Therefore, attempts to synchronize tumor cells in
a specific phase of the cell cycle are regarded as a potentially beneficial strategy to
enhance the efficacy of radiation therapy.88-90
After a dose of radiation, most surviving cells will be those that were in the S
phase of the cell cycle (Figure 1.4). Sufficient time must be allowed for cells to
redistribute before another dose is administered. This timed treatment, termed dose
fractionation, allows the redistribution of cells in radioresistant phases of the cell cycle
into more sensitive phases and is especially therapeutically beneficial for slower cycling
tumor cells.91
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Figure 1.4. Synchronized human kidney cells show a differential survival depending on cell cycle
phase in which they are irradiated. Cells are most sensitive to irradiation during mitosis and in G2, less
sensitive in G1, and least sensitive during the latter part of S phase.(adapted from Sinclair et al.)92

1.4.3 Repopulation (Regeneration)
The concept of cellular repopulation is an important biological predictor of
clinical outcome of fractionated radiation therapy.93,

94

The administration of radiation

therapy is usually divided into multiple doses and spaced out over several weeks. This
strategy provides normal tissues with some time to recover and regenerate during
prolonged treatment regimens. Although this temporal modulation of therapy allows
normal cells to repopulate, repopulation of cancer cells also occurs, increasing the
number of cells that need to be eliminated. It is this process of cancer cell proliferation
that is one of the main causes of treatment failures in radiation therapy.95
There are numerous studies that suggest accelerated repopulation during
fractionated radiation therapy in humans. In squamous cell carcinomas of the head and
neck, it was shown that the total radiation doses required to control 50% of tumors
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(TCD50) increased when the treatment lasted more than 4 weeks.96 Furthermore, the
doubling time of these cancers cells decreased from 2 - 3 months to 4 days after radiation
therapy. Other studies demonstrate that for every daily increase in the duration of
therapy, the likelihood that tumors will grow out of control increase by 1 – 1.5%, and the
radiation dose required to combat repopulation increases by about 0.5 – 1 Gy.97-99 Hence
there may be detrimental effects of prolonging treatment time for tumor control but this
may be tumor specific.
Clinical outcomes could potentially be improved by attempts to inhibit or limit
repopulation during radiotherapy. This can be achieved by using a modified doseschedule of treatment. Accelerated fractionation is a fractionation technique that shortens
the overall treatment time, to minimize tumor growth during treatment and prevent tumor
cells from repopulating.96, 100 This strategy has shown promise in tumor control for both
Burkitt’s lymphoma and squamous cell carcinomas of the head and neck.101-103 Other
studies comparing accelerated therapies and conventional therapies have concluded that
the accelerated schedule leads to an improvement in tumor control and overall
survival.104, 105

1.4.4 Reoxygenation
The level of oxygenation of a tumor is a major determinant of the effectiveness of
radiation therapy. Numerous studies have shown that poorly perfused hypoxic tumors are
two to three times more resistant to radiation and are associated with poor prognosis and
recurrence.106-110 This phenomenon is known as the oxygen enhancement ratio. Within a
tumor there is a dynamic and heterogeneous distribution of oxygen levels that exist
largely because of insufficient vascularization and unevenness of supporting stromal
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tissue.111 Oxygen is thought to behave as a direct radiosensitizer, inflicting DNA damage
through the generation of free radicals. Specifically, according to the “oxygen fixation”
hypothesis, exposure of ionizing radiation generates free radicals in water and DNA. The
DNA formed free radicals are able to react with O2 to generate peroxy radicals,
modifying the DNA by fixing O2. However, if O2 is absent, the DNA free radical will be
reduced to its original form.112
Strategies focusing on increasing tumor oxygenation through the use of
hyperbaric O2,113, 114 erythropoietin infusions,115, 116 and red blood cell transfusion have
been attempted.117 Unfortunately these approaches did not gain widespread clinical use
since these techniques are difficult to implement and studies were inconclusive.
Furthermore, the use of nitroimidazoles that mimic the effect of O2 are associated with
dose-limited toxicities.118 More recently, alternative strategies have been aimed at
selectively killing hypoxic tumor cells by using drugs that are known to be cytotoxic for
cells in hypoxic environments.119 Tirapazamine is one example of a an anticancer drug
that is readily reduced in hypoxic cells, forming free radicals that give rise to DNA DSBs
in a topoisomerase II dependent fashion.120 The specific mechanism of action is uncertain
but it is hypothesized that the drug acts a substrate for intracellular reduction. In the
presence of O2, the drug radical transfers its electron to molecular oxygen forming
superoxide and regenerating the initial drug. However, in the absence of O2, the drug
radical accumulates and can either itself cause cytotoxic damage or undergo further
reactions to generate more substantial toxins.120 Clinical trials with this compound
demonstrate therapeutic efficacy in patients with head and neck cancer or non-small cell
lung cancer.121, 122
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1.5 Clonogenic Assays
A clonogenic cell is a term that is given to a single cell that is capable of
proliferating and producing a substantial number of progeny. The radiation sensitivity of
this cell is experimentally determined using an in vitro clonogenic cell survival assay or
colony formation assay.123, 124 This type of assay is the gold standard in determining cell
reproductive death after radiation therapy and describes the relationship between the
radiation dose with the fraction of cells that survive. This type of assay can also be used
to assess the tumoricidal effectiveness of other cytotoxic agents. Generally, cells are
seeded into culture dishes before or after irradiating at different doses and allowed to
form colonies between 1 – 3 weeks. After this time has elapsed, the colonies are fixed,
stained with crystal violet, and counted using a light microscope. Clonogenic assasys
were used in this thesis to assess the in vitro survival of cell lines in response to various
doses of X-ray radiation in the presence or absence of the radiosensitizer.
Colonies with less than 50 cells are not counted for the survival calculation. These
cells may be physically present and struggle through 2-3 cell divisions, but if they have
lost the capacity to divide indefinitely and produce small colonies (< 50), then they are by
definition dead. On the other hand, surviving cells are those cells that have retained their
reproductive potential and proliferate indefinitely producing large clonogenic colonies. It
is these colonies that are included in the survival analysis.
A survival curve is a plot of the fraction of surviving cells on a logarithmic scale
against the cumulative radiation dose on a linear scale. At low doses, survival curves
typically have an initial shoulder representing an accumulation of sublethal damage. As
the radiation dose increases, the curve bends as the surviving fraction exponentially
19

decreases with further dose increments. The type of cell undergoing ionizing radiation,
recovery from sublethal injury, reoxygenation of hypoxic cells, redistribution of the cell
cycle and repopulation all affect the survival curve.
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1.6 Complications from Radiotherapy
While the pathological mechanisms of radiation injury begin immediately
following radiation therapy, the clinical and histological signs may take days, weeks,
months or even years after administration. For example, changes in the lung 6 weeks after
high dose therapy are mild compared to widespread fibrosis detected 6 months later.6 The
tolerance of normal tissues to radiation varies and dictates the dose that is prescribed in a
specified treatment regimen. Thus, an important distinction in radiation injury that must
be taken into account is the difference between early and late effects of normal tissues.

1.6.1 Acute (Early) Effects
Acute or late effects are a form of radiation induced normal tissue damage that
usually presents weeks after therapy. This type of radiation damage is most pronounced
in tissues with cell populations that are rapidly proliferating such as skin or mucosal
membranes. Symptoms arise when functional cells are compromised as part of cell death
and not regenerated. Some cells such as those in skin and the alimentary tract are
generally more tolerant to radiation and usually heal rapidly. As a result, acutely
developed symptoms are often self-limiting over the course of radiotherapy.
Other acute reactions, such as edema and erythema, can arise from mechanisms
that do not involve cell death. For example, ionizing radiation may activate multiple
cellular signaling pathways that stimulate pro-inflammatory cytokine release,125-127 downregulate physiological anticoagulants,128 and cause organ damage secondary to vascular
injury.129 These reactions may be responsible for the initiation of an inflammatory
response, increased vascular permeability leading to swelling, and the activation of the
coagulation cascade.
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1.6.2 Chronic (Late) Effects
Unfortunately, radiation is the gift that keeps on giving. Late effects are described
as radiation induced normal tissue damage occurring months, years or even decades after
radiation exposure.130,

131

The severity of symptoms vary, developing suddenly or

gradually over time, and are generally associated with tissues of cell populations with
slow turnover, such as brain, bones, muscle, kidneys, and liver.6 The underlying
mechanisms behind late effects are multifactorial and poorly understood, but it is
believed that damage to vasculature and immune reactions are main components in
exacerbating late effects including lesions such as fibrosis, necrosis, atrophy, and
fractures.
Radiation induces blood vessel injury resulting in increased permeability and
vasoactive cytokine release.132-134 This allows fibrin in the bloodstream to extravasate out
into surrounding tissues promoting collagen formation.126,

135

In addition, activated

lymphocytes in the circulation can adhere to damaged endothelial cells and narrow the
lumen restricting blood supply to downstream cells.6
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1.7 Radiation Dose Fractionation
Fractionation is a technique of treating malignancies with radiation therapy. In
this strategy the total dose of radiation to be administered is divided into several discrete
dose fractions and is often delivered over period of five to seven weeks. Conventional
fractionation is typically delivered once a day on weekdays at a dose per fraction of 2
Gray. This schedule of five fractions per week allows the recovery of normal cells from
radiation damage thereby avoiding severe toxic reactions and maximizing the effect of
radiation on cancer cells while minimizing off target toxicity.95 In general when more
than one fraction is administered per day, an inter-treatment interval of at least 6 hours
should be used. The benefit of this approach has been demonstrated with in vivo studies,
which have concluded that five daily fractions of 2.5 Gy result in higher levels of
apoptosis than either a single dose of 25 Gy or two fractions of 12.5 Gy separated by 5
days.136 Their rationale is that after each fraction of radiation, a new subpopulation of
radiosensitive cells is primed for radiation-induced apoptosis. Numerous other reports are
consistent with these findings.137, 138
Various dose fractionation strategies can be designed by adjusting either the
treatment duration or the radiation dose received per fraction. Most strategies however,
avoid increasing the dose per fraction, as these are associated with poor tolerability and
increased toxicity.96

1.7.1 Hyperfractionation
Hyperfractionation, is when the total radiation dose is divided into small doses
(smaller than conventional i.e 1.15 – 1.25 Gy) while keeping the duration of therapy
constant (treatments are given more than once a day). Patients selected for
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hyperfractionation therapy are those where treatment is limited by the dose tolerance of
late effect tissues. The rationale behind hyperfractionation is differential repair, in that
slowly responding tissues have a greater capacity of repairing sub-lethal damage (at
reduced dose fraction) than tumors. By significantly reducing the size per fraction and
increasing the number of fractions, resistant cells are allowed to redistribute themselves
through the cycle increasing the likelihood that they are in a relatively more
radiosensitive state by the next cycle.139, 140 However, redistribution also occurs in normal
cells and so no therapeutic benefit will be observed relative to acute normal tissue
responses. Cells responsible for late reactions tend to be slower cycling normal cells or
late responding tissues and are less sensitive to redistribution resulting in lower late toxic
events for a given level of tumor control.

1.7.2 Accelerated Fractionation
Patients whose tumors have a high proliferative capacity such as Burkitt’s
lymphoma and inflammatory carcinoma of the breast may benefit from accelerated
fractionation.139 This regimen uses shorter treatment durations while maintaining similar
doses as conventional radiation therapy. It often involves fewer than ten fractions per
week, but any number above five per week will accelerate the treatment time. For
example, a patient may receive seven 2 Gy treatments over the course of 5 days or be
treated 6 days a week. The main objective of this treatment strategy is to limit growth of
rapidly proliferating cells by applying radiation treatments with shortened inter-treatment
intervals in order to reduce the ability for tumor cell regeneration.96, 139 As this treatment
is accelerated, acute tissue toxicity can be worse, limiting the tolerance dose. Thus, on
days with multiple treatments, fractionation intervals must be as long as possible to allow
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repair of sub-lethal damage in slowly responding tissues and maximize the redistribution
of tumor cells. Also, because the fraction size remains unchanged, one would expect little
or no changes in slowly cycling cells for late responses especially since these cells do not
undergo rapid repopulation.

1.7.3 Accelerated Hyperfractionation
This strategy aims to improve the therapeutic ratio by combining both accelerated
and hyperfractionated treatment protocols. Here there is a decrease in both the dose
received per fraction, typically higher than hyperfractionation but lower than
conventional dose fractions, and the total treatment duration. However this approach is
limited by acute tissue toxicity as both of these strategies independently increase early
tissue responses necessitating breaks between fractions. Clinical trials comparing
continuous, hyperfractionated accelerated radiotherapy (CHART) with conventional
radiotherapy demonstrate a statistically significant improvement in the survival of
patients with locally advanced non-small cell lung cancer.141, 142

1.7.4 Hypofractionation
Historically, there were two main reasons for the introduction of clinical
hypofractionation. First, increased demand for radiotherapy and a shortage of treatment
units meant that patients received larger but fewer fractions so more patients could be
treated over time. Second, this strategy could lower the burden on patients who would not
have to frequent the hospital on a daily basis for several weeks.143,

144

With

hypofractionation the total dose of radiation is divided into doses that are larger than
conventional therapies (> 2 Gy). A larger dose fraction results in a shortened treatment
period counterbalancing the principal disadvantage of delivering large fraction sizes. The
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therapeutic benefit of hypofractionation is controversial with many studies raising
concerns of injury,145,

146

and little evidence to support its superiority to conventional

methods.147 However recently, Whelan and colleagues demonstrated that accelerated
hypofractionated whole breast irradiation was on par with standard radiation treatment in
women who had undergone breast conserving surgery for invasive breast cancer.148 The
implications of this study is that it will conserve large amounts of time and money for
patients while maintaining similar outcomes and side effects as the current standard.
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1.8 Limitations of Radiation therapy
The overall objective of radiation therapy is to maximize the dose of total
radiation delivered to the tumor. In theory, achieving a tumoricidal dose of radiation can
be achieved by exposing the tumor to large doses of radiation. However, this comes at the
expense of exposing surrounding normal tissues within the treatment boundaries
ultimately limiting the radiation doses that can be utilized. In general late tissue effects
are sensitive to changes in fraction size,140 while early tissue effects are more sensitive to
overall treatment time.149 Furthermore, there is patient-to-patient variability in the
severity of side effects after a session of radiotherapy, which can usually never be
predicted prior to treatment. As mentioned previously, these side effects can either
subside over time or limit future radiotherapy exposures. For example, patients with
genetic mutations like ataxia telangiectasia present with serious radiation reactions due to
repair in DNA after radiation exposure.150,
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Moreover, ionizing radiation can be

carcinogenic with the possibility of malignancies developing when patients are exposed
to either diagnostic or therapeutic doses of radiation. However, patients receiving higher
doses of radiation are at most risk for radiation-induced malignancies. Many studies have
reported patients developing second malignancies after receiving radiotherapy.152-155
Finally, through technological advances and image guided radiotherapy, geometric
radiation targeting can be administered with high precision, however, a major limitation
is the treatment of microscopic lesions and tumor margins that can be very difficult to
detect. While most of these techniques incorporate CT, MR and/or other imaging
techniques, there are no tools that measure the biological change or healthy tissue
function during the course of radiotherapy. Such advances in functional imaging using
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MRI and PET may lead to improvements in radiotherapy planning and tumor responses
while minimizing off target effects.156
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1.9 Radiosensitizers
Since current irradiation strategies may fail to kill all cancer cells within an
irradiation volume, it may be beneficial to selectively enhance radiation at the cellular
level. Consequently, many approaches have been developed to enhance the radiation
effects specifically within tumors. A radiosensitizer is an agent or drug that increases the
cytotoxic susceptibility of cancer cells to radiation therapy. Ideally a radiosensitizer
would act specifically on tumor cells sparing normal tissues, have favorable
pharmacokinetic profiles for tumor accumulation prior or during radiation therapy, and be
nontoxic.
In general radiosensitizers can be categorized into five groups: (i) oxygen
mimicking agents, (ii) sensitization by the structural incorporation of thymine analogues
into DNA, (iii) inhibitors of cellular repair processes and cell signaling processes, (iv)
agents that suppress intracellular thiols or other free radical scavengers, and (v) agents
that generate cytotoxic substances via radiation interaction with sensitizer.157

1.9.1 Oxygen Imitators
Oxygen, one of the most important physiological radiosensitizers, has two
unpaired electrons that can rapidly add to other free radicals to generate new
reactive radicals that can cause DNA strand breaks. Many approaches have
attempted to take advantage of this by increasing the oxygen supply to the tumor.
Hyperbaric oxygen was one of the earliest strategies to be used clinically that
demonstrated the value of increasing blood oxygen levels, however, difficulties in
simultaneous application of hyperbaric oxygen and radiotherapy, as well as severe
tissue radiation injury have limited their clinical use.158 Studies using efaproxial, a
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drug that non-covalently interacts with and lowers the affinity of hemoglobin for
oxygen thereby increasing the partial pressure of O2 in tissues and tumors,
demonstrates an increase in responsiveness for patients with brain metastasis.159
Furthermore, vasoactive agents such as nicotinamide in combination with carbogen
(95% oxygen and 5% carbon dioxide) that are capable of eliminating acute hypoxia
have shown promise in some clinical studies.160
Nitroimidazoles are an electron affinic (i.e ability to capture electrons) class of
drugs and commonly known as oxygen mimetics as they react similarly to DNA base
radicals. This type of drug is shown to be particularly useful in radiosensitizing hypoxic
cells with no detectable effect on normoxic cells.161 The most plausible explanation for
this is the abundance of oxygen in normal cells out-competes with nitroimidazole
radiosensitizers. 5-nitroimidazole is currently used for head and neck cancer treatments in
Denmark,160 and several nitroimidazole derviatives (2-nitroimidazole) have yielded
attractive sensitization enhancement ratios.162-164 Finally, nitric oxide, like oxygen is
highly reactive towards free radicals, and has also been shown to enhance the formation
of DSBs, although the mechanisms are not yet clearly understood.160

1.9.2 Thymine Analogues as Radiosensitizers
Some thymine analogues can serve as electron sinks during irradiation forming
DNA free radicals (Figure 1.5). During cellular DNA synthesis, cells are unable to
recognize the difference between thymidine and halogenated forms as the molecular size
of the halogens are similar to the methyl group of the thymine. Cells incubated with these
analogues start to incorporate them into their DNA. After irradiation, the halogen is
released resulting in a carbon free radical that can lead to DNA strand breaks.157
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Figure 1.5 Possible pathways by which hydroxyl radicals can add to the 5,6-double bond of
pyrimidines (1) to form a carbon-centred radical (2) that can either add oxygen to form a peroxyl radical (3)
or add to the oxygen atom in the nitro moiety of a nitroaromatic radiosensitizer (ArNO 2) to form a radical
adduct (6). In either case the intermediate radical (3) or (6) might abstract hydrogen from a neighbouring
sugar C–H bond (5′ in this example, although 3′-abstraction may occur) to transfer radical damage from
base to sugar (4) or (7), leading to a strand break (5) or (8).(adapted from Wardman et al.)157

1.9.3 Inhibitors of Cellular Repair and Cellular Processes
There are many different classes of DNA-targeted radiosensitizing agents that
have shown to be efficacious including 5-fluorouracil through inhibiting thymidilate
synthase,165 a key enzyme responsible in regulation of the supply of DNA precursors,
platinum containing compounds that inhibit DNA repair and enhance the formation of
platinum intermediates via radiation induced free radicals,166-168 gemcitabine which is a
strong radiosensitizer that inhibits the action of ribonucleotide reductase, an enzyme
responsible for producing deoxyribonucleotides that are used in DNA replication and
repair,169 and topoisomerase I targeted drugs that interfere with rejoining of DNA
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strands.170 Recently, new approaches have been aimed at targeting cell signaling and
growth factor receptors for radiosensitzation.157 The Ras family, an important regulator of
cellular growth and differentiation, is one of the most widely studied signaling pathways
with respect to radioresistance. Through inhibition of Ras functionality, radioresistance
can be reversed in cells over-expressing the Ras oncogene.157

The inhibition of

epidermal growth factor receptor (EGFR) and cyclooxygenase (COX) 2 are two other
approaches that are currently being investigated in pre-clinical studies.165

1.9.4 Depletion of Radioprotective Compounds
An alternative approach to increasing cellular radiosensitivty is to deplete or
inactivate the cells capacity to absorb/neutralize activated radiation intermediates.
Intracellular thiols in particular are important antioxidants that mitigate the damaging
effects of reactive oxygen species preventing many cellular components from damage.
Specifically, thiol-containing compounds, such as glutathione, are able to donate
electrons to unstable molecules such as free radicals. Therefore, initial attempts were
geared towards the depletion of intracellular thiols particularly through oxidation. While
in vitro studies seemed very promising, the in vivo concentration of thiols is much higher
than the tolerable doses of many agents outcompeting the oxidative effect.157 A much
more realistic approach of thiol depletion is through the inhibition of intracellular
biosynthesis. One example is L-S-buthionine sulphoximine, an inhibitor of gammaglutamylcysteine synthetase, which is responsible for the first step of glutathione
synthesis. In vitro analysis showed significant enhancement in radiosentization but
unfortunately this was not corroborated in in vivo evaluations.171-174 A likely explanation
for poor in vivo enhancement is that other than glutathione, cells contain many other
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antioxidants and thiols such as ascorbate, cysteine, and protein thiols.157 Circumin, the
yellow pigment of turmeric, has also been shown to confer radiosensitizing effects in
cancer cells.175 It has been suggested that a possible mechanism of radioprotection is
through the enhancement of ROS production by down-regulating Prp4K, a serine–
threonine protein kinase that plays a central role in cell signaling and proliferation, and
through the suppression of antioxidant enzymes.176, 177

1.9.5 Radiation Induced Radiosensitizers
Radiation induced radiosensitizers have recently attracted a lot of interest. These
agents primarily take advantage of the reactive chemical intermediates that are generated
within an irradiated region of interest. For example, Tanabe et al. showed that a prodrug
conjugate of fluoro-2′ deoxyuridine with a strong electrophile was released after ionizing
radiation,178 and Sykes et al attached DNA alkylating agents to 2,6-dintrophenyl that
were released following radiolytic reduction resulting in enhanced cell death.179 Redox
metals such as cobalt (III) and copper (II) have been investigated for their use as
radiosensitizers. Ahn et al. used cobalt (III) complexes, containing 8-hydroxyquinoline or
tetradentate macrocycles, as a redox target for radiation induced reducing radicals. Once
reduced, 8-hydroxyquinoline can alkylate DNA and inhibit cell proliferation.180
Many studies have indicated that molecules containing high atomic number (Z)
elements might serve as radiosensitizers.181 The number of DNA DSBs was found to
increase when radiation was applied in the presence of platinum containing
compounds.182 Furthermore, gadolinium, which has reached clinical trials, has shown
improved neurological time to progression in patients with brain cancer metastasis.183
With recent advances in nanotechnology and chemistry, various novel and effective
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nano-sensitizers have been developed and evaluated in biological systems including
carbon nanotubes,184 and platinum,185 gadolinium186, 187 and gold nanoparticles.186, 188 Of
these elements, gold is by far the most popularly examined nanoplatform in
radiosensitization and it was adapted for use in the work described in this thesis.
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1.10 Gold Nanoparticles
Nanoparticles are generally defined to be anything on the scale of 1 – 200 nm in
diameter and are being extensively investigated for their use in prevention, diagnosis, and
treatment of disease. This technology has the potential to extend life expectancy, improve
the quality of life, lower healthcare costs, and ultimately patient outcome.189
Nanotechnology has moved towards clinical translation in many fields including drug
delivery,190 immunizations,191, 192 image-guided surgery,193, 194 and imaging.195, 196 With
the growing number of nanoparticle formulations, the variety of materials used, the
number of distinct nano-platforms is too numerous to count.
Gold nanoparticles (AuNPs) have attracted considerable interest in the field of
medicine. Due to their unique chemical and physical properties, AuNPs have been shown
to be beneficial in many applications including catalysis, biosensors, cancer imaging,
photothermal therapy, and drug delivery.197,

198

AuNPs can be finely tuned to many

different shapes and sizes, decorated with stealth-like features for immune system
evasion and improve stability, functionalized with various targeting moieties to improve
tumor specificity, and are considered to be nontoxic.199,

200

In fact, aurothiolate and

colloidal gold have been historically used in medical practice as a treatment for
rheumatoid arthritis.201 Recently, studies have proposed the use of AuNPs as novel
radiosensitizers that can selectively enhance radiation therapy efficacy leading to
increased DNA damage and cell death.202, 203

1.10.1 Limitations to Clinical Translation
Currently, a major obstacle that must be overcome before AuNPs (and many other
nanoparticulate systems) can be translated to the clinic is slow elimination. It has been
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found that there is only a 9% fall in the content of gold in the liver from day 1 to 6
months, following the intravenous injection of 40nm AuNPs.204 This is consistent with a
number of similar studies, which saw little to no clearance of ~20 nm AuNPs over shorter
time periods (1 to 4 months).205, 206 It has been shown that whole-body clearance can be
improved through the use of small AuNPs (<6 nm), since these particles are small enough
to undergo glomerular filtration.207, 208 However, smaller AuNPs possess a smaller crosssectional area and shorter path length for x-ray attenuation and are much more rapidly
excreted through the kidneys.209 Therefore, they are expected to be less favorable for both
enhanced permeability and retention mediated tumor accumulation and targeted studies,
where AuNP accumulation is governed by blood residence time or the number of cell
surface receptors at the target site, respectively. Larger AuNPs are expected to provide
superior circulation, higher contrast-to-noise ratio, and better radioenhancement in these
applications. Larger AuNPs are also expected to have longer circulation times for CT
angiography. A major goal of this thesis was to develop a nanoformulation containing
AuNPs that exhibited a long circulation time but was still capable of being efficiently
excreted.

1.10.2 Mechanism of Gold Dose Enhancement in X-ray
Therapy
The mechanism of gold enhancement, in X-ray therapy, is dependent on the
energy of incident ionizing photons and different interactions between the photons and
AuNPs. Here, I will discuss three fundamental mechanisms of radiation enhancement
photoelectric effect, Compton scattering, and pair prodcution. The photoelectric effect is
the predominant mechanism of radiosensitization of high atomic number (Z) elements,
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for photons with energies in the range of 10 to 500 keV.210 The cross section of the
photoelectric effect varies with the atomic number approximately as Z3, meaning that
higher Z atoms will have a larger absorption cross section. The photoelectric effect is also
dependent on the energy of the photon, with a maximum cross section when the photon
energy is equal to the binding energy of orbital electrons. This effect decreases sharply as
energy is increased and varies as E-3 (Figure 1.6). The binding energies of electrons
bound to gold are 79 keV for the inner shells, 13 keV, and 3 keV for outer shells, while
those of soft tissue are on the order of 1 keV or lower resulting from the lower atomic
number of organic matter. Therefore gold would absorb significantly more energy than
soft tissue in the kilovoltage energy range. When photons with energies in these ranges
interact with AuNPs, they can produce electrons, characteristic X-rays of gold atoms, or
Auger electrons. Once an atom absorbs a photon an electron may be emitted resulting in
an ionized atom.

Figure 1.6. Comparison of mass energy absorption coefficients as a function of photon energy.211 (adapted
from Butterworth et al.)
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When photons of energy greater than the binding energy of an inner shell electron
collide, that electron is ejected leaving behind a vacancy in an orbital electron shell. As a
result, outer electrons in a higher energy state fill the vacancy in the lower energy orbital.
This process is accompanied by either a fluorescent photon or an Auger electron ejected
from an outer shell with an energy equal to the difference between the two orbital shells.
If multiple shells exist within an atom then further auger electrons can be generated as
outer shell electrons fill in the vacancies. This phenomenon is known as the Auger
cascade. The number of Auger electrons emitted is directly proportional to the atomic
number. Therefore high Z atoms are expected to generate much more Auger electrons.181
The range of these emitted electrons have been calculated to be around tens of
nanometers depositing their energy along their path and distributing radiation throughout
the system.181 Furthermore, the Auger electron “shower” can produce highly positively
charged ions, causing local Coulomb-force fields that can disrupt nearby cellular
strcutures.
The enhancement of radiation with high-Z material was first realized when DNA
damage was detected in lymphocytes isolated from patients receiving iodinated contrast
agents for X-ray imaging.212 Since then many other studies have demonstrated that
radiation therapy in combination with iodine suppressed tumor growth and improved
survival in animal models.213 Another interesting approach was the incorporation of
iodine into cellular DNA yielding a 3-fold improvement in in vitro radiosensitization.214
However this strategy is not as effective if insufficient levels of iododeoxyuridine is
substituted with thymine. Although the mechanisms of radiation enhancement of gold
nanoparticles are not well understood, it is currently believed that the interaction of X-
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rays with high Z atoms induces the release of photoelectrons and Auger electrons.210
Given that gold has a higher Z number, it is likely that gold as a radiosensitizer would be
much more effective than iodine.
When photon energies are greater than 500 keV, Compton effects begin to
dominate. The Compton effect is the incoherent or inelastic scattering between an X-ray
photon and an electron of an atom. In this interaction, only a part of the energy is
transferred to the electron. The resulting emitted electron is known a Compton electron
leaving behind an ionized atom or molecule. In contrast to photoelectric interactions
where most photoelectrons are inner electrons, Compton interactions increase for loosely
bound electrons. So most of the Compton electrons are valence electrons. In contrast to
Auger electrons, Compton electrons are capable of travelling several hundred microns.
For incident photons with energies higher than 1.02 MeV, a process known as
pair production dominates where the photon is absorbed by the nucleus with the
production of a positron and electron pairs. The probability of pair production increases
with the atomic number as Z2 and linearly with the energy of incident photons.
In this thesis, I evaluate the radiosensitizing capabilities of AuNPs using
orthovolatge energy ranges with the hope that it applies to the clinically relevant
megavoltage energies. The interaction of charged particles is more complex and beyond
the scope of this thesis, however, some studies have speculated that proton-AuNP
interactions lead to increased production of low energy delta-ray electrons producing a
high degree of lethal damage within the cells thus lowering the surviving fraction of
cells.215
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While most AuNP radiosensitization has primarily been attributed to their photon
absorption capabilities, recent studies highlight that a significant biological component
may be responsible for radiosensitization. In the absence of radiation, AuNPs have been
reported to induce ROS that cause oxidative DNA damage.211 In addition, AuNPs have
been shown to cause alterations in the cell cycle with an increase in cells at the G2/M
phase.216 In a recent study by Kang et al., the nuclear targeting of AuNPs has been shown
to cause cytokinesis arrest leading to the failure of complete cell division and
apoptosis.217 Although experimental evidence may suggest the involvement of biological
components in radiosensitization, the exact mechanisms are still not clearly understood.

1.10.3 Modeling Dose Enhancement of AuNPs
Clinically, most X-ray radiotherapy is administered in the MV energy range as
these energies have superior penetration capabilities along with a reduced dose delivered
to surrounding normal tissues. Until recently, most preclinical studies performed with
AuNPs were limited to kilovolatge X-rays, which can be attenuated by normal tissues and
have poor penetration capabilities, especially for deep-seated tumors. Some preliminary
simulations using AuNPs and radiation are suggestive that they may be effective at
clinically relevant radiation energies.
Most theoretical studies of high-Z dose enhancement are performed using Monte
Carlo modeling.218 These theoretical experiments simulate the probabilistic interaction of
photons and electrons based off the cross-section of different interaction processes. Using
these modeled interactions along with parameters that take into consideration the
attenuation of the medium, the production of secondary electrons through interaction with
biological structures and gold, as well as the irregularities in beam geometry, predictions
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regarding the dose distributed can be made.211 Recent studies have assessed the
enhancement effects of radiation in tumors containing high-Z materials. In a study
performed by Robar et al., gadolinium and iodine contrast media showed very little dose
enhancement between incident photon energies of 6 – 24 MV, however when lower
energy filters were removed, there was an improvement in the dose enhancement
factor.219 Ngwa et al. used Monte Carlo simulations to show that AuNPs may be used to
ablate tumor endothelial cells using brachytherapy sources of radiation with endothelial
dose enhancement factors ranging from 6.4 – 271.5, for AuNP concentrations ranging
from 7 to 350 mg/g.220 Several other studies also validated that AuNPs could be used
along with clinical brachytherapy sources for significant tumor dose enhancements.221, 222
In another study by Cho et al., Monte Carlo simulations were used to determine the dose
enhancements using three different gold concentrations at 140 kVp X-rays, 4, and 6
MV.223 The largest dose enhancement factors observed were those using the highest
concentrations of AuNPs (3% Au in tumor). Specifically, 2-MV and 6-MV photon beams
yielded enhancements between 1% and 7% depending on the AuNP concentration.
However, at 140-kVp dose enhancement effects that ranged from 211% to 560% were
obtained. Consistent with this study, other Monte Carlo reports have analyzed the
characteristics of secondary electrons when X-rays interact with AuNPs (50 kVp, 250
kVp, cobalt – 60, and 60 MV). It was confirmed that low energy photon beams and larger
diameter AuNPs were 2 – 3 fold more efficient in AuNP interaction compared to MV
energies. Moreover, secondary electron production increased by 10 to 2000 fold
compared to radiation without AuNPs and the electron trajectory for the beams used
ranged from 3 µm to 1 mm.224 Tsiamas et al. investigated the dose enhancement ratio due
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to AuNPs using various filtered beam energies (2.5, 4, 6.5 MV) and low Z linac targets.
They concluded that 2.5 MV AuNP therapy is possible for deep seated tumors with an
increase in the dose enhancement ratio by a factor of 2, as compared to a standard 6.5
MV linac.225 While most Monte Carlo simulations show little enhancement with AuNPs
at the megavoltage energies typically used in radiotherapy, some in vitro experiments
have reported significant radiosensitization using megavoltage X-ray sources.213, 226 In an
attempt to explain these discrepancies, McMahon et al. used Monte Carlo simulations to
calculate the radiation dose on the nanoscale. Their findings suggest that AuNP
radiosensitization is governed by dose inhomogenieties on the nanoscale level.227 Finally,
a recent study published by Dorsey et al., concluded that a 1 and 10mg/ml solution of
pegylated AuNPs showed 1.8 – 2 fold dose enhancement compared to a PEG solution or
water alone using unfiltered beam energies of 6 MV.200

1.10.4 In vitro Radiosensitization Using AuNPs
By far the majority of in vitro and in vivo studies analyzing AuNP mediated
radioenhancement rely on the enhanced permeability and retention effect (EPR). As a
tumor continues to grow, it will reach a level where metabolic requirements exceed the
ability of the vasculature supply.228 Consequently, the tumor will respond by secreting
factors to promote the process of angiogenesis resulting in the formation of new blood
vessels crucial for continued growth. Many of these rapidly forming blood vessels are
characterized by a non-intact basement membrane resulting in an increased permeability
to macromolecular structures.229 In addition, these actively growing tumors are often
equipped with impaired and disorganized lymphatic vessels, causing poor lymphatic
drainage resulting in retention of material in the tumor interstitium.228 This phenomenon
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of leaky blood vessels and ineffective lymphatic drainage is known as the EPR effect and
is a main driving force behind nanoparticle accumulation in malignancies for diagnostic
and therapeutic applications. Tumor targeting that relies solely on the nanoparticle’s
pharmacokinetic profile and EPR effect is most commonly referred to as passive
targeting, while strategies that achieve tumor delivery via specific interactions with either
cancer cells or their microenvironment is referred to as active targeting.
One of the earliest studies using gold for radioenhancement was performed by
Regulla and colleagues.230 In this study, enhanced radiation effects were observed in
mouse embryo fibroblasts that were exposed to gold surfaces compared to those exposed
to polymethylmethacrylate. Secondary electrons were found to travel a range of
approximately 10 µm. Following this study, numerous other experimental studies using
AuNPs over both orthovoltage and megavoltage ranges have been described. Many of
these reports are controversial as there are many parameters that must be considered
when performing AuNP radiosensitization such as size, shape, surface coating,
concentration, radiation type and energy, and origin of cell lines (Table 1.1, adapted from
Butterworth et al.). In an attempt to address these issues, Brun and coworkers
investigated AuNP radiation enhancement by altering AuNP concentrations, AuNP
diameter, and incident X-ray energy (range 14.8 – 70 keV). They determined that the
conditions with the most radiation enhancement were those using larger sized AuNPs,
high gold concentration, and 50 keV photons providing dose enhancement factors of 6.231
In a separate study, 1.9 nm AuNPs enhanced the response of bovine aortic endothelial
cell damage inflicted by X-ray irradiation, with a dose enhancement factor up to 24.6.232
While optimal sizes for AuNP radiation therapy may be inconclusive, it is generally
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accepted that radiation induced DNA damage will increase with increasing
concentrations of AuNPs.233 In vitro experiments using brachytherapy sources and
AuNPs have also been reported and initially demonstrated a biological effect with
irradiation up to 130% greater than without AuNPs.234
Most photoelectrons, Auger electrons, and other secondary electrons have low
energies and a short range in tissues (nm to µm) delivering lethal doses in their
immediate surroundings.235 The possibility of having AuNPs target specific cancer cells
may increase the production of secondary electrons within the vicinity of DNA
molecules, especially if they involve cellular internalization.236 Chattopadhyay et al. was
one of the first to validate this hypothesis by synthesizing trastuzumab-PEG-AuNPs.237
Briefly, SKBR-3 cells were irradiated after treatment with either phosphate buffered
saline, PEG-AuNPs, or trastuzumab-PEG-AuNPs. The DNA DSBs as measured by γH2AX foci increased 5.1 and 3.3 times for targeted AuNPs compared to cells treated with
PBS or PEG-AuNPs respectively. AuNPs modified with either cysteamine of thioglucose
have been shown to have differential accumulation in cancer cells. While cysteamine
modified AuNPs were preferentially limited to the cell membrane of MCF-7 breast
cancer cells, glucose-AuNPs are internalized and distributed throughout the
cytoplasm.238, 239 Furthermore, glucose-AuNPs exhibited enhanced irradiation (200 kVp)
induced cell death compared to cysteamine-AuNPs and irradiation alone. Finally, in
another independent study, radiotoxicity of proton therapy with AuNP internalization was
increased by approximately 15 – 20% compared to proton therapy without AuNPs.215
However, these results are inconclusive, as targeted AuNPs were not compared to nontargeted AuNPs.
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Table 1.1. Summary of in vitro radiosensitzation experiments using AuNPs
*SER- Surface Enhancement Ratio
*DEF- Dose Enhancement Factor
Author

Size
(nm
)
14

Concentration

Surface
coating

Cell model

Energy
source

DEF

SER

5 nM

Glucose

SKOV-3

90 kVp
6 MV

1.3
1.2

Jain et
al.226

1.9

12 µM

Thiol

DU145
MDA-231MB
L132

Chithrani
et al.213

14
74
50

1 nM

Citrate

HeLa

160 kVp
6 MV
15 MV
6 MeV e16 MeV
e220 kVp
6 MV e662 keV

1.002
1.0000
9
1.05
1.0005
1.0005
1
1

Liu et
al.240
2010

6.1

>1 mM

PEG

CT-26
EMT-6

Butterwor
th et al.241

1.9

2.4 µM
0.24 µM

Thiol

Kong et
al.238

10.8

15 nM

Rahman
et al.232

1.9

Roa et
al.216

Geng et
al.239

<1.41
<1.29
1.16
<1.12
1.35

1.09
1.0008
1.0006

1.171.16

6 keV e160 kVp
6 MV

1
1.02
1.002

2
1.1
1

DU-145
MDA-231MB
AG0-1522
Astro
L132
T98G
MCF-7
PC-3

160 kVp

1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01

<1
<1.67
<1.97
<1.04
<1
<1.91
<1.41
<1.07
1.3

Glucose
Cysteamine

MCF-7
MCF-10A

200 kVp
662 keV
1.2 MV

1.3
1.6

<1 mM

Thiol

BAEC

80 kV
150 kV
6 MV e12 MV e-

1.01
1.0000
8
1.0000
1
6.6
5.2
1
1

10.8

15 nM

Glucose

DU-145

662 keV

1.0000
8

>1.5

Zhang et
al.242
2008
Chang et
al.243

30

15 nM

Glucose
TGS

DU-145

200 kVp

1.0083
1.0083

>1.3
>1.5

13

11 nM

Citrate

B16F10

6 MV e-

1

1

Chien et
al.244

20

<2 mM

Citrate

CT-26

6 MV e-

1

1.19

20
1.4
2.9
3.7
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Zhang et
al.245
2009
Liu et
al.246
2008
Chattopadhyay et
al.237
2010
Brun et
al.231

4.8
12.1
27.3
46.6
4.7

0.095 –
3mM

Citrate

K562

2-10 kR
gamma

500 µM

PEG

CT-26

6 MV

1.3 – 1.6

30

0.3 nM

Trastuzumab
PEG

SK-BR-3

300 kVp

5.1

8.1
20.2
37.5
74
91.7

1 – 5 nM

Citrate

Plasmid DNA

30 kV
80 kV
80 kV
100 kV
120 kV
150 kV

< 3.3

1.10.5 In vivo Radiosensitization Using AuNPs
In 2004, Hainfeld et al. performed the first animal study evaluating enhanced
tumor radiosensitization using AuNPs. Using 1.9 nm AuNPs in combination with 250
kVp X-rays (30 Gy), overall tumor-xenograft mouse survival was 86% versus 20% for
radiation alone and 0% for gold only.188 Since then AuNPs radiosensitization has been
demonstrated in vivo with murine mammary ductal carcinoma,201 murine squamous cell
carcinomas,188 human sarcoma cells,203 and cervical carcinoma(See Table 1.2).247 In a
study by Zhang and colleagues, in vivo radiosensitization was studied using four different
sizes of PEG-AuNPs, and demonstrated that while all sizes can decrease tumor volumes
after gamma radiation (5 Gy), the smallest (4.8 nm) and largest (46.6 nm) particles tested
had weaker sensitization effects than 12.1 and 27.3 nm.248 However, in a recent study by
Zhang et al., glutathione coated AuNPs with sizes less than 2 nm have the ability to
accumulate preferentially within subcutaneous tumor bearing mice providing strong
radioenhancement for cancer therapy.247 More recently, Joh et al. showed that PEGAuNPs and radiation therapy can enhance DNA damage, tumor cell destruction, and
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improve survival in mice with orthotopic glioblastoma multiforme tumors.249
Intriguingly, they also showed that ionizing radiation could compromise the integrity of
the blood brain barrier significantly increasing the accumulation of AuNPs within brain
tumor bearing mice. All of these strategies mentioned are examples of passive tumor
targeting of AuNPs that are reliant on the EPR effect. To our knowledge, a study
conducted by Chattopadhyay and coworkers is the only one that assessed the in vivo
radioenhancement effects of AuNPs, using a tumor specific HER-2 targeted
nanoplatform.235 However, the benefits of having targeted-AuNPs versus untargeted were
not conclusive as there were no in vivo comparisons made, and AuNPs were
administered via intratumoral injections.
Very few in vivo studies have been carried out using MV photon energy beams
that are commonly used in radiotherapy. However, some emerging studies are suggestive
of the clinical potential of AuNPs in improving outcomes of radiotherapy. Using 6 MV
electrons with 13 nm AuNPs, tumor growth was significantly retarded and survival was
prolonged compared to radiation alone in mice with melanoma flank tumors.243 Increased
tumor sensitization with AuNPs has also been demonstrated using proton therapy.250
Proton beam irradiations of 45 MeV (10-41 Gy) were delivered to subcutaneous colon
carcinoma tumors in mice after receiving a single dose of 100 – 300 mg/kg of AuNPs,
which led to a 58 – 100% one year survival versus 11 – 13% in proton only irradiations.
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Table 1.2 Summary of in vivo radiosensitzation experiments using AuNPs
*DE- Dose Enhancement
Author

Size
(nm)

AuNP
Dose
(g kg-1)

Tumor
conc.
(mg g-1)

Surface
coating

Cell
model

Source
energy

Dose
(Gy)

Predicted
DE

1.9

0-2.7

7

Thiol

SCCVII

68 kV
157 kV

30

1.84
1.315

Hebert et al.201

5

0-0.675

0.1

DTDTPAGd

MCF7-L1

150 kV

10

1.01

Chang et al.243
Hainfeld et
al.188 2004

13
1.9

0-0.036
0-2.7

74
7

Citrate
Thiol

B16F10
EMT-6

MV e250 kV

25
26-30

1.01
1.56

Joh et al.203
2013

12.4

0-1.25

1.25

PEG

HT1080

175 kV

6 Gy

1.16

Joh et al.249
PLOS

12

0-1.25

0.15

PEG

U251

175 kV

20 Gy

1.3

Kim et al.250
2012

14

0-0.3

0.1 – 0.2

Citrate

CT26

Proton
40 MV

10-41
Gy

Zhang et al.248
2012

4.8
12.1
27.3
46.6

0-4

PEG

U14

Gamma
Rays

5 Gy

Chattopadhyay
et al.237

30

4.8

Herceptin

MDAMB-361

100 kV

11 Gy

n/a

n/a

n/a

n/a

6 Gy

0.01

0.01456

GSH
BSH

662kV

5 Gy

Hainfeld et
al.202

Atkinson et
al.251
Zhang et al.247
2014

1.5

U14

1.41
1.65
1.58
1.42
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1.11 X-ray Computed Tomography Imaging & Contrast
Agents
Developed in the 1970s, computerized transverse axial tomography is a technique
that acquires many X-ray projection images from different directions. Using dedicated
computer algorithms, 3D volume reconstructions are generated enabling the visualization
of internal anatomical features within the human body. Today, with the introduction of
modified detector technologies and the advent of spiral scanning, whole organs or the
body can be imaged in a matter of seconds with sub-millimeter resolution.
While many tissue structures may have varying X-ray attenuation characteristics,
it is often difficult to delineate abnormal tissue pathology accurately without the
administration of a contrast agent. Water-soluble iodinated compounds have long been
used as X-ray contrast agents. Iodinated compounds in clinical use have low molecular
weights, ranging from 127 Da for iodide to about 1600 Da for tri-iodobenze dimers (e.g.
iodixanol, 1550 Da). Because of their small size, iodinated contrast agents exhibit rapid
renal clearance and vascular permeation, necessitating short imaging times. As a result,
intra-arterial catheterization is often needed, which carries the risk of arterial puncture,
dislodgement of plaques, stroke, myocardial infarction, anaphylactic shock and renal
failure. Patients with impaired renal function carry a particular high risk for adverse
effects.209, 252
To overcome some of the disadvantages associated with low-molecular weight
contrast agents, chemists have used many different strategies to increase the molecular
weight of X-ray contrast media, e.g. iodinated polysaccharides,253polymeric triiodobenzenes,254 and cascade polymers carrying tri-iodobenzenes.255 Similar agents have
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also been prepared with dysprosium and gadolinium (Gd).256,

257

However, complex

chemistry and problems with tolerability have kept these agents from reaching clinical
trials.255
An alternative to using macromolecules is to incorporate many highly attenuating
atoms into nanoparticles. Nanoparticles offer an opportunity for longer circulation times,
visualization of the reticuloendothelial system (RES), blood pool imaging, and
lymphography. Molecular imaging is also possible since each nanoparticle is capable of
carrying many atoms with high atomic number, providing a mechanism to increase
contrast at the target site.258, 259 Over the past two decades, many nanoparticulate X-ray
contrast agents have been developed, including liposomes loaded with iodinated
compounds,260, 261 polymeric iodine-containing PEG-based micelles,262 iodine containing
perfluorocarbons,263, 264 bismuth sulfide nanoparticles,265 and AuNPs.188, 209 Of these, gold
nanoparticles have garnered a particularly high degree of interest. In comparison to
iodine, gold possesses a mass attenuation coefficient that is ~2.7-fold higher.266
Accordingly, it was found that 1.9 nm AuNPs exhibit a better contrast-to-noise ratio
(CNR) on both projection radiography (40-80 kVp) and computed tomography (CT) (80140 kVp).209, 266-268 Specifically, at equimolar concentrations, AuNPs exhibited an 89%
improvement over iopromide at low energies near the mammographic range (40 kVp)
and a 114% greater CNR at higher energies (140 kVp).266 Similarly, 30 nm AuNPs
attenuated 120 kVp X-rays 5.7 times more than the iodine-based agent, Ultravist.268 The
high attenuating properties of AuNPs has recently led to their successful implementation
as targeted molecular imaging agents in mice.258, 259 Notably, the additional benefits of
working with AuNPs are that the size and shape can easily be controlled and the surface
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can be modified with various functional groups. In contrast, while other nanoparticle
formulations, such as bismuth sulfide and tantalum oxide nanoparticles,269 may also
exhibit higher X-ray absorption than iodine (at 50 kVp), it is difficult to control their size
and there is a lack of chemical methods to modify their surface.265, 268
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1.12 Magnetic Resonance Imaging
Magnetic resonance imaging is a noninvasive imaging modality that utilizes
strong magnetic fields to produce clinically relevant images of not only tissue structure,
but also function.270 The primary molecules responsible for signal generation during
image acquisition are the protons in water, with intrinsic contrast provided by the spatial
differences in proton density and relaxation times. In general there are two relaxation
signals that characterize MR signals referred to as longitudinal (T1) and transverse
relaxation (T2) time constants. The longitudinal time constant T1, also called spin-lattice
relaxation, is the process by which, following a radiofrequency pulse, the magnetization
vector realigns along the longitudinal (z) axis as proton spins give their energy back to
the surrounding lattice, coming into equilibrium with its surroundings. The transverse
time constant T2, also called spin-spin relaxation, is the time required for the transverse
component of the magnetization vector to decay, and is a consequence of interactions
between spins as well as external field inhomogeneities. By taking advantage of the
different T1 and T2 time constants in tissues, MR images of the same anatomical
structures with varying degrees of hyperintesities and hypointensities can be obtained.
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1.13 Superparamagnetic Iron Oxide (SPIO) Nanoparticles
SPIO nanoparticles are predominately composed of a magnetite (Fe3O4) and/or
maghemite (ɤ-Fe2O3) iron core and a hydrophilic/hydrophobic surface coating.271,

272

These particles have the greatest application in providing useful contrast on T2 or T2*
weighted MR imaging, producing a hypointense (dark) signal. When an external
magnetic field is applied, the magnetic moments are oriented in the direction of the
magnetic field thereby enhancing the magnetic flux in their vicinity. The disturbances in
the local magnetic field results in a rapid de-phasing of surrounding protons following an
RF pulse, altering both their longitudinal and transverse relaxation characteristics, and
generating a detectable change in the MR signal. Due to their strong enhancement in
proton relaxation, SPIO nanoparticles have been extensively investigated as MR contrast
agents. While many of the clinical studies using SPIO are in early phase clinical trials or
discontinued, a few have been marketed.273
Over the past decades, studies using SPIO nanoparticles have shown potential
applications in MR hepatic imaging (as they are readily taken up by Kupffer cells), cell
tracking, cardiovascular imaging, and biomolecular detection.272 In cancer imaging, SPIO
can be used for the detection of lymph node metastases, which aids in cancer staging and
therapeutic planning.274, 275 While these applications are promising, a desirable goal is to
utilize SPIO nanoparticles for cellular and molecular imaging applications, to provide
earlier detection of malignancies prior to metastasis. However, a major hurdle for the
detection of non-RES lesions is the sensitivity limitations of some MR contrast agents.
As a result, many strategies have been utilized to improve SPIO nanoparticle sensitivity
including the optimization of MR hardware and pulse sequences, nanoparticle shape and
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size, SPIO cell specific targeting, and the development of SPIO nanocarriers. For
example, the development of an activatable SPIO nanoparticle probe has been shown to
increase contrast by improving site-specific accumulation.276 Other approaches have
significantly increased particle relaxivity by incorporating many SPIO nanoparticles
within the hydrophobic core of polymeric micelles.277,
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This approach has been

adapted in this thesis to create micelles that are capable of generating strong MR contrast.
SPIO was combined with AuNPs, to create a micelle that has both diagnostic and radiotherapeutic potential.
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1.14 Polymeric Micelles
Polymeric micelles offer a powerful multifunctional platform for drug delivery and
diagnostic imaging applications.279,

280

These nanoconstructs are composed of

amphiphilic block co-polymers with distinct hydrophobic and hydrophilic domains that
can self-assemble into supramolecular core-shell structures (usually 10 to 100 nm) in
aqueous solution. The hydrophobic micelle core provides an ideal carrier compartment
for hydrophobic drugs and nanoparticles,277 and the shell consists of a protective corona
that stabilizes the nanoparticles. Among the many different classes of amphiphilic block
copolymers used, polyethylene oxide (PEO)-b-polycaprolactone (PCL) or poly(lactic
acid) (PLA) have received the most interest as they are FDA approved materials with
potential benefits that span drug delivery and diagnostic applications.281 The dense PEG
corona of the PEG-b-PCL vesicles imparts stealthiness and is able to deter membrane
opsonization, and significantly extend in vivo circulation times.282
For example, the incorporation of insoluble anticancer agents into micelles has been
shown to improve drug circulation, enhance cytotoxicity at the target site and enable
delivery of higher doses to the tumor than with agents alone.283, 284 Other groups have
incorporated imaging agents including SPIO, for magnetic resonance imaging,
radioactive metals for positron emission tomographic imaging, and organic iodine for Xray/CT imaging.285 Until now, the only clinically approved micelle formulation is
Genexol-PM, a PEG-PLA micelle entrapped formulation of paclitaxel, used in the
treatment of breast cancer. Furthermore, polymeric micelles have the flexibility of
incorporating multiple types of compounds within the core for multimodal and
theranostic applications as well as surface bioconjugation for active targeting.277, 281
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In this thesis small (< 6 nm) AuNPs were encapsulated within the hydrophobic core
of polymeric micelles such that they would mimic AuNPs with larger core diameters and
significantly prolong their circulation in the blood. However, upon the hydrolysis of the
amphiphilic polymer, we hypothesized that that presence of small AuNPs could help to
improve the clearance from various organ systems and reduce long term retention. SPIO
was also encapsulated within the micelle to allow for MR imaging.
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1.15 Preface to Dissertation
While AuNPs have been used for diverse applications in both imaging and
therapy, their poor long-term elimination and low sensitivity in X-ray imaging is a major
limitation. This dissertation thesis is laid out to follow a sequence of findings that led to
the development of a nanoplatform for imaging and radiotherapy with improved
pharmacokinetics. The chapters are broken down as follows:
Chapter 2: Development of gold-loaded polymeric micelles with prolonged
circulation for combined X-ray imaging and radiation therapy.
Chapter 3: Preparation of superparamagnetic iron oxide and gold loaded micelles
for improved imaging sensitivity.
Chapter 4: Develop a targeted superparamagnetic iron based micelles for cell
specific targeting.
Chapter 5: Examination of the in vivo long-term toxicity, clearance, and organ
retention of gold-loaded polymeric micelles using two different sizes of AuNPs.
Chapter 6 is a summary of the primary discussion points that have been highlighted over
the course of this dissertation and future directions for this work.
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Chapter

2:

Development

of

Gold-Loaded

Polymeric

Micelles

for Computed Tomography–Guided Radiation

Therapy Treatment and Radiosensitization

2.1 Abstract
Gold nanoparticles (AuNPs) have generated interest as both imaging and
therapeutic agents. AuNPs are attractive for imaging applications since they are nontoxic
and provide nearly three times greater X-ray attenuation per unit weight than iodine. As
therapeutic agents, AuNPs can sensitize tumor cells to ionizing radiation. To create a
nanoplatform that could simultaneously exhibit long circulation times, achieve
appreciable tumor accumulation, generate computed tomography (CT) image contrast,
and serve as a radiosensitizer, gold-loaded polymeric micelles (GPMs) were prepared.
Specifically, 1.9 nm AuNPs were encapsulated within the hydrophobic core of micelles
formed with the amphiphilic diblock copolymer poly(ethylene glycol)-b-poly(εcaprolactone). GPMs were produced with low polydispersity and mean hydrodynamic
diameters ranging from 25 to 150 nm. Following intravenous injection, GPMs provided
blood pool contrast for up to 24 hours and improved the delineation of tumor margins via
CT. Thus, GPM-enhanced CT imaging was used to guide radiation therapy delivered via
91

a Small Animal Radiation Research Platform. In combination with the radiosensitizing
capabilities of gold, tumor-bearing mice exhibited a 1.7-fold improvement in the median
survival time, compared with mice receiving radiation alone. It is envisioned that
translation of these capabilities to human cancer patients could guide and enhance the
efficacy of radiation therapy.
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2.2 Introduction
Over the past two decades, many nanoparticle formulations have been evaluated
as computed tomography (CT) contrast agents, including liposomes loaded with
iodinated compounds,1-3 polymeric iodine-containing poly(ethylene glycol) (PEG)-based
micelles,4 iodine-containing perfluorocarbons,5, 6 bismuth sulfide nanoparticles,7 and gold
nanoparticles (AuNPs).8-10 Of these, gold nanoparticles have garnered a particularly high
degree of interest. This is largely due to the high mass attenuation coefficient of gold,
which is ~ 2.7-fold higher than iodine.11 Accordingly, it has been found that 30nm
AuNPs can attenuate 120 kVp x-rays 5.7 times more than the iodine-based agent,
Ultravist.10 Additional benefits of working with AuNPs include the ability to finely tune
their size and shape and modify their surface with various functional groups. While other
nanoparticle formulations, such as bismuth sulfide nanoparticles, may also exhibit a
higher x-ray absorption than iodine, it is difficult to control their size and there is a lack
of chemical methods to modify their surface.10, 12 Surface chemistry is important when
attempting to prolong systemic circulation, a prerequisite for tumor imaging and tumor
accumulation via the enhanced permeability and retention (EPR) effect.13 An extended
circulation also offers an opportunity to image the reticuloendothelial system (RES), the
blood pool, and in some cases the lymph system.
In addition to their use as CT contrast agents, AuNPs have also shown promise as
radiosensitizers. Radiosensitization is due to the high absorbance of gold and the
resulting deposition of energy in surrounding tissues from photoelectrons (i.e.
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photoelectric effect), Auger electrons, and the generation of free radicals.14, 15 Within the
kilovoltage energy range, the radiosensitization effect is generally attributable to the
photoelectric effect while Auger electrons are hypothesized to be responsible for energy
radiosensitization within the megavoltage range of radiation energies.16-19 It has been
shown that AuNPs in combination with radiation treatment can lead to an increase in the
number of DNA double-stranded breaks compared with radiation alone.14,

20-25

In one

recent study it was shown that 1.9 nm AuNPs could even lead to an increase in the
survival of tumor-bearing mice, compared with radiation therapy (RT) alone.9 However,
because of the rapid clearance of the small nanoparticles used in this study, the tumors
had to be irradiated immediately after AuNP administration. In general, rapid clearance
limits tumor-specific accumulation via EPR, and thus can limit the ability of small
AuNPs to guide, via CT, the precise delivery of radiation therapy.
When designing a treatment plan, radiation oncologists must take into account
several critical factors including the mapping of true tumor margins, which can
sometimes be challenging to define using current imaging techniques. Therefore, a more
accurate definition of tumor boundaries would facilitate more precise delivery of
radiation therapy and as a result decrease normal tissue exposure to undesirable
radiation.26-28 With this goal in mind, it is envisioned that long-circulating AuNPs that
appreciably accumulate in tumors via EPR can be used to guide RT planning and
treatment, through improved contrast-enhanced delineation of tumor boundaries via CT,
thus minimizing energy deposition in surrounding healthy tissues. In addition, AuNPmediated radiosensitization can also directly increase the radiation dose received by the
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tumor, thus providing a second complementary mechanism by which the overall
therapeutic index can be increased.
In this study, we describe the development of a multifunctional micelle that
simultaneously exhibits long circulation times, achieves appreciable tumor accumulation,
generates CT image contrast, and serves as a sensitizer for radiation therapy in cellular
and animal models at sublethal radiation doses. Specifically, using a microemulsion
synthesis method, we have been able to prepare gold-loaded polymeric micelles (GPMs),
with tunable hydrodynamic diameters ranging from 25 to 150 nm. The GPMs are formed
using the amphiphilic diblock copolymer poly(ethylene glycol)-b-poly(ɛ-caprolactone)
(PEG-b-PCL) and have tightly packed clusters of 1.9 nm AuNPs incorporated within the
hydrophobic core (Figure 2.1). We first evaluated the ability of GPMs to enhance doublestranded DNA breaks in vitro in response to radiation. Next, we assessed whether GPMs
are capable of generating contrast for CT blood pool and tumor imaging. Finally we
investigated whether the radiosensitization in cells translated to an improvement in
survivability in murine tumor xenograft models.

Figure 2.1. Schematic of gold-loaded polymeric micelles (GPMs). Gold nanoparticles are self-assembled
into the hydrophobic core of micelles, stabilized with the amphiphilic diblock copolymer PEG-b-PCL.
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Each GPM is composed of approximately hundreds to thousands of individual gold nanoparticles,
depending on their size.

2.3 Materials and Methods
Synthesis of 1.9 nm gold A uNPs
Dodecanethiol capped AuNPs were prepared according to the procedure
described by Brust et. al,46 using a two phase reduction of tetrachloroaurate (HAuCl4) by
sodium borohydride (NaBH4) in the presence of an alkanethiol. Briefly, 30 mL of an
aqueous solution of 30 mM HAuCl4 was mixed with 50 mM of tetraoctylammonium
bromide (TOAB) in 80 mL of toluene. The solution was stirred until the HAuCl4 solution
transferred into the organic phase. Then, 0.84 mM of 1-dodecanethiol was added to the
solution while stirring followed by the dropwise addition of a 0.4 M aqueous solution of
NaBH4. The resultant mixture was then stirred for at least 3 hours and precipitated twice
at -20°C in ethanol overnight to remove excess thiols. The precipitate was collected via
centrifugation and the supernatant was decanted. The remaining pellet was dissolved in
toluene.
Synthesis of GPMs
Gold loaded polymeric micelles were synthesized using oil-in-water emulsions
and stabilized using the amphiphilic diblock copolymer polyethylene glycol (4k) –
polycaprolactone (3k) (PEG-b-PCL). AuNPs were dissolved in toluene at 30 mg Au/mL
and PEG-b-PCL was also dissolved in toluene at a concentration of 50 mg/mL. A
combined solution (200 µL) of the diblock (4 mg) and the AuNPs (3.5 mg) was added
directly to a glass vial containing 4 mL of millipore water and the mixture was emulsified
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for approximately 3 minutes in an ultrasonic bath. The emulsions were then allowed to
stand overnight in a desiccator prior to their characterization and purification. The
resulting dark brown solution was centrifuged at 400 RCF for 10 minutes to remove the
largest micelles. The solution was then centrifuged twice at 3100 RCF for 30 minutes,
after which the supernatant was removed, and the pellet was re-suspended in pH 7.4
phosphate buffered saline (PBS). Different size fractions were collected using different
centrifugal rates. Free polymer and smaller sized particles were removed by diafiltration
using a MidGee hoop cross flow cartridge with 750 kDa molecular weight cutoff (GE
Healthcare, Piscataway, NJ, USA) and was then filtered through a 0.2 µm cellulose
acetate membrane filter (Nalgene, Thermo Scientific) to remove any oversized particles.
Finally the nanoparticles were concentrated using 50 kDa MWCO centrifugal filter units
(Millipore, Billercia, MA, USA).
Physicochemical analysis of GPMs
GPM stock solutions were diluted in Millipore water and deposited on 200-mesh
carbon coated copper grids (Polysciences, Warrington, PA) for TEM imaging using a
JEOL 1010 transmission electron microscope operating at 80 kV. Stock samples of GPM
were diluted in PBS for measuring the hydrodynamic diameter of the nanoparticles by
dynamic light scattering (DLS). These measurements were acquired using a Zetasizer
Nano-ZS (Malvern Instruments, Worcestershire, UK) using the non-invasive back-scatter
(NIBS) mode. Zeta potential measurements were carried out by diluting GPM stock
samples in PBS and the mean particle zeta potential was measured using a Zetasizer
Nano-ZS.
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Cell culture and γ-h2ax immunofluorescence
HT-1080 human fibrosarcoma cells (ATCC) were cultured and maintained in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin at 37°C and 5% CO2. Cells in chamber slides
were exposed to culture medium with 1 mM of AuNPs for 24 hours then irradiated using
a Small Animal Radiation Research Platform (SARRP) (150 kVp, 15 mA). After 12
hours post-irradiation, cells were fixed with 10% neutral buffered formalin (SigmaAldrich) for 10 minutes. Cells were then rinsed with PBS, and the nuclei were stained
with Hoechst 33342 (25 µM) for 15 minutes. The slides were permeabilized with 0.5%
Triton X-100 in PBS and then exposed to blocking buffer (PBS, 0.5% Triton X-100, 5%
normal chicken serum, 1% BSA) for 30 minutes at room temperature and subsequently
incubated overnight at 4oC with mouse monoclonal anti-phospho-histone γ-H2AX
primary antibody (JBW301, Upstate) at 1:1500 dilution in PBS (with 0.5% Triton X-100
and 1% BSA). Cells were washed with PBS and then incubated with chicken anti-mouse
Alexa 594 secondary antibody (Molecular Probes) at 1:1000 dilution in PBS (with 0.5%
Triton X-100 and 1% BSA) for 1 hour at room temperature. After rinsing with PBS, the
slides were mounted with Prolong Gold Antifade Reagent (Invitrogen) and coverslips.
Fluorescence imaging was performed using a Deltavision Deconvolution microscope
(Applied Precision) equipped with a 60x (1.42 NA) oil-immersion lens and
thermoelectrically cooled 12-bit monochrome CCD camera. Images were recorded as zstacks (0.3 µm steps). Following reconstructive deconvolution, the maximum values of
the pixels were used to assemble two-dimensional projections. Foci were counted
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automatically using ImageJ after applying a top-hat filter and constant value threshold
based on unirradiated controls.
Clonogenic A ssay
Cells were incubated for 24 hours in culture medium with or without 100 µg/mL
of GPMs in 100 mm dishes and then irradiated with the SARRP (150 kVp, 15 mA) at the
specified radiation doses (0 Gy, 2 Gy, 4 Gy and 6 Gy). After radiation, the cells were
washed three times with PBS, trypsinized, and plated at predetermined densities. The
plates were kept in a humidified incubator and maintained in a 37oC and 5% CO2
environment for 10 to 14 days. The cells were then stained with methylene blue and the
resulting colonies counted. A colony by definition had n > 50 cells. The surviving
fraction was calculated as (colonies counted) / (cells seeded x (plating efficiency/100)).
Each point on the survival curve represents the mean surviving fraction from at least
three replicates. The survival curves were fitted to a linear-quadratic equation: surviving
fraction = exp[-(αD+βD2)]. The sensitizer enhancement ratio (SER) was calculated as the
ratio of the mean inactivation doses, defined as the dose at which there is 37% survival
with and without GPMs.
Quantification of blood clearance via ICP-OES
Approximately 6 week old female nu/nu nude mice (n = 3) were used for the
GPMs blood clearance experiments. The GPMs were injected retro-orbitally at a dose of
approximately 100 ppm in 200 µL of injected solution. Prior to injection, an aliquot of
the GPM solution was saved for inductively coupled plasma – optical emission
spectroscopy (ICP-OES) for the determination of the gold concentration of injected
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sample. Blood samples (10 µL each) were collected from each animal using the tail-nick
method at 1 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h, and 48 h post-injection.
Contrast Enhanced in vivo CT imaging and biodistribution analysis
Approximately 6 week old female nu/nu nude mice (Charles River Laboratory,
Charles River, MS, USA) were maintained in accordance with the Institutional Animal
Care and Use Committee of the University of Pennsylvania. Mice were anesthetized
using isoflurane, and HT-1080 cells were injected subcutaneously into the back left flank
(2 x 106 cells in 0.1 mL of PBS). Tumors were grown until the mean diameter was
approximately 7 – 8 mm, and pre-contrast cone beam CT imaging was performed using a
Small Animal Radiation Research Platform, SARRP (Gulmay Medical, Inc.). CT
imaging was conducted at 50 kVp (0.5 mA), and 1440 projections were used to
reconstruct the cone-beam images using the algorithm provided by the manufacturer.
Immediately following the pre-contrast image acquisition, either GPMs or 1.9 nm
AuroVistTM gold nanoparticles (Nanoprobes, Yaphank,NY) were intravenously injected
into the HT-1080 tumor-bearing mice (n = 3 for each group). Using isoflurane to
anesthetize the mice, both contrast agents were administered by retro-orbital injection
(650 mg Au/kg in 0.2 mL). Post-contrast images were collected 30 min, 24 h, and 48 h
post-injection with the same imaging parameters used for pre-contrast images. After 48
hours, the animals were sacrificed and the tumors, livers, spleens, kidneys, hearts, and
lungs were harvested. Tissue samples were thoroughly washed with PBS and blotted dry
to minimize the contribution of any nanoparticles remaining in the bloodstream. The
tissue were weighed and digested in HNO3 overnight at 70°C. Following the overnight
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digestion, HCl was added to dissolve the gold. Samples were diluted with Millipore water
and analyzed for gold content using ICP-OES.
Toxicity studies
Approximately 6 week old female nu/nu nude mice were randomized into four
groups of 3 animals per group receiving 650 mg Au/kg, or sham-injected with PBS.
Animals were weighed and observed regularly for clinical signs for up to 1 week postinjection. Animals were euthanized by CO2 at 1 day and 1 week after intravenous gold
injections and 0.3 mL blood was removed from the right ventricle immediately after the
cessation of breathing. Blood chemistry analytes included blood urea nitrogen (BUN),
phosphate,

albumin,

globin,

gamma

glutamyl

transpeptidase

(GGT),

alanine

aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total
bilirubin, cholesterol, and creatinine
In vivo radiation therapy
Approximately 6 week old female nu/nu nude mice were anesthetized using
isoflurane, and HT-1080 cells were injected subcutaneously into the back left flank (2 x
106 cells in 0.1 mL of PBS). Tumors were grown until the mean diameter was
approximately 7 – 8 mm. Next, tumor-bearing mice were split into four groups of 7 each
– the first group received 6 Gy RT only; the second group received an intravenous
injection of GPMs (650 mg Au/kg in 0.2 mL) 24 hours prior to a single dose of 6 Gy RT;
the third group received GPMs only (i.e. no RT), and the fourth group received no GPMs
and no RT. When applicable, GPMs were administered by retro-orbital injection. In all
groups receiving RT, CT imaging was used to localize the isocenter of the tumor.
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Radiation therapy was administered using a SARRP (175 kVp, 15 mA) and delivered
through a 17 mm diameter collimator. Mice were monitored for tumor growth, and were
sacrificed when the tumor volume reached 1300 mm3. Tumor volumes were calculated
assuming an ellipsoidal tumor shape (1 / 2 x length x width2).47 Survival time to this
endpoint was calculated from date of treatment.

2.4 Results and Discussion
Characterization of 1.9 nm A uNPs
Hydrophobic AuNPs were prepared with dodecanethiol as a capping agent.
Transmission electron microscopy (TEM) was used to characterize the mean core size of
the individual hydrophobic AuNPs. TEM images showed a uniform distribution of
AuNPs with a core size of 1.93 ± 0.16 nm (Figure 2.2). Purity was confirmed via UV-vis
spectroscopy (Figure 2.3).

Figure 2.2. (A) Transmission electron micrograph of 1.9 nm AuNPs. Scale bar is 20 nm. (B) Core size
distribution of 1.9 nm AuNPs. The mean size and standard deviation is shown.
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Figure 2.3. UV-vis absorption spectrum of 1.9 nm AuNPs with a broad surface plasmon resonance
ranging from 490 nm – 510 nm.

Synthesis and Characterization of GPMs
GPMs were prepared by encapsulating 1.9 nm AuNPs within the diblock
copolymer PEG-b-PCL, using a microemulsion method. These GPMs were soluble in
aqueous solutions owing to the hydrophilic PEG corona of the diblock copolymer.
Following synthesis and purification of the GPMs, six different sizes (25 – 150 nm,
Figure 2.4) were collected using differential centrifugation, as confirmed by dynamic
light scattering (DLS). The DLS measurements demonstrate particle measurements with
a low polydispersity index for all GPM fractions (< 0.1). TEM was used to determine the
morphology of the GPMs and the packing of AuNPs within the hydrophobic core. TEM
micrographs revealed a narrow distribution of spherical GPMs with tightly packed
clusters of AuNPs contained within the hydrophobic core of the micelles (Figure 2.4).
The TEM micrographs also revealed a low polydispersity, correlating well with the DLS
measurements. The zeta potential of the various GPMs formulations was near neutral. A
summary of the GPM physical-chemical properties is provided in Table 2.1.
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Figure 2.4. Size and morphology of GPMs. (A) Dynamic light scattering profiles of six GPM formulations
with mean sizes ranging from 25 - 150 nm, in phosphate buffered saline, pH 7.4. (B) Transmission electron
microscopy (TEM) images of the same six GPM formulations, respectively. The electron micrographs
reveal a narrow monodispersed distribution of spherical GPMs, with tightly packed gold clusters contained
within the hydrophobic core (all scale bars = 100 nm).

Table 2.1. Summary of GPM physical-chemical properties
Hydrodynamic
Diameter (nm)
30.9 ± 2.4
57 ± 5.7
78.6 ± 3.8
97.8 ± 3.4
130.2 ± 2.7
153.8 ± 6.3

Core Size

(nm)

26.8 ± 10.4
39.5 ± 10.3
54.8 ± 7.1
70.4 ± 16.8
106.3 ± 11.5
115.2 ± 20.3

Polydispersity
Index
0.088
0.063
0.05
.049
0.042
.055

Zeta potential
(mV)
-1.34 ± 0.17
-1.01 ± .05
-0.95 ± 0.3
-1.17 ± 0.04
-1.5± 0.23
-1.62 ± 0.85

Evaluation of GPMs as a radiosensitizer
GPMs with a hydrodynamic diameter of approximately 75 nm were selected for a
more detailed evaluation as radiosensitizing agents. This size was selected because it was
produced in significantly higher yields than the other sizes and was thus more amenable
for in vivo testing. To evaluate the radiosensitization effects of the 75 nm GPMs in vitro,
HT-1080 human fibrosarcoma cells were irradiated (4 Gy) or mock irradiated in the
presence or absence of GPMs and analyzed for double-stranded breaks (γ-h2ax staining)
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(Figure 2.5a-b). Immunofluorescent images revealed very low levels of γ-h2ax foci
(observed as bright fluorescent spots) in unirradiated cells, regardless of the presence of
GPMs. In contrast, high levels of γ-h2ax foci were observed within the nuclei of cells that
received radiation treatment, with a noticeably higher number of double-stranded breaks
in cells that were treated in the presence GPMs. Quantitatively, there were very few γh2ax foci per unit area in unirradiated controls, as expected, and there was no statistically
significant difference between cells incubated in the presence or absence of GPMs.
However, when cells were irradiated, the number of γ-h2ax foci increased and a
statistically significant difference was observed between cells irradiated in the presence
and absence of GPMs. Compared to cells receiving radiation only, the cells that were
irradiated in the presence of GPMs exhibited roughly a 2.2 times higher density of DNA
double-stranded breaks. Furthermore, clonogenic survival assays revealed a decrease in
survival of HT-1080 cells irradiated in the presence of GPMs compared to those
receiving irradiation alone (Fig. 2.5c). A statistically significant difference in survival (p
< 0.05) was observed for radiation doses of 4 and 6 Gy. Using the linear-quadratic model
to assess the enhancement of radiation effects, it was estimated that GPMs produced a
sensitizer enhancement ratio (SER) of approximately 1.2, which is consistent with
previous studies that utilized AuNPs as a radiosensitizer.22, 29
(C)
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Figure 2.5. In vitro evaluation of radiation induced DNA double-stranded breaks in the presence and
absence of GPMs. (A) Immunofluorescent imaging of γ-h2ax foci in HT-1080 cells incubated with or
without GPMs in the absence (top) or presence (bottom) of irradiation (4 Gy). (B) Quantitative analysis of
γ-h2ax foci density (# foci/um2) for n > 100 cells in each treatment group. Error bars represent 95%
confidence intervals. (C) Clonogenic assay of HT-1080 cells treated with and without GPMs and given
radiation doses of 0, 2, 4 and 6 Gy. Error bars represent the mean survival ± standard error of at least three
replicates.

Stability of GPMs in serum
Prior to evaluating GPMs as an imaging and radiosensitizing agent in living
subjects, the stability of 75 nm GPMs was evaluated in fetal bovine serum (Figure 2.6).
Upon incubating the GPMs with 100% serum for 24 h at 37°C, there was no difference in
the size of the GPMs as determined by DLS and no visible precipitates were observable
in the solution. Moreover, no evidence of leaching of AuNPs from the micelle or
alteration in the micelle structure was observed on TEM images following incubation in
serum (Figure 2.7), suggesting that GPMs are sufficiently stable for in vivo studies. It
should be noted that all of the micelle samples (i.e. all size fractions) also appear to be
stable in PBS at pH 7.4 for months with no observable changes in hydrodynamic
diameter or structure, as determined by DLS and TEM, respectively.

Figure 2.6. Mean hydrodynamic diameter of GPMs in fetal bovine serum as determined by dynamic light
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scattering. GPMs were incubated at 37°C and the hydrodynamic diameter was measured over the course of
24 hours.

Figure 2.7 Transmission Electron Microscopy image of GPMs in fetal bovine serum prior to (left) and 24
hours after (right) incubation at 37ᵒC.

GPM pharmacokinetics
Long circulating particles, that are able to avoid rapid clearance from the
bloodstream via glomerular filtration and the reticuloenodthelial system (RES), are
necessary for EPR-driven tumor accumulation. Therefore, if GPMs are to be used to help
delineate tumor margins and guide radiation therapy, it is necessary for them to exhibit a
long circulation half-life. It was determined that the circulation half-life of 75 nm GPMs
is ~ 1 hour during the early distribution phase and 8.7 hours during the elimination phase
(Figure 2.8). This long circulation time is likely governed by the dense hydrophilic PEG
coating present on the micelle.
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Figure 2.8. Blood clearance profile and CT imaging of GPMs in blood pool. (A) ICP-OES analysis of gold
content in blood at various times following the intravenous administration of GPMs to mice (n = 3). (B)
Serial CT coronal views of a mouse following retro-orbital injection of 200 µL of GPMs solution (650 mg
Au/kg). Coronal view of heart and liver (top) and inferior vena cava and kidneys (bottom) are shown.

The ability of GPMs to generate contrast in vivo was validated in mice. Images
acquired 30 minutes post-injection demonstrated enhancement of the great vessels and
minor branches such as the renal vessels and interlobular vessels (Figure 2.8).
Furthermore, the cardiac chambers were readily visualized demonstrating the potential
use of GPMs as a blood-pool contrast agent. After 24 hours there was residual
enhancement of the heart and great vessels indicative of the long circulation time of the
GPMs. The administered dose of GPMs (650 mg Au/kg) was well within the range of
clinically approved intravenous contrast agents. For example, Iodixanol (VISIPAQUE) is
typically administered at doses ranging from 300 to 1200 mg I/kg body weight.
Additionally, the dose utilized in this study was lower than what was used in prior studies
that employed gold as a radiosensitizer (i.e. > 1350 mg Au/kg).9, 29
The biodistribution of GPMs was evaluated at 48 hours and at 1 week postinjection by performing an ICP-OES analysis of gold content within the heart, kidneys,
lungs, spleen, liver, feces, and urine (Table 2.2). All organs examined showed a marked
reduction in gold accumulation between these two time points, including the liver and
spleen. Specifically, ICP-OES findings revealed a 28% reduction of gold in the liver and
a 47.5% reduction of gold in the spleen. Evaluation of gold content within feces and
urine suggests that the primary route of clearance was biliary excretion.
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Table 2.2. Biodistribution of GPM in mice at 48 hours and 1 week post-injections displayed as a
percentage of injected dose (%ID) and percentage of injected dose per gram of tissue (%ID/g)
Organs

%ID (48 hr)

%ID/g (48 hr)

%ID (1 week)

%ID/g (1 week)

Heart
Kidney
Lungs
Spleen
Liver
Feces
Urine

0.1 ± 0.02
0.7 ± 0.1
0.4 ± 0.1
11.6 ± 0.3
17.6 ± 1.8
2.0 ± 0.06
not determined

1.1 ± 0.2
1.9 ± 0.2
2.6 ± 0.7
104.3 ± 14.6
13.9 ± 0.4
0.6 ± 0.02
0.006 ± 0.001

0.05 ± 0.004
0.4 ± 0.01
0.04 ± 0.005
6.3 ± 0.6
12.6 ± 1.0
0.64 ± 0.04
not determined

0.4 ± 0.01
1.1 ± 0.1
0.3 ± 0.01
61.9 ± 5.2
10.0 ± 0.5
0.19 ± 0.01
0.002 ± 0.000

Toxicity analysis
The intravenous injection of GPMs at 650 mg Au/kg into healthy mice led to no
signs of illness, weight loss (Figure 2.9), or change in activity. Notably, the amount of
gold administered was well below the LD50, which was previously reported to be 3.2 g
Au/kg.9 A toxicological analysis of mice 1 day and 1 week following the administration
of GPMs (650 mg Au/kg) revealed normal blood chemistry, compared to saline injected
controls (Table 2.3).

Figure 2.9. Whole animal weights of tumor-free mice treated with 650 mg Au/kg GPMs (0.2 mL)
compared with mice sham injected with phosphate buffered saline (0.2 mL). Data reflect average weights
and n = 3 for all groups.
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Table 2.3. Serum clinical chemistry of mice injected with 650 mg Au/kg GPMs (0.2 mL) and sampled at
24 hours and 1 week compared with mice sham injected with phosphate buffered saline (0.2 mL). All
values were within normal limits and n = 3 for all groups. Data is recorded ± standard error.

Day 1 GPMs
Control
Day 7 GPMs
Control

BUN

Albumin

ALT

AST

Alk. Phos.

GGT

24.3 ± 3.9
25 ± 2.1
30.3 ± 3.5
20 ± 2.6

2.4 ± 0.1
2.4 ± 0.1
2.4 ± 0.3
2.3 ± 0.2

157.7 ± 111.7
180 ± 89.3
93 ± 29.5
139 ± 4.4

377 ± 146.5
337 ± 122.1
245.3 ± 102.9
267.3 ± 78.1

114 ± 7.1
129.7 ± 11.8
62.3 ± 2.9
68.7 ± 10.7

5.3 ± 0.3
9 ± 1.5
12.7 ± 3.9
23.1 ± 13.3

Total Bil.

Cholesterol

Calcium

Creatinine

Glucose

Phosphorus

Day 1 GPMs
0.5 ± 0.2
99.3 ± 9.8
8.9 ± 0.4
0.2 ± 0.0
168.7 ± 24.5
8.5 ± 0.3
Control
1.1 ± 0.0
91.3 ± 2.7
8.6 ± 0.4
0.2 ± 0.0
195.7 ± 34.1
10 ± 0.4
Day 7 GPMs
0.9 ± 0.6
77.3 ± 5
8.8 ± 0.1
0.2 ± 0.1
279.7 ± 10.3
7.7 ± 0.5
Control
1.5 ± 0.9
180 ± 45
9.1 ± 0.6
0.1 ± 0.0
195.7 ± 34.1
8.6 ± 1.6
*BUN, creatinine, total bili (total bilirubin), and cholesterol are in units of mg/dL. ALT, AST, alk. phos.
(alkaline phosphatase), and GGT are in units of U/L. Albumin is in units of g/dL. Blood samples were
obtained from mice injected with 400 mg Au/kg of GSM or sham injected with saline. Data is recorded ±
standard error.

GPMs as a CT contrast agent
The ability of GPMs to accumulate within tumors at sufficient levels to provide
CT contrast was confirmed in mice bearing HT-1080 flank tumors. Axial tumor slices of
3 different tumor-bearing mice were analyzed pre-contrast as well as 30 min, 24 h and 48
h post-contrast (Figure 2.10). The variation of signal enhancement from slice to slice was
accounted for by normalizing the signal to the corresponding para-spinal muscles for
each slice. In the pre-contrast image, the tumor on the flank of the mouse located between
the thigh and para-spinal muscles is not clearly delineated. At the 30 minute time point,
there is no qualitative or statistical difference in contrast enhancement within the tumor
compared to the pre-contrast image. However, at 24 hours and 48 hours post-contrast, the
tumor is revealed as a hyper-intense heterogeneously enhancing region with well-defined
margins. These enhancements in tumor contrast were statistically different from both the
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pre-contrast and 30 minute time points. This result is likely due to the extravasation of
GPMs out of leaky vasculature and accumulation within the tumor owing to the EPR
effect. This distinction between tumor and normal tissue can help in the design of
radiation treatment of cancer by enabling visualization of regional tumor margins and
spread, to help localize and maximize radiation doses to malignancies while minimizing
exposure to normal tissue. Notably, within the tumor margins, the contrast enhancement
was somewhat heterogeneous, likely due to variations in the ability of GPMs to penetrate
far beyond the vascular wall.

Figure 2.10. In vivo CT images and intensity analysis of nu/nu nude mice with HT-1080 flank tumors. (A)
Representative CT images in the axial plane prior to injection (pre-contrast) and 30 min, 24 h and 48 h
post-injection of GPMs (n = 3) or AuroVistTM (n = 3). Tumor boundaries are indicated by white arrows. (B)
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Quantitative analysis of CT images. Signal intensity of each tumor was normalized to adjacent paraspinal
muscle. For contrast measurement, the relative signal intensity, RSI, was calculated as the quotient of the
post-contrast to pre-contrast normalized tumor intensity. Statistically significant values of p < 0.05 are
indicated with an asterisk.

To demonstrate the importance of a long circulating platform for effective
extravasation and accumulation in tumors, 1.9 nm control AuNPs were also administered
to tumor-bearing mice and imaged 30 min, 24 h and 48 h post-contrast. At each time
point, no visible tumor contrast enhancement was observed, compared with pre-contrast
images. This is likely because > 90 % of the particles are cleared within the first 30
minutes.8

Figure 2.11. ICP-OES analysis of gold distribution at 48 hours following the administration of GPMs or
AuroVistTM. The percent injected dose per gram of tissue was calculated by measuring the concentration of
gold in excised organs via ICP-OES. There is a statistically significant increase in the accumulation of gold
in tumors of mice receiving GPMs (p < 0.05) compared to mice injected with AuroVistTM.

To quantitatively determine the amount of GPMs and 1.9 nm AuNPs delivered to
the tumor, as well as other organs, the liver, spleen, lung, heart, kidneys, and tumor were
harvested 48 hours post-injection and the gold content was analyzed by ICP-OES (Figure
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2.11). Mice injected with GPMs had the highest levels of gold in the liver and spleen, and
only modest levels of gold in the heart, lungs, and kidneys. In contrast, mice injected with
1.9 nm AuNPs had higher levels of gold within the kidney, lower uptake in the liver and
spleen, and very modest uptake in the heart and lungs. This difference in organ
distribution is expected since the mechanism of elimination differs for both formulations.
In general neutrally charged particles with hydrodynamic sizes smaller than ~ 6 nm are
cleared from the systemic circulation via glomerular filtration and excreted in the urine,30
whereas particles greater than ~ 6 nm are primarily cleared by the RES system.31 This
disparity in elimination was also supported by in vivo CT imaging. Following GPM
administration, the spleen and liver gradually brighten over the course of 48 hours
(Figure 2.12); in contrast, mice injected with AuroVistTM exhibit very bright contrast
within the kidneys and bladder at early time points of CT imaging and gradually return to
baseline at 24 hours post-injection. With respect to tumor delivery, mice injected with
GPMs displayed a statistically significant 6-fold increase in gold accumulation compared
to mice injected with AuroVistTM. From the ICP-OES data, the average concentration of
gold within the tumor was calculated to be 0.57 ± 0.1 mg/mL and 0.14 ± 0.01 mg/mL for
mice injected with GPMs and AuroVistTM, respectively. In general, the sensitivity for Au
detection using CT imaging is estimated to be around 0.5 mg/mL.21 However, as a result
of the heterogeneous distribution of Au within the tumor, some regions likely have gold
concentrations well above this lower detection limit. Furthermore, these tumor
concentrations were well above the 0.1 mg Au/mL, where a radiosensitization effect was
observed in vitro. Importantly, this circulation-mediated increase in nanoparticle delivery
was sufficient to provide CT contrast prior to tumor radiation therapy. This demonstrates
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the importance of having a long circulating platform since the improvement in delivery
has the ability to yield significant contrast enhancement for CT-guided radiation therapy.

Figure 2.12. Computed tomography images of mice injected with AuroVistTM or GPMs. (A) The kidneys,
ureter and bladder (arrows) are enhanced during early imaging time points following the injection of
AuroVistTM, but no contrast is evident at 24 h or 48 h, consistent with renal clearance. (B) The spleen
(arrows) is observed as early as 5 minutes post-injection of GPMs and contrast continues to increase over
the next 48 h, indicative of RES uptake.

Radiosensitization of tumors with GPMs
To specifically examine the therapeutic effects of using GPMs as radiosensitzers
in vivo, nu/nu mice bearing 7 - 8 mm subcutaneous HT-1080 flank tumors were divided
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into four groups (n = 7 per group). The first two groups were the unirradiated controls
with one of the two groups receiving GPMs. The next two groups received either
radiation therapy (6 Gy) alone or were injected with GPMs 24 hours prior to radiation
treatment. Notably, contrast enhancement was visible within the tumors of mice receiving
GPMs, which enabled CT-guided stereotactic radiation. Mice were monitored for tumor
growth and were sacrificed when the tumors reached the predetermined threshold volume
(1300 mm3). The survival time was measured from the time of radiation (or mock
irradiation). Mice that received GPMs prior to radiation therapy exhibited a statistically
significant (p < 0.05) improvement in median survival (68 days), compared to mice
treated with radiation alone (38 days) (Figure 2.13). It should be noted that all mouse
groups appeared to tolerate GPMs very well over the course of study with no observable
changes in behavior or symptoms of poisoning such as loss of appetite, diarrhea, or
vomiting. For the group receiving radiation only, two mice were sacrificed prior to the
threshold volume cutoff due to an ulcerated tumor in one and severe emaciation in
another. The general observable trend in tumor growth post radiation therapy was a
reduction in tumor growth, followed by a reduction in tumor volume and then eventual
tumor re-growth (Figure 2.14). Only one mouse out of seven in the radiation-only group,
with a slow growing palpable tumor, survived 90 days post treatment. In contrast, 3 of the
7 mice that received GPMs prior to radiation survived 90 days post therapy. Two out of
the three mice had complete remission with no palpable tumor while the third mouse had
a palpable static tumor. With respect to the unirradiated groups, GPMs alone had no
effect on tumor growth compared to untreated controls. These results suggest that the
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EPR-dependent accumulation of GPMs within tumors can guide and enhance the efficacy
of radiation therapy.

Figure 2.13. Kaplan-Meier survival analysis. A survival analysis was performed for tumor bearing mice (n
= 7 per group) receiving no treatment (dotted grey line), GPMs only (dotted black line), irradiation only
(solid grey line), or irradiation 24 h after retro-orbital injection of GPMs (solid black line). GPMs were
administered at a dose of 650 mg Au/kg. The radiation dose administered was 6 Gy at 150 kVp. The
asterisk indicates statistical significance (p < 0.05).
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Figure 2.14. Tumor growth curves of mice receiving GPMs with radiation therapy (blue) or radiation
therapy alone (red).

2.5 Conclusion
Gold nanoparticles present a promising platform for therapeutic and imaging
(theranostic) applications because of their unique physical-chemical properties, their
ability to be easily functionalized and their safety profile. Gold has been used in medical
practice throughout history and continues today as a treatment for rheumatoid arthritis.32
Numerous animal studies suggest that AuNPs are also very well tolerated.33-38 In fact,
several AuNP formulations have even entered clinical trials for cancer treatment,
including CYT-6091 and AuroShell®. In this study 1.9 nm AuNPs were encapsulated
within the biocompatible and biodegradable polymer PEG-b-PCL, forming gold-loaded
polymeric micelles. An anticipated benefit of this GPM formulation over pegylated, solid
AuNPs of similar size is that it is easy to incorporate other anticancer and/or other
metallic nanoparticles into the micelle core,39-41 if additional functionality is desirable.
Moreover, we believe that the presence of many small AuNPs (1.9 nm) may allow for
more rapid dissolution and excretion, compared with a single large AuNP. It was
previously reported that with 40 nm solid AuNPs there is only a 9% fall in the content of
gold in the liver from day 1 to 6 months.42 In addition, many studies report inefficient
clearance and a persistent accumulation of AuNPs within the reticuloendothelial
system.43-45 In contrast, we observed more than a 28% fall in gold content within the liver
between day 2 and day 7. These results are very promising, although a more complete
analysis must still be performed to study additional and later time points before a
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definitive conclusion can be drawn.
In summary, we showed that GPMs were capable of enhancing radiation-induced
DNA double-stranded breaks in a cell culture model, consistent with prior work with
solid AuNPs.14,

15, 20-25, 29

Furthermore, because of their extended clearance half-life,

GPMs exhibited improved EPR-dependent accumulation in murine tumor xenografts,
compared to individual 1.9 nm AuroVistTM nanoparticles. The higher levels of GPM
accumulation in the tumor provided clear and quantifiable improvement in CT contrast.
The combination of CT-guided radiation therapy and gold-mediated radiosensitization
led to a statistically significant increase in the mean survival time of tumor-bearing mice
compared with mice receiving radiation alone. Accurate delineation of tumor extent and
tumor-specific radiosensitization is important for radiotherapy, due to radiation dose
limitations of the surrounding normal tissue. Therefore, we envision that GPMs can be
used someday in a tractable manner to both guide and enhance the efficacy of radiation
therapy.
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Chapter 3: Development of a Multi-Functional
Nanoplatform for Imaging, Radiotherapy, and the
Prediction of Therapeutic Response

3.1 Abstract
Gold nanoparticles have garnered interest as both radiosensitzers and computed
tomography (CT) contrast agents. However, the extremely high concentrations of gold
nanoparticles required to generate CT contrast is far beyond that needed for meaningful
radiosensitization, which limits their use as combined therapeutic-diagnostic – theranostic
– agents. To establish a theranostic nanoplatform with well-aligned radiotherapeutic and
diagnostic properties for better integration into standard radiation therapy practice, we
developed a gold- and superparamagnetic iron oxide nanoparticle (SPION)-loaded
micelle (GSM). Intravenous injection of GSMs into tumor-bearing mice led to selective,
tumoral accumulation, enabling magnetic resonance (MR) imaging of tumor margins.
Subsequent irradiation led to a 90-day survival of 71% in GSM-treated mice, compared
with 29% for irradiation-only mice. Furthermore, measurements of the GSM-enhanced
MR contrast were highly predictive of tumor response. Therefore, GSMs may not only
guide and enhance the efficacy of radiation therapy, but may allow patients to be
managed more effectively.
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3.2 Introduction
External beam radiation therapy is an integral part of current treatment strategies
for a variety of cancer types, both for initial therapy and recurrence. Increasingly, more
targeted approaches using stereotactic radiosurgery are also being used to maximize the
dose to the tumor volume while limiting off-target side effects. Moreover, a wide range
of radiosensitizers, including existing chemotherapeutic agents, are being explored to
specifically enhance ionizing radiation within tumor tissue without going above the
relative dose limitations of surrounding normal tissue.1,2 Some of the most promising
nanotechnology candidates being evaluated as radiosensitizers utilize high-Z materials
(i.e. high atomic number), such as gold nanoparticles (AuNPs), to significantly enhance
the dose of radiation therapy.3-7 AuNP-mediated radiosensitization is due to the greater
absorption and deposition of energy in surrounding tissues from photoelectrons, Auger
electrons, and characteristic X-rays.8-9

10-14

It has been shown that the administration of

AuNPs can lead to a statistically significant increase in median survival in tumor-bearing
mice compared with radiation therapy alone.15-18
Accurate dosimetry planning prior to radiation treatment requires radiation
oncologists and radiation physicists to consider a number of critical factors including the
mapping of tumor margins, which can often be difficult to assess using current imaging
techniques. AuNPs have long been exploited as computed tomography (CT)-contrast
agents and recently have been used to assist with the delineation of tumors boundaries to
guide external beam irradiation, thereby simultaneously serving as both a therapeutic and
imaging agent.8,19 The results from these studies have been encouraging, with tumorbearing mice exhibiting enhanced tumor contrast and improved median survival when
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treated with AuNPs in combination with radiation therapy, compared with radiation
therapy alone.17,18 However, a debilitating limitation of this approach is the considerable
mismatch between the lower detection limit of gold on CT systems (mM concentration
range) and the tumoral concentration required for gold-mediated radiosensitization (µM
range). This disparity therefore would require the administration of supratherapeutic
doses – on the order of grams Au/kg body weight8 – to perform imaging studies prior to
initiating radiotherapy treatment.
Magnetic resonance (MR) imaging is an integral component of the workup for
many tumors and increasingly utilized for treatment planning. Consequently,
nanoplatforms that include MR contrast agents could be organically integrated into
standard radiation therapy practice. Superparamagnetic iron oxide nanoparticles
(SPIONs) are a popular class of MR contrast agent that generate contrast by rapidly dephasing the magnetic moments of proximal water molecules.20 SPIONs are capable of
generating T2-weighted contrast enhancement in MR imaging at nanomolar
concentrations and can therefore be detected by MR at concentrations far lower than
those at which AuNPs can be detected via CT.20
Herein, we report the design and testing of a multifunctional nanoplatoform
consisting of Gold- and SPIO-nanoparticle loaded polymeric Micelles (“GSMs”) with
well aligned radiotherapeutic and diagnostic (“RadioTheranostic”) properties. The
AuNPs and SPIONs were encapsulated within the hydrophobic core of micelles formed
with the biodegradable, amphiphilic diblock copolymer poly(ethylene glycol)-b-poly(ɛcaprolactone) (Figure 3.1a). The physical-chemical properties of GSMs and their
contrast- and radio-enhancement characteristics were first evaluated in vitro. A focused
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pharmacokinetic and toxicity analysis was subsequently performed in healthy mice.
GSMs were then translated into a murine tumor xenograft model in order to assess their
in vivo imaging, therapeutic, and prognostic benefits.

Figure 3.1. (A) Schematic of gold- and SPIO-nanoparticle loaded polymeric micelles (GSMs). Gold and
SPIO nanoparticles are self-assembled into the hydrophobic core of micelles, stabilized with the
amphiphilic diblock copolymer PEG-b-PCL. Each GSM is composed of approximately hundreds to
thousands of individual gold nanoparticles and tens to hundreds of SPIO nanoparticles. (B) Dynamic light
scattering profile of GSMs in phosphate buffered saline, pH 7.4. The average hydrodynamic diameter is
100 nm. (C) Transmission electron microscopy (TEM) image of a single GSM. The electron micrograph
reveals the incorporation of two size populations of nanoparticles (gold, 1.9 nm; SPIO, 12 nm) tightly
packed within the hydrophobic core (all scale bars = 100 nm). (D-E) Energy dispersive X-ray spectroscopy
analysis on GSM with Au and Fe signals respectively. (F) CT phantoms of GSMs and gold-loaded
polymeric micelles (GPMs) with a sensitivity detection limit around 500 µg Au/mL. (G) MR phantoms of
GSMs and GPMs (sensitivity detection limit 12.5 µg Au/mL (3.48 µg Fe/mL).
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3.3 Materials and Methods
Materials
Laboratory stock chemicals, as well as iron and gold salts, were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Cell culture materials (medium, serum, trypsin,
and antibiotics) were purchased from Invitrogen (Carlsbad, CA, USA). Other materials
were ordered as specified.
Synthesis of hydrophobic 1.9 nm gold nanoparticles
Dodecanethiol-capped gold nanoparticles, 1.9 nm in diameter, were prepared by
the reduction of gold salts in a two-phase reaction, as previously described by Brust et al.
46

Briefly, a 30 mM solution of HAuCl4 (30 mL) was mixed with 80 mL of a 50 mM

solution of tetraoctylammonium bromide in toluene, with the addition of 170 mg (84
mmol) of 1-dodecanethiol. While this two-phase solution was stirring vigorously, a 25
mL aqueous solution of 400 mM NaBH4 was added dropwise at a rate of 1 mL per
minute. The resulting mixture was then allowed to stir for three hours. Next, the aqueous
phase was removed from the organic phase, which contained the AuNPs. The organic
solution was then diluted with three volumes of 95% ethanol, and the mixture was
precipitated overnight at -20°C. The resulting precipitate was then collected via
centrifugation and the supernatant removed. Finally, the gold nanoparticles were
resuspended in toluene to a final concentration of ~ 40 mg/mL.
Synthesis of hydrophobic 12 nm SPIO nanoparticles
Oleic acid stabilized SPIO particles were prepared by thermal decomposition as
previously described by Park et al.47 After allowing the reaction to cool to room
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temperature, two volumes of acetone were added and the resulting mixture was
centrifuged to precipitate the nanoparticles. The particles were then washed in 10 mL
hexane and precipitated again using 35 mL of acetone followed by centrifugation. This
washing procedure was repeated until the supernatant was clear. The particles were then
allowed to air dry and dissolved in toluene at ~ 40 mg/mL.
Synthesis of gold-superparamagnetic iron oxide polymeric micelles (GSMs)
GSMs were prepared using an oil-in-water emulsion-based self-assembly method.
First, polyethylene glycol (4k) – polycaprolactone (3k) (PEG-b-PCL) was dissolved in
toluene to a concentration of 50 mg/mL. A solution (205 µL) containing AuNPs (4 mg),
SPIO (1 mg), and PEG-b-PCL (4 mg) was then injected into a glass vial containing 4 mL
of dH2O and the sample was sonicated (Branson Ultrasonics, Danbury, CT, USA) until a
homogenous mixture was obtained. The toluene was then left uncapped and allowed to
evaporate overnight. For large scale preparation, this synthesis was easily scaled up by a
factor of 10 using a sonic dismembrator (Fisher Scientific, Waltham, MA, USA).
Purification of size-specific GSMs
GSM samples were first centrifuged at 1,000 RCF for 30 minutes to remove large
aggregates. The resulting supernatant then underwent diafiltration using a MidGee hoop
cross flow cartridge with 750 kDa molecular weight cutoff (GE Healthcare, Piscataway,
NJ, USA) in order to remove small impurities and exchange the solution into PBS. GSMs
were then passed through a 0.22 µm SFCA filter (Millipore, Billercia, MA, USA) to
remove oversized particles. Finally, this filtered solution was centrifuged at 31,000 RCF
for one hour, and the pellet was resuspended in PBS. Micelles were then concentrated as
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needed using 50 kDa MWCO centrifugal filter units (Millipore, Billercia, MA, USA) and
exchanged into cell culture media as necessary.
The concentrations of gold and iron in a given micelle sample were measured by
Genesis ICP-OES (Spectro Analytical Instruments GMBH; Kleve, Germany) at the
Department of Earth and Environmental Sciences, University of Pennsylvania, PA, USA.
Analytical standards were purchased from RICCA Chemical Company (Arlington, TX,
USA), and nitric acid and hydrochloric acid were purchased from Fisher Scientific. All
dilutions were done using deionized water (≥ 18 MΩ-cm) obtained from a Millipore
water purification system.
Metal nanoparticle and GSM physicochemical characterization
AuNP and SPIO size distributions were verified by TEM. Stock samples were
diluted in dH2O and deposited on 200-mesh carbon coated copper grids (Polysciences,
Warrington, PA, USA) for TEM imaging with a JEOL 1010 transmission electron
microscope. Mean particle diameters and standard deviations were assessed by measuring
the diameters of 50 individual particles in ImageJ. GSM size distributions and zeta
potentials were measured in pH 7.4 phosphate buffered saline (PBS) by dynamic light
scattering using a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK). GSMs
were also imaged by TEM, using the same method used for individual metal
nanoparticles. GSM relaxivities (r1 and r2) were measured using a Bruker mq60 tabletop
MR relaxometer (1.41 T, 60 MHz). The gold and iron content of the GSMs was assessed
using both a Genesis ICP-OES and energy dispersive X-ray spectroscopy (EDS) mapping
using a JEOL 2010F transmission electron microscope.
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Determination of contrast sensitivity limit
The radiologic sensitivity was determined for both CT and MRI imaging
modalities using 100 nm GSMs. A 384-well plate (well volume of 100 uL) was prepared
using GSMs (100 nm diameter) in dH2O with concentrations ranging from 0 to 3,000 µg
Au/mL. The same setup was duplicated in parallel on the same plate using 100 nm Auonly micelles (GPMs) as a nanoparticle control. A row of pure dH2O was included
between the rows of GSMs and GPMs as a no-particle control. The CT image was taken
at 55 kVp, 5 mAs using the Small Animal Radiation Research Platform (SARRP) at the
Perelman School of Medicine of the University of Pennsylvania. The MR image was
taken with a 9.0 T magnet at the Small Animal Imaging Facility of the University of
Pennsylvania using a gradient echo multislice (GEMS) sequence, TR = 200 ms, and TE =
5 ms. Images were analyzed using ImageJ software. For the CT phantom, Hounsfield
units were computed for each well based upon a linear transformation setting HUair = –
1000 and HUdH2O = 0. In order to reduce image noise, the final CT phantom image was
constructed by averaging together all of the image slices containing a full view of all
pertinent wells from five separate CT scans of the phantom. For the MRI image, the
contrast ratio (CR) was computed as the ratio of the average well intensity for micelle
and water containing wells, respectively. Statistical analysis (α = 0.05) was then
performed to determine the lowest concentrations at which the GSMs gave a contrast
signal significantly different from baseline (i.e. CR = 1 or HU = 0) in each modality. A
similar analysis was performed for the Au-only micelles.
Cell culture and tumor model
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HT-1080 mammalian fibrosarcoma cells were cultured and maintained at 37°C
and 5% CO2 in minimum essential media (MEM), supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin / streptomycin. Six-week old female nu/nu nude mice
(Charles River Laboratory, Charles River, MA, USA) were maintained according to the
regulations of the Institutional Animal Care and Use Committee of the University of
Pennsylvania. Mice were anesthetized using isoflurane and, for xenograft tumor models,
HT-1080 cells (2 x 106 cells in 0.2 mL PBS) were injected into the left flank by
subcutaneous injection.
In vitro assessment of radiosensitization
The radiosensitization effects of GSM were assessed using a γ-h2ax assay to
quantify the number of DNA double-stranded breaks (DSBs) per unit cell area. The assay
was performed using HT-1080 cells, plated at 100,000 cells per well in 4-well chamber
slides (Nunc Lab-Tek II CC2 Chamber Slide System, Thermo Scientific, Waltham, MA).
Three different treatment conditions were evaluated: 100 nm GSMs at a concentration of
100 µg Au/mL, 100 nm AuNP-only micelles (GPMs) at 100 µg Au/mL, and no micelles.
After a 24-hour incubation period, the samples were irradiated with 4 Gy of radiation
(150 kVp, 10 mA) using the SARRP at the Perelman School of Medicine of the
University of Pennsylvania. Three cohorts of treatment slides were used, one each for the
time points T = 0 hours (no radiation), T = 6 hours post-radiation, and T = 12 hours postradiation. At each time point, cells were fixed in 10% neutral buffered formalin (SigmaAldrich) for 10 minutes. After being rinsed with PBS, the nuclei were stained with
Hoechst 33342 (25 µM) for 15 minutes. Slides were then permeabilized with 0.5% Triton
X-100 in PBS and exposed to a blocking buffer composed of PBS, 0.5% Triton X-100,
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5% normal chicken serum, and 1% BSA, for 30 minutes at room temperature. Cells were
then incubated overnight in a humidified chamber at 4ºC with mouse monoclonal antiphosphohistone γ-h2ax primary antibody (JBW301, Upstate) at 1:1500 dilution in PBS
(with 0.5% Triton X-100 and 1% BSA). After approximately 24 hours, slides were
washed with PBS, and a chicken anti-mouse Alexa 594 secondary antibody (Molecular
Probes) was applied at 1:1000 dilution in PBS (with 0.5% Triton X-100 and 1% BSA) for
1 hour. Finally, slides were incubated for 12 hours with ProLong Gold antifade reagent
(Invitrogen) and coverslips applied. Fifteen images were captured of the each slide using
a Deltavision deconvolution microscope (Applied Precision) equipped with a 60x (1.42
NA) oil-immersion lens and thermoelectrically cooled 12-bit monochrome CCD camera.
Images were recorded as z-stacks with 0.3 µm steps. Each image was then processed and
analyzed in order to quantify the number of foci (DSBs) per unit cell area using a custom
ImageJ macro developed by co-author M. Vido.
In vitro characterization of dose-dependent radiosensitization effects
The dose dependence of 100 nm GSMs on radiosensitization was evaluated using
a clonogenic assay. Briefly, HT-1080 cells were grown to confluence, as described
above, and plated at increasing cell concentrations ranging from 200 cells to 4,000 cells
in 60 mm x 15 mm Petri dishes. Prior to irradiation at 150 kVp, 10 mA, the media was
aspirated away and 3 mL of 100 nm GSMs in media were applied to each plate. Each
plate was then exposed to 0 Gy, 2 Gy, 4 Gy, or 6 Gy of radiation, with plates originally
seeded with higher cell concentrations receiving the higher doses of radiation. Following
radiation, the GSM media was aspirated away and replaced with fresh media. The assay
was completed once for each of the following GSM concentrations: 0 µg Au/mL, 25 µg
135

Au/mL, 50 µg Au/mL, 100 µg Au/mL, and 200 µg Au/mL. After waiting 14 days,
colonies were stained with methylene blue. The surviving fraction was then calculated as
S = (number of colonies counted) / (cells seeded * %plating efficiency). Survival curves
were fit to the linear quadratic model, where S = exp[-(αD + βD2)], for the dose, D, and
the constants, α and β. A sensitizer enhancement ratio was computed for each GSM
treatment condition by first computing the mean inactivation dose (MID),48 where
!

MID = !

!
!

!

∗ 𝑒 ! ∗ (1 − erf 𝑧 ), for 𝑧 =

!
! !

. The SER for a given GSM concentration

was then equal to the ratio SER = (MID for radiation alone) / (MID for radiation +
GSMs). GSMs were sterilized before use in this assay by prior irradiation for 500
minutes at 11 Gy/min.
Blood distribution, clearance, and tumor delivery
Three nude mice with HT-1080 tumor xenografts were injected intravenously
under anesthesia with 100 nm GSMs in PBS at dose of 400 mg Au/kg body weight. Postinjection, 10 µL blood samples were collected via the tail-nick method from each animal
at the following times: 0.5, 1, 2, 4, 6, 8, and 24 hours. After the final aliquot of blood was
collected, the animals were sacrificed and the brain, thyroid, heart, lungs, liver, spleen,
small bowel, large bowel, kidneys, inguinal lymph nodes, tumor, skin, bone, and muscle
were removed from each animal. Organ samples were washed with dH2O to minimize
contamination from any nanoparticles still circulating in the blood. The blood samples
and organs were then analyzed for gold content by ICP-OES. Organ samples were
weighed into Teflon PFA vials (Savillex, Minnetonka, MN, USA) and digested overnight
at 37°C with 70% nitric acid to digest the organic material. HCl was added the next day
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to dissolve the AuNPs. Blood samples were dissolved directly in aqua regia. Blood GSM
content was calculated as the percent of the injected dose per gram of blood analyzed
(%ID/g). Organ GSM content was similarly calculated as the percent of the injected dose
present per gram of organ/tumor tissue.
Toxicity studies
Approximately 6 week old female nu/nu nude mice were randomized into four
groups of 3 animals per group receiving 650 mg Au/kg or sham-injected with PBS.
Animals were weighed and observed regularly for clinical signs of toxicity. Animals
were euthanized by CO2 1 day and 8 days after intravenous injections and 0.3 mL blood
was removed from the right ventricle immediately after the cessation of breathing. Blood
chemistry

analytes

included

blood

urea

nitrogen

(BUN),

albumin,

alanine

aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total
bilirubin, cholesterol, creatinine, and gamma-glutamyl transpeptidase (GGT).
In vivo testing of GSMs as a radiosensitizer and MR contrast imaging agent
Four cohorts of mice were prepared with HT-1080 fibrosarcoma tumors in their
left, hind flank as described above. One cohort (n = 8) was preserved as an untreated
control. The next cohort (RT-only, n = 8) was irradiated with 6 Gy of radiation at 17 kVp
and 10 mA using the SARRP. Another cohort (GSM-only, n = 7) was injected
intravenously with 100 nm GSMs in PBS at a dose of 400 mg Au/kg body weight. Prior
to contrast administration, the final cohort (GSM+RT, n = 7) was first imaged by CT (55
kVp, 5 mAs) and MRI (GEMS sequence, 200 ms TR, 5 ms TE). Next, the GSM+RT
mice were injected as described above with 100 nm GSMs. Twenty four hours later, post-
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injection images were acquired using MRI and CT, followed by a single 6 Gy irradiation
at 150 kVp and 10 mA. Tumor volumes were monitored thrice weekly using a dial
caliper, and the tumor volume was computed as V = (π/6)*A*B*C, for A, B, and C, the
three tumor diameters. Mice were deemed ready to enter the treatment protocol when
their average tumor diameter was between 7 and 8 mm. Mice were sacrificed if their
average tumor volume rose above 1,300 mm3, if their tumors became severely ulcerated,
or if the mice appeared emaciated (as per IACUC regulations). Progression was defined
as occurring on the first of three consecutive days of increasing volume, following the
initial period of tumor shrinkage after irradiation. Remission was defined as occurring on
the first of three consecutive days of zero palpable tumor volume, following the initial
period of tumor shrinkage post-irradiation.
Pre- and post-contrast MR images were analyzed using ImageJ software. The
average intensity inside a region of interest (ROI) drawn around the tumor and inside a
region of nearby muscle was computed for each image. The relative signal intensity (rSI)
was computed as the ratio of average intensity inside the tumor ROI to average intensity
inside the muscle ROI for a given image. Finally, the contrast enhancement of a given
mouse was then computed as the ratio of post-contrast and pre-contrast CT scores.
Using tumor volume data, the average initial rate of tumor shrinkage postradiation was computed for the GSM+RT mouse cohort. The initial rate of tumor
shrinkage was computed using the largest tumor volume reached before the tumor began
shrinking and the tumor volume reached approximately 15 days later (or on the first day
of tumor remission, if it occurred before 15 days). These average tumor shrinkage rates
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were then correlated to the contrast enhancement for the mice from which they were
derived.
Numerical and statistical analysis
All numerical and statistical analysis was performed in Microsoft Excel. Where
appropriate, a Student’s t-test was used to determine if differences were statistically
significant. For the survival studies, the Prism 5 (GraphPad software) was used to
perform log-rank survival analysis on data presented in Kaplan-Meier curves. All error
bars are reported as standard error of the mean.
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3.4 Results and Discussion
Physical characterization of GSMs
Dodecanethiol-terminated AuNPs and oleic acid-stabilized SPIONs were
synthesized with mean diameters of approximately 1.9 nm and 12 nm respectively, as
measured by transmission electron microscopy (TEM) (Figure 3.2). Using an oil-in-water
emulsion method, GSMs were then prepared with a mean hydrodynamic diameter of 100
nm and low polydispersity (PDI < 0.10) (Figure 3.1b). Although the different sizes of the
AuNPs and SPIONs allow TEM to provide a cursory determination that both particle
types have been incorporated into the micelles (Figure 3.1c), the presence of both Au and
Fe was further verified through energy dispersive X-ray spectroscopic analysis of the
micelles (Figure 3.1d-e). Furthermore, the spatial arrangement of particles in the micelles
was examined using tomographic electron microscopy. These data illustrate that SPIONs
can be found throughout the entire GSM volume, interspersed with the smaller AuNPs,
and are not restricted to either the center or the periphery of the hydrophobic core.
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Figure 3.2. Electron micrographs of (A) AuNPs and (B) SPIO nanoparticles were acquired using a JEOL
1010 transmission electron microscope (scale bars = 30 nm). (C) The size distribution of AuNPs and SPIO
nanoparticles was determined by measuring the diameter of 50 individual particles. The average diameters
of these particles are 2.20 ± 0.44 nm and 13.6 ± 2.72 nm (± standard deviation), for AuNPs and SPIONs
respectively.

The average mass ratio of gold-to-iron in these samples was 5.53 ± 0.50:1, as
determined by inductively coupled plasma optical emission spectroscopy (ICP-OES).
GSMs were easily mass-producible and yielded a longitudinal relaxivity r1 = 0.536 ±
0.121 mM-1s-1 and a transverse relaxivity r2 = 232.9 ± 11.7 mM-1s-1 at 1.41 T (60 MHz)
(Figure 3.3). The zeta potential of GSMs was -1.55 ± 0.19 mV.
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Figure 3.3. GSM transverse relaxivity (r2) was measured using a Bruker mq60 tabletop MR relaxometer
(1.41 T, 60 MHz) for five different batches of GSMs. The average r2 relaxivity for these batches was found
to be 236.9 mM-1 s-1.

A ssessment of GSM imaging characteristics
To assess the lower detection limits of GSMs via CT (Figure 3.1f) and MR
(Figure 3.1g), phantom images were acquired using decreasing concentrations of GSMs
dispersed in deionized water. GSMs were compared to micelles containing AuNPs only,
i.e. gold-loaded polymeric micelles (GPMs),18 to determine the effects of substituting
SPIONs for AuNPs on CT contrast.
The concentration at which both GSMs and GPMs showed a statistically
significant difference in Hounsfield units from baseline (HU of deionized water = 0) was
500 µg Au/mL (at 55 kVp, 0.5 mA), which was consistent with previous studies.21 There
was no significant difference in the Hounsfield units between the GSM or GPM wells,
indicating that, at this Au:Fe ratio, the addition of Fe had no substantial effect on CT
contrast. Figure 3.1g shows that the lower detection limit for detecting GSMs by T2
weighted MR was 12.5 µg Au/mL (3.48 µg Fe/mL). No MR contrast from baseline was
detected using GPMs for all concentrations, which was expected given that GPMs do not
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contain any paramagnetic material. Therefore, 40-fold less GSMs are required for
detection via MR imaging than either GSMs or GPMs for detection via CT imaging.
Evaluation of GSM radiosensitizing properties
To evaluate the radiosensitization effects of GSMs in vitro, HT-1080 human
fibrosarcoma cells were irradiated (4 Gy) or mock irradiated in the presence of GSMs
(100 µg Au/mL), GPMs (100 µg Au/mL), or no micelles, and analyzed for doublestranded breaks (γ-h2ax staining) (Figure 3.4a). The number of DNA double-stranded
breaks correlates with the overall absorbed radiation dose.22,23 It was found that the
number of γ-h2ax foci / 100 µm2 (observed as bright fluorescent spots) was enhanced by
1.4 and 2.2 times at 6 hours and 12 hours post-radiation respectively (Figure 3.4b), when
either GPMs or GSMs were applied, compared with radiation alone. Both GSMs and
GPMs

provide

statistically

similar

amounts

of

radiosensitization

in

vitro.

Immunofluorescent images revealed very low levels of γ-h2ax foci in unirradiated cells,
regardless of the presence of GPMs or GSMs.
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Figure 3.4. In vitro evaluation of radiation induced DNA double-stranded breaks and cell survival in the
presence and absence of GSMs/GPMs. (A) Immunofluorescent imaging of γ-h2ax foci in HT-1080 cells
incubated with GSMs (100 µg Au/mL), GPMs (100 µg Au/mL) or without micelles in the absence (top) or
presence (bottom) of irradiation (4 Gy, 150 kVp). (B) Quantitative analysis of γ-h2ax foci density (#
foci/um2) for n > 100 cells in each treatment group. Error bars represent 95% confidence intervals. The
number of γ-h2ax foci / 100 µm2 (observed as bright fluorescent spots) was enhanced by 1.4 and 2.2 times
at 6 hours and 12 hours post-radiation respectively. (C) Clonogenic assay of HT-1080 cells treated with and
without GSMs (25, 50, 100, and 200 µg Au/mL) and given radiation doses of 0, 2, 4 and 6 Gy (150 kVp).
Error bars represent the mean survival ± standard error of at least three replicates. (D) Plot of sensitizer
enhancement ratio (SER) vs concentration of GSMs. The SER increases linearly as the GSMs
concentration is also increased (R2 = 0.993).

Clonogenic assays were performed on HT-1080 cells that were treated with
increasing GSM concentrations and radiation at 4 Gy, revealing a dose dependent
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response to both radiation dose and GSM concentration in vitro (Figure 3.4c). The
sensitizer enhancement ratio (SER), a measure of how effectively a radiosensitizer
reduces tumor cell proliferation, increased linearly (Figure 3.4d, R2 = 0.993, slope p <
0.001) as the concentration of GSMs was increased. The SER for a GSM dose of 100 µg
Au/mL was 1.32, which is comparable to the SER for other AuNP formulations found in
the literature.17,24
GSM Pharmacokinetics and phamacodynamics
To evaluate the pharmacokinetic and pharmacodynamic properties of GSMs, the
blood clearance profile (Figure 3.5a), organ biodistribution (Figure 3.5b), and blood
chemistries (Table 3.1) were acquired following intravenous injection of GSMs into HT1080 tumor-bearing, nu/nu mice. The clearance of GSMs from circulation followed a biexponential profile with a 1.45 h half-life for the distribution phase and a 17.5 h half-life
for the elimination phase (Figure 3.5a).
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Figure 3.5. Blood clearance profile of GSMs. (A) ICP-OES analysis of gold content in blood at various
times following the intravenous administration of GSMs to mice (n = 3). (B) ICP-OES analysis of gold
distribution at 24 hours and 8 days following the administration of GSMs. The percent injected dose per
gram of tissue was calculated by measuring the concentration of gold in excised organs via ICP-OES.
There is a statistically significant decrease in the content of gold in tumors of mice receiving GSMs (p <
0.05).

146

Table 3.1. Blood Chemistry* Serum clinical chemistry of mice injected with 450 mg Au/kg GSMs (0.2
mL) and sampled at 24 hours and 1 week compared with mice sham injected with phosphate buffered
saline (0.2 mL). All values were within normal limits and n = 3 for all groups. Data is recorded ± standard
error.
BUN

Albumin

ALT

AST

Alk. Phos.

Day 1 GSMs
Control
Day 8 GSMs
Control

25.7 ± 3.2
24.3 ± 1.3
21.5 ± 3.6
16.0 ± 3.7

3.1 ± 0.3
2.7 ± 0.3
2.4 ± 0.1
2.3 ± 0.7

501 ± 149
430 ± 290
121 ± 18
318 ± 190

927 ± 183
506 ± 194
336 ± 78
421 ± 227

157 ± 48
111 ± 13
109 ± 26
78 ± 18

GGT

Total Bil.

Cholesterol

Creatinine

Day 1 GSMs
Control
Day 8 GSMs
Control

45.4 ± 16.9
15.2 ± 7.3
15.0 ± 4.7
27.0 ± 9.4

4.5 ± 0.9
1.7 ± 0.7
1.1 ± 0.2
1.5 ± 0.6

200 ± 4
91 ± 2
112 ± 26
173 ± 45

0.10 ± 0.2
0.18 ± 0.2
0.13 ± 0.2
0.18 ± 0.2

*BUN, creatinine, total bili (total bilirubin), and cholesterol are in units of mg/dL. ALT, AST, alk. phos.
(alkaline phosphatase), and GGT are in units of U/L. Albumin is in units of g/dL. Blood samples were
obtained from mice injected with 400 mg Au/kg of GSM or sham injected with saline. Data is recorded ±
standard error.

The organ biodistribution of GSMs, as percent injected dose per gram of tissue
(%ID/g), was acquired 24 hours and 8 days post-injection of GSMs. The high proportion
of GSMs found in the spleen and liver suggest that GSMs are cleared primarily through
the reticuloendothelial system, as has been previously observed for other PEG-b-PCL
micelle formulations.18 It is interesting to note that there is high GSM uptake within the
inguinal lymph nodes, an observation consistent with GSM extravasation and/or
trafficking of cells from other lymphoid organs.
Gold is primarily excreted within feces, with very little found in the urine. Similar
amounts of gold are found in the feces on both day 1 and day 8 post-injection, suggestive
of continual excretion. Accordingly, the concentration of Au found in the spleen and the
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liver decreases significantly over the course of a week. This result is very encouraging, as
most tissue biodistribution studies that have been performed following the injection of
AuNPs composed of a single, large gold core (> 10 nm) have indicated very poor
excretion profiles.25-28 For example, it has been found that there is only a 9% fall in the
content of gold in the liver from day 1 to 6 months, following the intravenous injection of
40nm AuNPs.28 It is hypothesized that the encapsulation of very small (1.9 nm) AuNPs
into a larger GSM construct may facilitate more rapid dissolution and excretion than
larger, single-particle systems.
The intravenous injection of GSMs (400 mg Au/kg) into healthy mice led to no
signs of illness, change in activity, or weight loss (Figure 3.6). Notably, the amount of
gold administered was well below the LD50, which was previously reported to be 3.2 g
Au/kg.29 A toxicological analysis of mice 1 day and 8 days following the administration
of GSMs (400 mg Au/kg) revealed blood chemistries that were not statistically different
from those of saline injected controls (Table 3.1).
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Figure 3.6. Whole animal weights of tumor-free mice treated with 400 mg Au/kg GPMs compared with
mice sham injected with phosphate buffered saline. Data reflect average weights (n = 3) for each group.
The average weights of the two cohorts do not differ significantly over the studied time period (p > 0.05).

In vivo imaging and therapy
HT-1080 cells were injected subcutaneously into the back left flank (2 x 106 cells
in 0.1 mL of PBS) of 6 week old female nu/nu mice. Tumors were grown until the mean
tumor diameter was approximately 7 – 8 mm. Next, tumor-bearing mice were split into
four cohorts – (i) no treatment (n = 8); (ii) GSMs only (400 mg Au/kg, n = 7); (iii)
radiation therapy (RT) only (6 Gy, n = 8); (iv) GSMs plus RT 24 h post-injection (n = 7).
Animals in the GSM+RT cohort were imaged using MRI and CT both prior to and 24 h
following GSM injection. After imaging, mice underwent tumor localized radiation
therapy and were followed for 90 days with their tumor sizes measured periodically.
Representative pre- and post-contrast images of a single mouse using both CT and
MRI are shown in Figure 3.7a-b. Note that at this GSM dosage no enhancement is visible
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with CT imaging, but the tumor is hypointense on MRI, consistent with SPIONs
accumulation, effectively revealing the proximal edge of the tumor. To quantitatively
determine the amount of GSMs delivered to the tumor, an analogous study was
performed (n = 3), whereby the tumors were harvested 24 hours post-injection and the
gold content was analyzed by ICP-OES. It was determined that the tumors possessed
6.64% ID of Au/g tumor (6.64% ID of Fe/g, assuming intact GSMs). Upon adjusting for
tumor volume, the average concentration of gold within the tumor was calculated to be
0.55 ± 0.17 mg Au/mL (99 ± 3 µg Fe/mL). This is at the lower detection limit for gold by
CT (i.e. ~ 0.5 – 1.0 mg/mL), but well above the lower detection limit for SPION via MRI
(i.e. ~ 0.87 – 1.74 µg Fe/mL). These tumor concentrations are also well above the 0.1 mg
Au/mL needed for a radiosensitization effect, based on the in vitro analysis. A silver
enhancement stain performed on tumor histology sections of mice injected with GSMs
confirmed the presence of AuNPs throughout the tumor. No enhancement was observed
in mice that were administered saline (Figure 3.7c).
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Figure 3.7. In vivo imaging and intensity analysis of a single nu/nu nude mouse with a HT1080 flank
tumor. (A) Representative CT (top) and MR (bottom) images in the axial plane prior to injection (precontrast) and 24 h post-injection (postcontrast) of GSMs (400 mg Au/kg) (n = 7). Tumors are indicated by
white arrows. No enhancement is visible via CT imaging. (B) Quantitative analysis of CT and MR images.
Signal intensity of each tumor was normalized to adjacent paraspinal muscle. For contrast measurement,
the relative signal intensity, RSI, was calculated as the quotient of the post-contrast to pre-contrast
normalized tumor intensity. Statistically significant values of p < 0.05 are indicated with an asterisk. (C)
Representative histologic sections of HT-1080 tumors excised from mice 24 hours after i.v. injection with
saline (left) or GSMs (right) stained with H&E (top) and a silver enhancement (bottom). (D) Plot of initial
rate of tumor volume decrease vs the % change in tumor contrast for all mice (n = 7) receiving GSMs (400
mg Au/kg) plus radiation therapy (6 Gy, 150 kVp) in the survival study (see Figure 5). There is a strong
linear correlation between the contrast enhancement and tumor response (R2 = 0.95).
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Following imaging, mice were monitored for tumor growth and were sacrificed
when the tumors reached the predetermined threshold volume (1,300 mm3). The survival
time was measured from the time of radiation (or mock irradiation). Mice that received
GSMs prior to radiation therapy exhibited a statistically significant (p < 0.05)
improvement in median survival (75.6 ± 9.2 d), compared to mice treated with radiation
alone (50.4 ± 10.6 d) (Figure 3.8a). It should be noted that all mouse groups appeared to
tolerate GSMs very well over the course of study with no observable changes in behavior
or symptoms of hepatic or gastrointestinal toxicity, such as loss of appetite, diarrhea, or
vomiting. The mean survival times for the control and GSM-only mice were not
statistically different at 20.0 ± 2.5 d and 25.7 ± 2.6 d, respectively. The general
observable trend in tumor growth post radiation therapy was a reduction in tumor growth,
followed by a reduction in tumor volume and then either eventual tumor re-growth or
remission (Figure 3.8b). A significantly larger (p < 0.05) proportion of mice from the
GSM+RT group derived a complete response with no discernable tumor (71%) compared
to the mice in the RT-only group (14%). Note that of the two surviving mice in the RTonly group, one mouse derived a complete response and the other mouse had a residual,
palpable but stable mass at the end of the study period.
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Figure 3.8. (A) A Kaplan-Meier survival analysis was performed for HT-1080 tumor-bearing mice
receiving no treatment (n = 8, dotted grey line), GSMs only (n = 7); (dotted black line), radiation therapy
(RT) only (n = 8, solid grey line), or radiation therapy plus 24 h intravenous injection of GSMs (n = 7, solid
black line). GSMs were administered at a dose of 400 mg Au/kg. The radiation dose administered was 6
Gy at 175 kVp. The asterisk indicates statistical significance (p < 0.05). (B) Average tumor volumes over
time of mice receiving GSMs with radiation therapy (solid line) or radiation therapy alone (dotted line).

To evaluate the predictive value of GSM–enhanced MR imaging, we compared
the tumor contrast enhancement to the rate of tumor volume decrease following
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irradiation. The analysis revealed a strong correlation (R2 = 0.95) between contrast
enhancement and tumor response (Figure 3.7d). This relationship is consistent with the in
vitro data linking GSM dose to the efficacy of radiosensitization and provides a
promising mechanism to guide follow-up treatment accordingly.
The GSMs reported here address the aforementioned disparity between the dose
of gold-only particles needed to obtain therapeutic benefit and the dose needed for
imaging enhancement. The MR imaging enhancement provided by GSMs was highly
robust, due to their high transverse relaxivity (r2 = 233 mM-1s-1) and consequent
nanomolar sensitivity. This is similar to the characteristics of SPIO-only formulation30
and allowed tumor boundaries to be readily identified and the extent of GSM uptake to be
assessed. Therefore, GSMs could enable radiation oncologists in more accurately
planning both the geometric and dosimetric aspects of radiation therapy.
Unlike

many

other

dual

imaging-treatment

nanoparticles,

which

use

chemotherapeutics as their payload,31,32 GSMs are not inherently cytotoxic and only exert
their therapeutic effects under the influence of ionizing radiation. Coupled with the need
for lower concentrations to achieve imaging, these properties render GSM extraordinarily
safe. Accordingly, the administration of GSMs did not result in any significant changes in
weight, blood chemistry, or behavior.
At the radiation energies tested, GSMs provided a potent dose-dependent
enhancement of DNA double-stranded breaks and SER in vitro. They also significantly
increased survival and tumor response in vivo, compared with radiation treatment alone.
The linear relationship between the contrast enhancement and therapeutic response
further supports the dose dependent radiosensitization of tumor cells. The GSM-mediated
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radiation enhancement effects are expected to allow physicians to increase the efficacy of
a given overall dose or radiation therapy administered, with no incremental risk to normal
tissues.
While MR contrast and therefore GSM localization correlated with the initial rate
of tumor volume decrease, there was no correlation observed between the level of image
contrast and overall therapeutic outcome. This dissociation of initial response and clinical
end point may be due to differences in the tumor microenvironment (e.g. hypoxia,
inflammatory reaction, heterogeneous vasculature), which predispose certain tumors to
either an early, necrotic response or a delayed apoptotic response to radiation therapy.
The relationship between gold-enhanced radiation therapy and the mechanism of tumor
cell death bears further investigation.
The accumulation of GSMs in tumors is mediated by the EPR effect. However,
EPR has been shown to vary from tumor to tumor with the level of tumor
vascularization.33-35 Differences in vascularization lead to variations in the tumoral
delivery of nanoparticle-based therapeutic agents and thus a large variability in
nanoparticle treatment efficacy.36 However, because GSM-enhanced MR imaging can be
used to quantify the tumor penetrance, tumor dosimetry planning can be adjusted
accordingly.
While EPR alone may not be sufficient to produce widespread dissemination of
GSMs throughout all tumors, the administration of GSMs over the course of a
fractionated radiation therapy regiment may promote the spatially targeted delivery of
GSMs into the tumor. Recent MRI studies have shown that radiation can increase the
permeability of tumors to gadolinium in human patients.39 Additionally, it has recently
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been shown that radiation therapy can enhance the delivery of nanopolymers (diameter ≈
40-70 nm),40 pegylated near-infrared fluorescent probes,41 and pegylated AuNPs
(diameter ≈ 23 nm)17 to tumors in murine models. These data suggest that targeted
radiation therapy can enhance the uptake of circulating nanoformulations by increasing
vascular and interstitial permeability.
At 150 kVp, the most likely mechanism for the dose enhancement effects of gold
is the photoelectric effect,8,9 leading to extensive DNA damage. The attenuation of Xrays with depth at this energy makes the treatment of superficial tumors by external beam
radiation, the enhancement of brachytherapy, and the enhancement of intra-operative
radiation therapy three possible applications for GSMs. Furthermore, other research has
already illustrated the efficacy of gold nanoparticles in enhancing radiation therapy at
higher, megavoltage energies (e.g. 6 MV) more commonly seen in the clinical treatment
of deep-seated tumors.24,42 As the photoelectric cross-section is nearly zero at these
higher energies, the likely radiosensitization mechanism is not photoelectric, but
potentially relies on the generation of reactive oxygen species to cause cellular damage or
on other scattering mechanisms.43,44 The use of platinum (atomic number ZPt = 78) to
enhance proton beam therapy suggests that GSMs (ZAu = 79) may also have a role in
enhancing proton-mediated radiation therapy.45
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3.5 Conclusions
In conclusion, incorporating GSMs with radiation therapy could augment cancer
treatment by facilitating imaging, increasing the efficacy of therapy, and helping to
predict response. Moreover, since GSMs are prepared using a highly modular synthetic
pathway, additional components, including standard and alternative therapeutics could
readily be incorporated into the micelle’s core while targeting moieties (e.g. tumorspecific antibodies or Fab’s) can be coupled onto the unobstructed micelle surface,
further broadening the range and types of tumors that can be effectively treated. The
extravasation properties of these particles may also make them useful in treating diseases
localized to regional lymph nodes, such as Hodgkin’s lymphoma. Therefore, it is
envisioned that translation of GSM to oncology could have far reaching implications.
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Chapter 4: Superparamagnetic Iron Oxide Nanoparticle
Micelles Stabilized by Recombinant Oleosin for Targeted
Magnetic Resonance Imaging

4.1 Abstract
A wide variety of nanoplatforms are being developed for the diagnosis and detection of
malignancies. However, a major limitation of many of these approaches is that they
exploit passive mechanisms of targeting. Passively targeted nanoparticles accumulate
preferentially in tumors primarily due to the EPR effect, but nanoparticle retention is
nonspecific relying primarily on high vascular permeability and poor lymphatic drainage
at the tumor site. Conversely, actively targeted nanoparticles exploit targeting and
binding to specific receptors present on tumor cells. Therefore the use of an actively
targeted nanoplatform can achieve higher tumor retention, facilitate nanoparticle
internalization for improved efficacy, and improve tumor specificity. To facilitate the
introduction of targeting molecules onto micelle formulations, a naturally occurring
surfactant protein oleosin was used to stabilize superparamagnetic iron oxide clusters.
Functionalization of these particles with targeting ligands (e.g. Her2/neu affibody) was
then achieved by simply fusing the biologically relevant motifs to oleosin using standard
cloning techniques. Using this approach, nanoparticle formation and functionalization
was completed in one step without the requirement of post-synthesis surface
modifications. Specific targeting was confirmed through cell binding assays in the
presence and absence of a competitive inhibitor and quantified using magnetic relaxation
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techniques. We envision that oleosin stabilized nanoparticle micelles will represent a
promising platform for therapeutic and imaging applications, since size, charge, targeting
moiety, and solubility can all be easily modified with high precision and essentially no
variability.
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4.2 Introduction
Superparamagnetic iron oxide (SPIO) nanoparticles have gained interest for use
as magnetic resonance contrast agents, with the ability to provide T2 weighted contrast
enhancement on MR imaging applications.1-4 Their strong contrast enhancing capabilities
have rendered them useful for molecular imaging applications with various targeting
molecules being conjugated to the surfaces of SPIO nanoparticles.5-8 These strategies
have the potential to increase tumor accumulation, specificity, and therapeutic efficacy.
The prerequisite for any targeted nanoparticles is the successful bioconjugation of ligands
onto the nanoparticle surface, some which have low reaction efficiencies, require
multiple conjugation steps, and often create products with poorly oriented antibodies.
Developing recombinant proteins that can stabilize SPIO nanoparticles would allow for
the functionalization of particles in the formulation step by directly modifying the protein
through molecular biology.
We chose to engineer the naturally occurring surfactant protein oleosin.9 Oleosin
is expressed in plant seeds with the native function of stabilizing fat reservoirs called oil
bodies. The protein consists of three domains, a central hydrophobic domain flanked by
two hydrophilic arms on the C- and N-terminus.9,

10

The protein resembles a hairpin

structure with a proline knot embedding in the central hydrophobic domain that forces a
180° turn.11 Recombinant oleosin has been exploited for it surfactant nature in many
biotechnology applications.12-17
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4.3 Materials and Methods
Gene synthesis
Genes were created using standard molecular biology techniques. All mutants
were confirmed through DNA sequencing. Oleosin-30G(-)was created from the template
Oleosin-30G18 using sequential PCR steps with the following primers: 1S 5’ –
GATCAGCATGATCAACACACCGGTGACCAGCTCACCCACCCACAGGACCAGC
AACAAGGCCCCTCAACCGGCGAACTCGCTCTCGGTGCGACTCC -3’, 2S 5’ –
AATTCAATAGGATCCGAAGCCACCACAACCAACGACCAGCACCATGTCACCA
CCACCCAACCCCAAGATCAGCATGATCAACACACC

–

3’,

1AS

5’

–

TATCTGCTGGCCCAAGTCGTTCGTGTTCTGGCCCGTCTGCTCCCCCACATCCT
GCAATTCCCCGTTCACGTTATCCTGCCACTGAAACCCGGTAACACC – 3’, 2AS
5’

–

TTCTGCCCTTCGTTCCCACCACCCTGACCCTGACCCTGGCCCTGGTCA

CCCATTTCATGGGCCGTATGCTGTATCTGCTGGCCCAAGTCG – 3’, 3AS 5’ –
TTTATGAATCTCGAGTCAGTCATCGTGGTGGTGGTGGTGGTGGTTCCCCCCTT
CGTTCTGCCCTTCGTTCCCACC – 3’. The Oleosin-30G(-) PCR product was cloned in
the expression vector pBamUK. The Her2 affibody was amplified using the primers Her2
1S 5’ – GATGCGCAGGCGCCGAAAGGCGGCGGTGGCGGTAGC – 3’, and Her2
fusion AS 5’ – GGTTGTGGTGGATCCTTTCGGCGCCTGC – 3’ and cloned into the
vector pBamUK-Oleosin-30G to create pBamUK-Her2-Oleosin-30G. The gene for the
expression of the Her2 affibody alone was created using the following primers: Her2 1S
5’ – GATGCGCAGGCGCCGAAAGGCGGCGGTGGCGGTAGC – 3’, and Her2 AS 5’
– TAGATAATTCTCGAGTTTCGGCGCCTGCGCATCG – 3’ and cloned into
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pBamUK. pBamUK adds a 6-histidine tag onto the C-terminus of the protein to allow for
immobilized metal affinity chromatography (IMAC).
Protein production and purification
Mutants were expressed under the control of the lac promoter in E. coli (BL21
DE3, Stratagene). The protein mutants were solubilized according to the B-PER protocol
and purified using IMAC following the Hispur Ni-NTA resin protocol. Mutants were
expressed under the control of the lac promoter in E. coli (BL21 DE3, Stratagene).
Cultures

were

grown

until

OD600~0.7

and

induced

with

isopropyl

β-D-1-

thiogalactopyranoside to a final concentration of 1.0 mM (Fisher Scientific). Cells were
pelleted at 5,000 RPM and frozen at -20°C prior to purification. Oleosin-30G(-) and the
Her2 affibody were expressed solubly, whereas the fusion Her2-Oleosin-30G was
expressed in inclusion bodies. The protein mutants were solubilized according to the BPER protocol for soluble or insoluble proteins respectively. Unpurified protein solutions
were added to Ni-NTA beds (Hispur Ni-NTA resin, Thermo Scientific) and allowed to
bind to the column ~ 1 hour at room temperature. Protein was washed and eluted in
fractions according to the Hispur protocol. Protein concentration was measured using a
Nanodrop-1000 (Fisher Scientific). Buffer exchanges were completed with dialysis or
with centrifugal filters (Amicon Ultra, 3 kDa, Millipore).
Protein sequences
Oleosin-30G(-)
GSEATTTNDQHHVTTTQPQDQHDQHTGDQLTHPQDQQQGPSTGELALGATPLF
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GVIGFSPVIVPAMGIAIGLAGVTGFQWQDNVNGELQDVGEQTGQNTNDLGQQIQ
HTAHEMGDQGQGQGQGGGNEGQNEGGNHHHHHHDD
Her2-Oleosin-30G
VDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLND
AQAPKGSTTTYDRHHVTTTQPQYRHDQHTGDRLTHPQRQQQGPSTGKLALGAT
PLFGVIGFSPVIVPAMGIAIGLAGVTGFQRDYVKGKLQDVGEYTGQKTKDLGQKI
QHTAHEMGDQGQGQGQGGGKEGRKEGGKLEHHHHHH
Her2
VDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLND
AQAPKLEHHHHHH
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PA GE)
SDS-PAGE gels were run in MES buffer with NuPAGE Novex 4–12% Bis-Tris
mini gels (Invitrogen). After electrophoresis, the gels were stained with SimplyBlue
Safestain (Invitrogen) and destained in water overnight. The resulting gel was imaged
with a Kodak Gel Logic 100 Imaging station.
Matrix assisted laser desorption/ionization time of flight mass spectroscopy (MA LDITOF)
MALDI-TOF spectra were used to confirm the molecular weights of the mutants.
Sample spots were created with 0.5 µL protein in pH 7.4 phosphate buffered saline (PBS)
and 0.5 µL saturated sinapinic acid solution (50/50 acetonitrile/water + 0.1% TFE).
Spectra were collected on an Ultraflextreme MALDI-TOF (Bruker, Billerica, MA).
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Circular dichroism (CD)
Far-UV CD spectra were collected on an AVIV 410 spectrometer (AVIV
Biomedical Inc.) at 25 °C in 1 mm quartz cuvettes. Protein concentration was 10 µM in
10 mM phosphate, 140 mM NaF due to the high signal from the Cl- ion in PBS.
Fe2O3 synthesis
Superparamagnetic iron oxide nanoparticles were synthesized according to a
protocol adapted from Cheon et al.19 Briefly, 0.6 mmol of Fe(CO)5 dissolved in 0.3 mL
of ortho-dichlorobenzene (ODCB) was rapidly injected into a hot solution containing 1.2
mL of ODCB and 0.6 mmol of dodecylamine (DDA). The resulting mixture was
maintained at 180ºC under aerobic conditions. During this process, the initial orange
color of the solution gradually changed to slightly brownish black. After 9 hours, the
resulting solution was cooled to room temperature and an approximately 3-fold volume
excess of toluene was added to adjust the solubility of the nanocrystals. The nanoparticle
solution was then centrifuged to remove nanoparticle aggregates. After adding ethanol
into the remaining solution, resulting black flocculates were isolated by centrifugation.
Nanoparticle assembly and purification
Fe2O3-oleosin micelles were synthesized using an oil in water emulsion and
purified using sequential centrifugation as previously reported.20 Fe2O3-oleosin micelles
were synthesized using an oil in water emulsion and stabilized with Oleosin-30G(-).
Fe2O3 nanoparticles were dissolved in toluene at a concentration of 80 mg/mL. Protein
stocks were diluted into sterile PBS to a concentration of 2 mg/mL. The FeO
nanoparticles in toluene (50 µL) were directly injected to the protein solution and
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sonicated until a uniform emulsion was created and no visible iron aggregates existed.
The emulsion was allowed to dry overnight at room temperature. The particles were
purified using sequential centrifugation. The solution was centrifuged at 380 RCF for 10
minutes and large aggregates were removed in the pellet. The supernatant was
centrifuged at 4646 RCF for 30 minutes and the resulting supernatant was removed. Two
pellets exist from this spin, a soft soluble pellet, and a hard, insoluble pellet of
aggregates. The soft pellet was removed and used for further studies. The nanoparticles
were concentrated and solution exchanges were completed using centrifugal filters
(Amicon Ultra, 50 kDa MWCO, Millipore).
Dynamic light scattering
Dynamic light scattering of nanoparticle solutions was performed on samples in
PBS using a Malvern Zetasizer Nano ZS (Westborough, Massachusetts). Each sample
was run in triplicate.
Cryogenic transmission electron microscopy (Cryo-TEM)
Cryogenic transmission electron microscopy was performed at the University of
Pennsylvania in the Nanoscale Characterization Facility (Philadelphia, PA). Lacey
formvar/carbon grids (Ted Pella) were rinsed in chloroform to remove the formvar
template. The resulting grids were carbon coated with a Quorum Q150T ES carbon coater
(Quorum Technologies, United Kingdom). Grids were cleaned with hydrogen/oxygen
plasma for 15 seconds using the Solarus Advanced Plasma System 950 (Gatan,
Pleasanton, CA). A 2 µL drop of nanoparticles in PBS was deposited onto the grid and
added to a Gatan Cp3 cryoplunger (Gatan, Pleasanton, CA). The samples were blotted by
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hand and plunged into liquid ethane. Grids were transferred to a Gatan CT3500TR
cryoholder (Gatan, Pleasanton, CA) and immediately inserted into a JEOL 2100 HRTEM
(JEOL, Tokyo, Japan) operating at 200 keV. Micrographs were imaged with an Orius
SC200 digital camera.
Stability
Particles were incubated at 37°C for 5 days in either PBS or DMEM plus
glutamax, 10% FBS, and penicillin streptomycin. DLS measurements were taken daily to
monitor for particle degradation or aggregation.
Cell lines
NIH/3T3 and T6-17 cells (i.e., NIH/3T3 cells engineered to stably express the
Her2/neu receptor, kindly provided by Dr. Mark Greene, University of Pennsylvania)
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum, 1% penicillin/streptomycin at 37°C, and 5% CO2.
Cell V iability A ssay
The viability and proliferation of cells in the presence of FeO-oleosin
nanoparticles were evaluated by 3-[4,5-dimethylthialzol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT, Sigma) assay. The assay was performed in triplicate in the following
manner. NIH/3T3 cells were seeded into 96-well plates at a density of 1 x 104 cells per
well in 200 µL of media and grown overnight. The cells were then incubated with various
concentrations of FeO-oleosin (0, 0.025, 0.05, 0.075, 0.1, and 0.15 mg Fe/mL) for 4
hours. Following incubation, cells were incubated in media containing 0.1 mg/mL of
MTT for 1 hour. Thereafter, MTT solution was removed, and precipitated violet crystals
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were dissolved in 200 ìL of DMSO. The absorbance was measured at 560 nm.
Her2/neu targeting
T6-17 and NIH/3T3 cells were incubated with 100 µg Fe/mL of Her2/neutargeted SPIO micelles for 45 minutes in full media in triplicate. The media was removed
and the cells were washed with PBS two times to remove any unbound micelles. Cells
were trypsinized and counted. Cell suspensions were diluted to 0.4 × 106 cells/mL and T2
relaxation times were measured using a benchtop relaxometer (Bruker mq60).
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4.4 Results and Discussion
We have previously engineered oloesin to self-assemble into vesicles, fibers or
sheets

by

creating

a

family

of

truncation

mutants

thereby

varying

the

hydrophilic/hydrophobic ratio of the surfactant protein.21 Further truncations of the
hydrophobic block have led to soluble oleosin mutants that spontaneously self-assemble
in aqueous solution as a function of concentration.22 These proteins can be highly
engineered for specific applications. We present here the engineering of oleosin mutants
to stabilize and target iron oxide protein micelles for enhanced magnetic resonance
imaging (Figure 4.1A).
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Figure 4.1. (A) Cartoon depiction of Her2/neu targeted iron oxide nanoparticle micelles stabilized by
oleosin. (B) Protein purity is accessed to be > 95% pure by SDS-PAGE (lane 1: Oleosin-30G(-), lane 2:
Her2/neu-Oleosin-30G, lane 3: Her2/neu affibody). (C) Circular dichroism indicates an unordered structure
for the charged mutant Oleosin-30G(-). (D) CD spectra for the fusion Her2/neu-Oleosin-30G show
contributions from the helical Her2/neu affibody and the unordered Oleosin-30G. (E) CDSSTR analysis of
CD spectra shows increased helical structure in the fusion compared to Oleosin-30G indicating that the
affibody is likely folded on the N-terminus of the oleosin mutant.

Two oleosin genes were engineered, one to stabilize the FeO micelles and a
second to target the resulting clusters to Her2/neu+ cells. Previously it has been shown
that oleosin can be engineered to stabilize various interfaces such as emulsion droplets21
and bubbles.18 In order to provide adequate repulsion between the micelles, we mutated
the hydrophilic arms of oleosin-30G to be negatively charged. Negative nanoparticles
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have also been shown to limit nonspecific cell targeting.23-25 Specifically, all positive
amino acids as well as any tyrosine residues in the hydrophilic arms were mutated to Q,
N, D, or E depending on the location and local charge. The negative charge was spread
evenly across the hydrophilic arms with an average negative amino acid every six
residues. This mutant is called Oleosin-30G(-). To directly target Her2/neu+ cancer cells,
we have fused a Her2/neu affibody onto the N-terminus of the oleosin mutant Oleosin30G. This targeted mutant is named Her2/neu-Oleosin-30G. The Her2/neu affibody was
expressed independently as a competitive inhibitor for cell studies. Mutants were made
using standard molecular biology techniques and cloned into the expression vector
pBamUK, which adds a 6-histine tag on the C-terminus of the protein for immobilized
metal affinity chromatography (IMAC). Oleosin mutants were confirmed through DNA
sequencing. Vectors were transformed into the Escherichia coli strain BL21 (DE3) for
expression. Her2/neu-Oleosin-30G was insoluble and expressed in inclusion bodies
whereas Oleosin-30G(-) was soluble. Mutants were purified using IMAC. Protein yields
were ~ 24 mg, ~ 80 mg, and ~ 65 mg of purified protein per liter of culture for Her2/neuOleosin-30G, Oleosin-30G(-), and Her2/neu respectively. SDS-PAGE indicates highly
purified products after IMAC (Figure 1B). The band for Oleosin-30G(-) runs much
higher than expected on the gel, likely due to its highly negative charge. Molecular
weights were confirmed with MALDI-TOF (Oleosin-30G(-) expected: 14956, measured:
14958; Her2/neu-Oleosin-30G: expected: 21714, measured: 21713; Her2/neu expected:
7771, measured: 7773).
Protein secondary structure was elucidated with circular dichroism. The parent
molecule Oleosin-30G is a highly unordered protein.18 CD indicates that Oleosin-30G(-)
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remains unordered after the various mutations to the hydrophilic arms (Figure 4.1C). The
secondary structure of Her2/neu-Oleosin-30G was investigated to ensure correct affibody
folding as a fusion partner. The Her2/neu affibody is a highly helical protein (Figure
4.1D) and when fused to oleosin, the Her2/neu-Oleosin fusion displays structure from the
helical affibody and the unordered oleosin backbone (Figure 4.1D). The spectra were fit
with the CDSSTR analysis method using Dichroweb (Figure 4.1E).26-28 The analysis
shows clear helical structure in the fusion protein indicating that the affibody is likely
folded in the fusion.
SPIO-oleosin micelles were assembled through an emulsion method. SPIO
nanoparticles solubilized in toluene were injected into solutions of protein in PBS. The
emulsion was sonicated and the toluene was allowed to evaporate overnight at room
temperature. This led to a heterogeneous mixture of micelles. SPIO-Oleosin micelles
were purified using stepwise centrifugation.20 Cryo-TEM of the various separation
fractions indicates large aggregated particles are removed in pellet after low RCF spins
and excess protein and small particles in the supernatant of the high RCF spins (Figure
4.2). The mass ratio of the particles to the protein, the oil volume fraction, and the
particle stabilization coat all play an important role in the formation of packed
nanoclusters. The oil volume fraction and mass ratio of protein to iron was optimized.
Previous studies used an oil volume fraction of 4.8% for particle formation and a 4:4 ratio
of nanoparticle to surfactant (mg:mg).20 We found that decreasing the volume fraction of
toluene in the emulsion to 1.2% and increasing the protein concentration greatly affected
the resulting structures. The optimal particles were created by injecting 50 uL of toluene
containing 4 mg of SPIO-dodecylamine coated nanoparticle into a 4 mL solution of
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protein in PBS at a concentration of 2 mg/mL (Figure 4.3).
!"

#"

$"

%"

Figure 4.2. Cryo-TEM micrographs of the various fractions during purification. (A) The hard, insoluble
pellet after the high RCF spin shows large aggregates of particles stuck together. (B) The soft, soluble
pellet that is extracted and used for further studies shows individual nanoclusters. (C-D) The supernatant
after the high RCF contains excess protein (C) and small nanocluster (D). All scale bars are 200 nm.
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Figure 4.3. Optimization of iron-to-protein ratio and oil volume fraction. Increasing the amount of
surfactant and decreasing the volume of toluene used in the emulsification led to highly packed particles
with little-to-no aggregates present after purification.

Dynamic light scattering of the purified particles show a monodisperse population
with an average hydrodynamic diameter of 113 nm (peak: 127 nm, PDI = 0.104) (Figure
4.4A). Purified particles were imaged using cryo-TEM (Figure 4.4B). The micrograph
displays tightly packed iron oxide nanoparticles and no visible excess protein on the
particles. Particles from three independent batches were directly measured from
micrographs and found to have an average diameter of 74 ± 33 nm (n = 660 particles)
(Figure 4.4C). As expected, the number average diameter measured in micrographs is
less than the hydrodynamic diameter measured by DLS. The DLS data are skewed to
higher diameters due to increased intensity of scattering from larger particles.
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Figure 4.4. (A) Dynamic light scattering reveals a monodisperse population of micelles with an average
diameter of 113 nm (PDI=.104). (B) Cryo-TEM micrograph of FeO micelles stabilized by Oleosin-30G(-)
in PBS. (C) Particle size distribution measured directly from cryo-TEM images. The average particle size
was found to be 74 ± 33 nm (standard deviation, n = 660 particles). This diameter is significantly lower
than the hydrodynamic diameter from DLS due to the increased scattering from larger particles. (D) Protein
stabilized particles are stable over 5 days in buffer (PBS) and serum at 37°C as measured by DLS. (E)
Particles show high relaxivity with an r2 value of 407.2 ± 4.0 mM-1 s-1. (F) The r1 value was found to be
4.47 ± 0.46 mM-1 s-1.

The surface charge of SPIO particles has been shown to have significant impact in
the uptake by cells.4 Zeta potential measurements indicated a negative surface charge at
of -12.5 ± 1.7 mV. The high negative charge is needed to provide repulsive electrostatic
interactions between the emulsion droplets during particle formation reducing
aggregation. The particles show long-term stability in buffer (PBS) and serum with no
significant change in the hydrodynamic diameter over 5 days at 37°C (Figure 4.4D). The
particles display extremely high relaxivity with an r2 value of 407.2 ± 4.0 s-1 mM-1 and an
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r1 value of 4.47 ± 0.46 s-1 mM-1. The potential cytotoxicity of the nanoparticles was
assessed using an MTT assay. Over all concentrations, cell viability remained above 97%
for the 4-hour incubation with particles (Figure 4.5A).
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Figure 4.5. (A) Particles show no toxicity between 25 and 150 µM after 4 hours of incubation at 37°C with
NIH/3T3 cells. (B) Functional evaluation of the Her2/neu SPIO-oleosin micelles conjugates. SPIO-oleosin
and Her2/neu-SPIO-oleosin were incubated with either Her2/neu+ and Her2/neu- cells in the presence and
absence of excess free affibody. Free affibody served as a competitive inhibitor to confirm specific binding
of the Her2/neu receptor. Relaxivity measurements of cells incubated with SPIO-oleosin micelles or
Her2/neu-SPIO-oleosin micelles were acquired.
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Table 4.1. Physical and magnetic properties of oleosin stabilized nanoparticles
113 ± 36
74 ± 33
-12.5 ± 1.7
407.2 ± 4.0
4.47 ± 0.46
91.1

Hydrodynamic diameter (nm)
Number diameter (nm)
Zeta potential (mV)
R2 (mM-1 s-1)
R1 (mM-1 s-1)
R2/R1

Her2/neu+ targeted micelles were created by blending Her2/neu-Oleosin with
Oleosin-30G(-) at 10% by weight in the PBS solutions (0.8 mg Her2/neu-Oleosin-30G:
7.2 mg Oleosin-30G(-)). The micelles were prepared and purified in the same manner.
The blending of the targeted mutant into the micelles did not change the size of the
micelles as measured by DLS (Figure 4.6A) or the stability of the particles over time
(Figure 4.6B). The surface charge of the particles remains negative but slightly increased
to -10.7 ± 0.8 mV.
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Figure 4.6. Characterization of Her2+ functional nanoparticles. (A) DLS spectra shows monodisperse
particles with a peak at 131 nm (PDI = 0.11) indicating that the Her2-Oleosin-30G blending into the
micelles does not affect the overall size. (B) Functionalized particles are stable in PBS and serum for up to
5 days at 37°C.
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FeO micelles were incubated with Her2/neu- (NIH/3T3) and Her2/neu+ (T6-17)
cells at a concentration of 100 µg/mL for 45 minutes. The T2 relaxation time for the
NIH/3T3 cells showed no difference between negative control particles, targeted
particles, or cells incubated without particles, indicating little to no nonspecific binding
(Figure 4.5B). In the Her2/neu+ cell line, the cells incubated with the targeted particles
show a significantly lower T2 relaxation time, consistent with the presence of SPIO,
compared to cells with the negative control particles or cells incubated without particles.
A competitive binding study was completed by adding excess Her2/neu affibody to the
T6-17 cells before and during the incubation with the targeted particles. The affibody
competition led to a significant increase in the T2 time. Therefore, these results provide
clear evidence that Her2/neu oleosin micelles provide cell specific targeting.
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4.5 Conclusions
This work demonstrates the engineering of the naturally occurring surfactant
protein oleosin to stabilize and target FeO nanoparticle micelles to Her2/neu+ cells. The
functionalization of these particles is trivial due to the ease of incorporating biologically
relevant motifs into the protein through molecular biology. These particles are extremely
stable and display high relaxivity. We envision oleosin stabilized nanoparticle micelles
will represent a promising platform for targeted enhanced imaging applications.
Specifically, varying the surface charge and appending specific stealth ligands29 to the
particles could engineer nanoparticle shells to be nontoxic and maintain long circulation
times.
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Chapter 5: Biodistribution and Clearance of Gold Loaded
Polymeric Micelles Using 0.9 and 5 nm Gold Nanoparticles

5.1 Abstract
Long-circulating gold nanoparticles (AuNPs) have garnered a great deal of
interest as both imaging and therapeutic agents. However, their protracted elimination
and long-term persistence within many organ systems remains a concern for clinical
translation. To improve the excretion of long-circulating nanoparticles, we prepared ~80
nm biodegradable polymeric micelles with 0.9 nm or 5 nm AuNPs tightly packed within
the hydrophobic core. These gold-loaded polymeric micelles (GPMs) were expected to
allow for improved excretion of gold, compared with single large AuNPs, owing to the
smaller size and larger surface-to-volume ratio of the individual AuNPs within the
micelle. Following intravenous administration of GPMs, organs were harvested and
examined for gold content using inductively coupled plasma optical emission
spectrometry (ICP-OES) for up to 3 months post-injection. While both GPM
formulations showed significant clearance of gold over time, micelles containing 0.9 nm
AuNPs showed a 72% and 67% reduction in gold content in the liver and spleen,
respectively, between 1 day and 3 months post-injection, compared with a 38% and 35%
reduction in mice receiving 5 nm GPMs. Furthermore, feces and urine analysis revealed
approximately 7.5 and 100 times more gold, respectively, in mice that received 0.9 nm
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GPMs one day after injection. These findings suggest that the excretion profile of
inorganic nanomaterials may be improved if clusters of small inorganic materials are
used in favor of single solid particles.

5.2 Introduction
The use of gold nanoparticles (AuNPs) in biological applications began in 1971
when Faulk and Taylor invented the immunogold staining procedure for electron
microscopy.1 Since then, AuNPs have attracted considerable interest across a wide range
of biomedical applications. For example, AuNPs have been utilized for catalysis,
biosensors, cancer imaging, photothermal therapy, and drug delivery.2, 3 The widespread
interest in using AuNPs for imaging and therapeutic applications stems from their ability
to be finely tuned to many different shapes and sizes, ease of surface modification,
unique optical properties, high attenuation coefficient, and the strong evidence indicating
that gold is nontoxic.4,

5

In fact, aurothiolate and colloidal gold have historically been

used in medical practice as a treatment for rheumatoid arthritis.6
Despite the beneficial aspects of using AuNPs in biomedical applications, a major
lingering concern with their clinical translation is their long-term retention within many
organ systems, most notably the liver and spleen. For example, it has been found that
there is only a 9% drop in the content of gold in the liver from day 1 to 6 months,
following the intravenous injection of 40nm AuNPs.7 This is consistent with a number of
similar studies, which saw little to no clearance of ~ 20 nm AuNPs over shorter time
periods (1 to 4 months).8,

9

As these inorganic particles are not readily biodegradable,

they can potentially result in liver and immune system damage,10 raising concerns about
their long term toxicity and biosafety.11, 12 Previous studies have shown that whole-body
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clearance can be improved through the use of small AuNPs (< 6 nm), since these particles
are small enough to undergo glomerular filtration.10,

13, 14

However, smaller AuNPs

possess lower blood residence times due to their rapid renal excretion.15 As a result, they
are expected to be less favorable as blood pool agents for computed tomography (CT)
angiography and for tumor targeting via enhanced permeability and retention, where
nanoparticle accumulation is generally governed by blood residence time.16, 17 Moreover,
larger AuNPs are also expected to be superior for receptor-targeted imaging/therapeutic
studies, whereby the number of localized nanoparticles is limited by the number of cell
surface receptors at the target site. Therefore, larger AuNPs would presumably allow for
higher total accumulation of gold.
In this study, we examined whether a AuNP formulation could be prepared that is
above the size threshold for renal clearance, but still exhibit favorable tissue clearance
and excretion profiles. Specifically, we prepared ~80 nm gold-loaded polymeric micelles
(GPMs) with sub-6 nm AuNPs tightly packed within the hydrophobic core (Figure 5.2 A,
B). The blood clearance profile, tissue biodistribution, and excretion of gold was
evaluated over a 3 month time period. Blood chemistry as well as liver and spleen
histology were also examined for indications of toxicity.
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5.3 Materials and Methods
Synthesis of 0.9 nm gold A uNPs
Dodecanethiol-capped 0.9nm AuNPs were prepared through the reduction of gold
chloride

triphenylphospine

(AuClPPh3)

with

tert-butylamine-borane

(C4H14BN),

according to the procedure described by Li et. al.18 Briefly, 0.375 mmol of AuClPPh3 was
added to 21 mL of ethanol at room temperature. The resultant mixture was stirred and
3.75 mmol of the tert-butylamine-borane reducing agent was added. After 30 minutes,
48µL of dodecanethiol was added and the dark brown solution was stirred for at least an
hour. The solvent was then evaporated in a vacuum centrifuge and the particles were
resuspended in toluene followed by centrifugation to remove any insoluble material. This
was repeated twice.

Synthesis of 5 nm gold A uNPs
Dodecanethiol-capped 5nm AuNPs were prepared using a two-phase reduction of
tetrachloroaurate (HAuCl4) with sodium borohydride (NaBH4), followed by the addition
of an alkanethiol, according to the procedure described by Brust et al.19 Briefly, 25mL of
an aqueous solution of 35mM hydrogen HAuCl4 was mixed with 50 mM of
tetraoctylammonium bromide (TOAB) in 70 mL of toluene. The solution was stirred until
the HAuCl4 solution transferred into the organic phase. This was followed by the drop-
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wise addition of a 0.4 M aqueous solution of NaBH4. Then, 0.84 mM of dodecanethiol
was added to the solution while stirring. The resultant mixture was then stirred for at least
3 hours and precipitated twice at -20°C in ethanol overnight to remove excess thiols. The
precipitate was collected via centrifugation and the supernatant was decanted. The
remaining pellet was dissolved in toluene.

Synthesis of GPMs
Gold-loaded polymeric micelles were synthesized using oil-in-water emulsions
and stabilized using the amphiphilic diblock copolymer polyethylene glycol (4k) –
polycaprolactone (3k) (PEG-b-PCL).17 AuNPs, either 0.9nm or 5nm, were dissolved in
toluene at 40 mg Au/mL and PEG-b-PCL was also dissolved in toluene at a concentration
of 40 mg/mL. A combined solution (200 µL) of the diblock (4 mg) and the AuNPs (4
mg) was added directly to a glass vial containing 4mL of dH2O and the mixture was
emulsified for approximately 3 minutes in an ultrasonic bath. The emulsions were then
allowed to stand overnight in a desiccator prior to their characterization and purification.
The resulting dark brown (0.9 nm) / dark purple (5 nm) solution was centrifuged at 400
RCF for 10 minutes to remove the largest micelles. The solution was then centrifuged
twice at 3100 RCF for 30 minutes, after which the supernatant was removed, and the
pellet was re-suspended in pH 7.4 phosphate buffered saline (PBS). Free polymer and
smaller sized particles were removed by diafiltration using a MidGee hoop cross flow
cartridge with 750 kDa molecular weight cutoff (GE Healthcare, Piscataway, NJ, USA).
The GPMs were then filtered through a 0.2 µm cellulose acetate membrane filter
(Nalgene, Thermo Scientific) to remove any oversized particles. Finally the nanoparticles
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were concentrated using 50 kDa MWCO centrifugal filter units (Millipore, Billercia, MA,
USA). The gold concentration was determined by inductively coupled plasma optimal
emission spectroscopy (ICP-OES, Spectro Analytical Instruments GMBH; Kleve,
Germany).

Tissue distribution and blood clearance
Thirty-six nude mice (n = 18 per group) were injected intravenously under
anesthesia with 75 nm GPMs (containing either 0.9nm or 5nm AuNPs) in PBS at dose of
150 mg Au/kg body weight and then bled and sacrificed at various times after the
injection of the agent. Specifically, three mice from each group was bled at 1 h, 2 h, 6 h,
12 h, 24 h, 3 d, 7 d, 14 d, 1 mo, and 3 mo, and the blood collected and analyzed for gold
by ICP-OES. Each mouse was bled twice. Therefore, 10 uL blood samples were collected
via the tail-nick method from three animals at the following times: 1 hour and 3 days, 2
hours and 7 days, 6 hours and 14 days, 24 hours and 1 month, and 1 hour and 3 months.
At the second bleed time point, the mice were euthanized by CO2 and 0.3 mL blood was
removed by cardiac puncture from the right ventricle immediately after the cessation of
breathing. After the final aliquot of blood was collected the brain, heart, lungs, kidneys,
spleen, liver, skin, small bowel, large bowel, pancreas, thyroid, femur, and inguinal
lymph nodes were removed from each animal. Three additional mice per GPM
formulation were used for three additional blood collections at 5 minutes, 10 minutes,
and 15 minutes and sacrificed at 24 hours and organs harvested. Organ samples were
washed with PBS to minimize contamination from any nanoparticles still circulating in
the blood. The blood samples and organs were then analyzed for gold content by ICP-
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OES. Organ samples were weighed into Teflon PFA vials (Savillex, Minnetonka, MN,
USA) and digested overnight at 60°C with 70% nitric acid to digest the organic material.
HCl was added the next day and the digest continued to dissolve the inorganic material.
Blood samples were dissolved directly in aqua regia. Blood GPM content was calculated
as the percent of the injected dose per gram of blood analyzed (%ID/g). Organ GPM
content was similarly calculated as the percent of the injected dose present per gram of
tissue.

Toxicity studies
Blood samples obtained by cardiac puncture were analyzed for blood chemistry
analytes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase, and total bilirubin(TBIL). All samples were analyzed by the diagnostic core
laboratories at the University of Pennsylvania School of Veterinary Medicine

Hematoxylin and eosin (H&E) staining
Hematoxylin-eosin (HE) staining was performed using 5 µm thickness sections
from formalin-fixed, paraffin-embedded tissue blocks. Specimens were fixed in formalin
(Fisher Scientific, Waltham, MA) immediately after harvesting and followed by gradient
dehydration with 70%, 95%, and 100% ethanol. Tissue were then processed in xylene
(Fisher) and embedded in paraplast tissue embedding medium (Fisher). Slides were
prepared using Microm HM550. Paraffin sections were deparaffinized in xylene followed
by rehydration with 100%, 95%, 70% ethanol and then Milli-Q water (Millipore,
Bedford, MA) before the staining. Harris hematoxylin (Fisher) was used for nuclei
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staining. Excess hematoxylin was removed by dipping slides in acid alcohol (Leica
Biosystems, Richmond, VA). Slides were then placed in running warm water until the
nuclei turned blue. Eosin (Leica Biosystems) was used to stain for cytoplasm. Slides were
later mounted using permount (Fisher) after clearing with xylene.
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5.4 Results and Discussion
Characterization of 0.9 and 5 nm A uNPs
Hydrophobic AuNPs with dodecanethiol as a capping agent were prepared with
low polydisperity and diameters of 0.93 ± 0.19 and 4.66 ± 0.57 nm, respectively,
according to an analysis of transmission electron microscopy (TEM) images (Figure 5.1).
Purity was further confirmed via UV–vis spectroscopy Figure 5.1).

Figure 5.1. (A) Transmission electron micrograph of 0.9 nm AuNPs. Scale bar is 20 nm. (B) Core size
distribution of 0.9 nm AuNPs. The mean size and standard deviation is shown. (C) UV-vis absorption
spectrum of 0.9 nm AuNPs. (D) Transmission electron micrograph of 5 nm AuNPs. Scale bar is 20 nm. (E)
Core size distribution of 5 nm AuNPs. The mean size and standard deviation is shown. (F) UV-vis
absorption spectrum of 5 nm AuNPs.

Synthesis and Characterization of GPMs
GPMs were prepared by encapsulating either 0.9 or 5 nm AuNPs within the
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diblock copolymer PEG-b-PCL, using a microemulsion method described previously.17
These GPMs were soluble in aqueous solutions owing to the hydrophilic PEG corona of
the diblock copolymer. Following synthesis and purification of the GPMs, ~ 80 nm
GPMs were collected using differential centrifugation, as confirmed by dynamic light
scattering (DLS) (Figure 5.2 C). The DLS measurements demonstrate particle
measurements with a low polydispersity index for both GPM formulations (< 0.1). TEM
was used to determine the morphology of the GPMs and the packing of AuNPs within the
hydrophobic core. TEM micrographs revealed spherical GPMs with tightly packed
clusters of AuNPs contained within the hydrophobic core of the micelles (Figure 5.2
D,E). The zeta potential of the various GPM formulations was near neutral. A summary
of the GPM physical-chemical properties is provided in Table 5.1.

Figure 5.2. Schematic and size analysis of GPMs. Schematic of (A) 0.9 nm GPMs and (B) 5 nm GPMs.
Both GPM formulations consist of AuNPs encapsulated within the hydrophobic core of micelles formed
using the biodegradable diblock co-polymer PEG-b-PCL. (C) Dynamic light scattering profiles of 0.9 nm
and 5 nm GPMs. Representative transmission electron microscopy (TEM) images of a (D) 0.9 nm and (E) 5
nm GPM. All scale bars = 100 nm.
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Table 5.1. GPM physical-chemical properties
AuNP size
(nm)

Hydrodynamic
diameter (nm)

Polydispersity
index

Zeta potential
(mV)

0.9
5

79.8 ± 3.9
78.5 ± 2.4

0.083
0.075

-1.5 ± 1.10
-1.04 ± 0.84

GPM Pharmacokinetics
Following intravenous administration, 0.9 and 5 nm GPMs exhibited similar
blood clearance profiles with circulation half-lives of ~ 1.5 hours and ~ 2.6 hours,
respectively (Figure 5.3).

Figure 5.3. (A-B) Blood clearance profile using ICP-OES analysis of gold content in blood at various
times following the intravenous administration of (A) 0.9 nm GPMs and (B) 5 nm GPM in mice (n = 3).

The biodistribution of GPMs was evaluated at 1 day, 3 days, 1 week, 2 weeks, 1
month, and 3 months post-injection (150 mg Au/kg) by performing an inductively
coupled plasma–optical emission spectroscopy (ICP-OES) analysis of gold content
within the brain, thyroid, lungs, heart, liver, spleen, small bowel, large bowel, kidneys,
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pancreas, sublingual lymph nodes, skin, bone, muscles, feces, and urine. As expected, the
largest fractions of gold were observed in the spleen and liver (Figure 5.4).

Figure 5.4. Measurement of gold content in primary excretory organs and waste. The percent injected dose
of gold per gram of tissue was measured in the (A) spleen, (B) liver, (C) feces, (D) small bowel, (E)
kidneys and (F) urine at various times following the intravenous administration of 0.9 nm and 5 nm GPMs.
All measurements of gold were acquired via ICP-OES. Asterisk indicates statistical significance (p < 0.05)
between 0.9 nm GPM and 5 nm GPM groups.

Higher levels of gold were observed in the spleen following intravenous injection
of the 5 nm GPMs, compared with the 0.9 nm GPMs, for all time points studied.
However, both groups showed a marked reduction in gold accumulation between one day
and three months post-injection. Specifically, there was a 35% reduction of gold in the
spleen of mice that received 5 nm GPMs and a 55% reduction of gold in the spleen of
mice that received 0.9 nm GPMs.
Initially, the levels of Au within the liver were higher for the 0.9 nm GPM group
(40.3 ± 6.3 %ID/g), compared with the 5 nm GPM group (23.7 ± 2.5%ID/g). However,
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after 3 months the Au content dropped more dramatically in mice that received the 0.9
nm GPMs (65%) compared to the 5 nm GPMs (38%). As a result, the 0.9nm GPMs
group (14.3 ± 1.5 %ID/g) and 5 nm GPMs group (14.7 ± 1.4 %ID/g) had similar levels of
gold retained in the liver at this later time point.
Hepatobiliary excretion appeared to be the primary pathway for gold removal,
with measureable levels of gold detected in the feces following injection of both 0.9 nm
and 5 nm GPMs. However, this excretion pathway appeared to be significantly more
efficient for the 0.9 nm GPMs, compared to the 5 nm GPMs, with approximately 7.5
times more gold detected in the feces one day post-injection. For both groups, the gold
content in the feces decreased over the duration of the study with no detectable levels at 3
months.
Consistent with the more efficient removal of gold from 0.9 nm GPMs via the
hepatobiliary system, qualitatively higher levels of gold were also found in the small
bowel, although not statistically significant, one day and 3 days post-injection, compared
with mice receiving 5 nm GPMs. By one week and at all subsequent time points, similar
levels of gold were observed in the small bowels for both GPM formulations. Evidence
of hepatobiliary excretion is consistent with previous studies, which have shown that 17
nm AuNPs that are taken up by Kupffer cells and hepatocytes are secreted primarily by
hepatocytes within the first 24 hours through the hepatobiliary pathway, after which they
are cleared through Kupffer cells through mechanisms that are poorly understood.20, 21
The quantity of gold found in the kidneys was far lower than what was found in
the liver and spleen for both the 0.9 nm and 5 nm GPM groups. This is not surprising
considering that GPMS are too large to undergo glomerular filtration. It was anticipated
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that the GPMs would be predominantly taken up by the reticuloendothelial system (RES)
prior to breakdown of the polymeric micelle and release of the encapsulated AuNPs.
Nonetheless, a measureable amount of gold was detected in the kidneys, with statistically
significant lower levels of gold found one day, 1 month and 3 months post-injection of
the 0.9 nm GPMs, compared with 5 nm GPMs. This difference was most pronounced at
the later two time points. Interestingly, there also seemed to be some renal excretion of
gold from mice that received 0.9 nm GPMs. In fact, approximately 100-fold more gold
was detected in the urine one day following the administration of 0.9 nm GPMs (0.29 %
ID/g) compared with 5 nm GPMs (0.003 % ID/g). These urine concentrations gradually
decreased to undetectable levels at 3 months. We attribute the difference between the two
GPM formulations to be a direct result of the difference in the sizes of encapsulated
AuNPs. Since 0.9 nm AuNPs are much smaller than the size cut-off limit for successful
glomerular filtration, even if opsonized, they should enjoy more efficient excretion into
the urine than the larger 5 nm AuNPs.
Two organs that appeared to exhibit somewhat surprising levels of gold following
the injection of the 5 nm GPMs were the brain and heart (Figure 5.5). Specifically, in the
brain we detected 2.8 ± 0.3 %ID/g one day post-injection, compared with only 0.14 ±
0.03% ID/g for 0.9 nm GPMs. Although not high per se, this level of gold is readily
measureable. Nonetheless, it is likely that gold from the 5 nm GPMs did not penetrate the
blood-brain barrier considering their large size and that levels of gold were at or near the
detection limit after just one week post-injection. Gold would presumably not be cleared
from brain in such a short timeframe if it has entered the brain parenchyma. The presence
of gold does not seem to be an artifact since it was found to be at similar levels in all of
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the mice at one and three days post-injection. Notably, others have also reported the
presence of low levels of AuNPs (15 nm and 50 nm) in brain 24 hrs after intravenous
injection.22

Figure 5.5. Measurement of gold content in the brain and heart. The percent injected dose of gold per gram
of tissue was measured in the (A) brain and (B) heart at various times following the intravenous
administration of 0.9 nm and 5 nm GPMs. All measurements of gold were acquired via ICP-OES. Asterisk
indicates statistical significance (p < 0.05) between 0.9 nm GPM and 5 nm GPM groups.

In the heart, the gold content was 2 times greater one day following the
administration of 5 nm GPMs (3.1 ± 0.2 %ID/g) compared with 0.9 nm GPMs (1.5 ± .06
%ID/g). Both groups showed a reduction in gold content (75% for 5 nm GPMs and 86%
for 0.9 nm GPMs) in the heart over 3 months, however, mice receiving 5 nm GPMs
possessed higher levels of gold at all time points.
In the skin, the gold content fluctuated between 2 and 12 %ID/g (on average)
during the duration of the studies with no statistically significant differences between the
0.9 nm and 5 nm GPMs during the 3 month time period (Figure 5.6). The skin has long
been shown to be an important site of accumulation for nanoparticles that are
administered intravenously. Studies have shown that AuNPs can exit blood vessels in the
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skin and be phagocytosed by dermal macrophages and dendritic cells.23 As these
phagocytes become saturated they begin to accumulate in the pericellular space of the
dermis and subcutaneous tissue. In fact, this phenomenon was visible in the skin of mice
injected with GPMs, which did have some discoloration. The distribution of GPMs in the
skin of mice was heterogeneous with some areas exhibiting a dark purplish hue and other
areas showing little to no change in skin color.

Figure 5.6. Measurement of gold content in the lymph nodes and skin. The percent injected dose of gold
per gram of tissue was measured in the (A) lymph nodes and (B) skin at various times following the
intravenous administration of 0.9 nm and 5 nm GPMs. All measurements of gold were acquired via ICPOES. No statistically significant difference (p < 0.05) was observed between 0.9 nm and 5 nm GPM
groups.

High overall levels of gold were also observed in the lymph nodes of mice
following the injection of 0.9 nm and 5 nm GPMs, with levels exceeding 20 %ID/g at
various time points for both groups (Figure 5.6). However, due to the high variability, no
statistically significant differences were observed between the groups at any one time
point. High lymph uptake was not completely unexpected considering that many studies
have shown the accumulation of nanomaterials in lymph nodes, in the size range of 10 –
300 nm.

23-28

It has been postulated that nanomaterials can slowly extravasate from the
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vascular to interstitial space, and are then transported to lymph nodes through the
lymphatic vessels. Alternatively, it has also been suggested that nanoparticles can be
taken up by the RES and trafficked to the lymph nodes.
For most of the other organs that were examined, including the thyroid, pancreas,
large bowel, and muscle, there was a general trend of higher levels of gold in mice
injected with 5 nm GPMs, compared with 0.9 nm GPMs (Figure 5.7). However, at most
time points the differences were not statistically different and the overall levels of gold
were quite low, <2.5 %ID/g (on average). Both groups showed a significant reduction in
gold content over the 3-month time period in each of these organs.

Figure 5.7. Measurement of gold content in various organs. The percent injected dose of gold per gram of
tissue was measured in the (A) thyroid, (B) pancreas, (C) large bowel, (D) muscle, (E) bone and (F) lungs
at various times following the intravenous administration of 0.9 nm and 5 nm GPMs. All measurements of
gold were acquired via ICP-OES. Asterisk indicates statistical significance (p < 0.05) between 0.9 nm GPM
and 5 nm GPM groups.
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In bone, the levels of gold were generally higher in mice receiving 0.9 nm GPMs,
particularly at early time points, but again the differences were not statistically significant
(Figure 5.7). Similar levels of gold were observed in the lungs following the injection of
0.9 nm and 5 nm GPMs for all time points (Figure 5.7). A significant reduction in gold
was observed in both bone and lungs following the injection of 0.9 nm and 5 nm GPMs.
Toxicity Analysis
The intravenous injection of 0.9 nm and 5 nm GPMs into healthy mice led to no
signs of illness, change in activity, or weight loss (Figure 5.8). A toxicological analysis of
mice 1 day, 1 week, 1 month and 3 months following the administration of GPMs
revealed blood chemistry levels within normal limits, despite being highly variable
(Figure 5.9). It should be noted that enzyme levels can fluctuate due to the method and
rate of blood collection, time of day in which blood was collected, and level of animal
physical activity and are therefore highly variable in nature.23

Figure 5.8. Whole animal weights of mice treated with 0.9 nm or 5 nm GPMs (150 mg Au/kg). Data reflect
average weights (n = 3) for each group.
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Figure 5.9. Hematological analysis of mice treated with GPMs. Blood enzyme levels of female nude
athymic mice were acquired 1 day, 7 days, 1 month, and 3 months days post-injection of 150 mg Au/kg of
0.9 nm GPMs (grey) or 5 nm GPM (black). Grey dotted lines denote the “normal” analyte levels. The
specific enzymes analyzed were (A) alkaline phosphatase (ALKP), (B) alanine transaminase (ALT), (C)
aspartate aminotransferase (AST), and (D) total bilirubin (TBIL).

Histology of liver and spleen
To further evaluate the potential toxicity of GPMs, histological analysis was
performed on the liver and spleen 1 day, 1 week, 1 month, and 3 months following the
injection of 0.9 nm and 5 nm GPMs. Hematoxylin and eosin (H&E) stains of these
organs showed no evidence of abnormal pathology or adverse effects (Figure 5.10).
These results are consistent with previously established literature touting the safety
profile of AuNPs.11, 29-34
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Figure 5.10. Histological of liver and spleen for mice treated with GPMs. Mice (n=3 per group) received a
single intravenous injection of 0.2 mL of either PBS (control), 0.9 nm GPMs, or 5 nm GPMs (150 mg
Au/kg dose in PBS) followed by dissection of the liver and spleen at the indicated times. Sections were
stained with H&E and images were acquired via light microscopy at 10x magnification.
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5.5 Conclusions
Numerous reports have indicated that AuNPs are poorly cleared from the
reticuloendothelial

system

following

intravenous

administration.

For

example,

Balasubramanian et al showed that in rats injected with 20 nm PEG AuNPs, gold levels
in the liver and spleen remain high even at 2 months follow up (6 % reduction in gold).8
In another study by Sadauskas et al, analysis of livers in mice injected with 40 nm AuNPs
resulted in only a modest 9% reduction in gold content over a 6-month time period.7 Goel
et al found that the gold content in the liver was reduced by approximately 50%
following the injection of 33 nm PEG AuNPs, but that levels of gold in the spleen
remained essentially unchanged 3 months post-injection.9 In this study we investigated
the organ distribution and retention of GPMs, which consist of clusters of 0.9 or 5 nm
AuNPs encapsulated within the hydrophobic micelle core, for up to three months postinjection. As expected, accumulation was highest in organs rich in macrophages (liver,
spleen, lymph nodes). However, in contrast to the many studies that report inefficient
clearance and a persistent accumulation of AuNPs within the reticuloendothelial system,
we observed a 65% and 55% reduction in gold content in the liver and spleen,
respectively, between 1 day and 3 months following the injection of 0.9 nm GPMs. A
38% and 35% reduction in gold content was observed in the liver and spleen,
respectively, following injection of 5 nm GPMs. A reduction of gold in most other organs
was observed as well. The primary mechanism of excretion seemed to be via the
hepatobiliary systems, although some renal clearance was also observed. In general,
GPMs containing 0.9 nm AuNPs seemed to exhibit more efficient excretion compared to
5 nm GPMs, with higher levels of gold detected in the feces and urine at earlier time
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points (1 – 7 days). Both the 0.9 nm and 5 nm GPMs were found to be biocompatible
with no evidence of toxicity as measured by blood chemistry, loss in body weight, signs
of distress, and histological analysis of liver and spleen tissue sections. Overall, these
findings suggest that the excretion profile of inorganic nanomaterials may be improved if
nanoparticles formed from clusters of small inorganic materials are used in favor of
single solid particles.
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Chapter 6: Summary Discussion, Future Directions and
Concluding Remarks

6.1 Summary Discussion
6.1.1 GPMs for CT Imaging and Radiation Enhancement
Due to their unique physical, chemical and optical properties, AuNPs have been
proposed for use in many diverse biomedical applications including biosensors, photoresponsive agents, drug delivery vehicles, and therapeutic agents.1 Furthermore, the high
electron density and atomic number of gold nanoparticles has proven to be valuable for
electron and X-ray attenuation. Initially proposed by Hainfeld et al.,2 the intravenous
administration of AuNPs has been shown to provide blood pool contrast enhancement in
X-ray imaging. Since then many studies have used AuNPs as contrast agents for X-ray
imaging including metabolic disorders,3 malignancies,4 and cardiovascular diseases.5
However, a limitation of Hainfeld’s study is the rapid clearance of AuNPs, which can
limit EPR driven accumulation necessary for successful contrast enhanced tumor
imaging. We have shown that by encapsulating small AuNPs within micelles, we can
significantly improve the nanoparticle blood circulation time as compared to single
AuNPs and potentially improve AuNP elimination. Furthermore, this enhanced
circulation was visible in CT images with GPMs remaining in the bloodstream for a
much longer duration. The advantage of prolonging nanoparticle blood residence time is
to increase the accumulation of nanoparticles within the tumor. When the nanoparticles
first enter the tumor circulation, a small percentage will exit the vasculature due to the
EPR effect while the majority will remain in the systemic circulation. The longer the
215

nanoparticles remain in the circulation, the higher the probability that more particles will
permeate across the leaky tumor vasculature and enter the tumor interstitium. Indeed, this
was shown in CT images of tumor bearing mice where gold mediated contrast was
clearly visible in mice administered GPMs but not in mice receiving single 1.9 nm
AuNPs. This GPM enhanced CT image was used to guide the delivery of a single 6 Gy
dose of X-ray radiation therapy that yielded improved survival when compared to nonirradiated and irradiated controls. These results are truly exciting as they have the
potential to spare normal healthy tissue on two fronts. First, the use of contrast enhanced
image guided radiation therapy could provide a more accurate morphological
representation of tumor geometry and margins for maximizing therapeutic delivery
within the lesion. Second, the use of AuNPs as radiation enhancing agents could reduce
the overall dose required for complete tumor eradication, and therefore reduce the
exposure of adjacent healthy tissues to further radiation.

6.1.2 GSMs for MR Imaging and Radiation Enhancement
The main motivation for introducing superparamagnetic iron oxide nanoparticles
(SPIO) into our micelles was the apparent mismatch between the GPM dose needed for
radiation enhancement and the lower detection limit of GPMs via CT. In our GPM in
vitro studies, we observed approximately a 2.2 fold increase in DNA-DSBs as well as a
decrease in cell survival at Au concentration of 0.1 mg/ml. However, the minimum
concentration of Au that can be detected using CT imaging is approximately 0.5 mg/ml.
This five-fold difference in concentration means that large doses of Au are required to
provide sufficient tumor contrast for guiding radiation therapy, and that the concentration
of Au within the tumor exceeds the 0.1 mg/ml needed for effective radiosensitization.
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The incorporation of SPIO nanoparticles with AuNPs in micelles enabled contrast
enhanced imaging using MRI. As a result, MRI and CT phantoms of GSMs showed a
sixty six fold improvement in sensitivity using MR. Furthremore, in vivo imaging
demonstrated that while no tumor contrast enhancement was observed using CT imaging,
MRI contrast was clearly visible producing a hypointense image within the tumor.
For each group of animals receiving radiation therapy, an MR image was acquired
both pre-injection and twenty-four hours after injection of GSM prior to the
administration of radiation. Intriguingly, the amount of tumor contrast generated on T2
weighted MR imaging correlated linearly with the rate of tumor reduction therapy after
therapy meaning that those tumors with the most MR contrast exhibited higher reductions
in tumor volume post therapy. While image contrast did correlate with tumor response,
there was no correlation with overall survival. A likely explanation could be that some
cancer cells may have been excluded from the treatment volume resulting in a
repopulation of cells and tumor relapse. Furthermore, as a result of the heterogeneous
distribution of nanoparticles in the tumor, some areas within the tumor may experience
more radiation enhancement than others resulting in differential cell death. Moreover,
alternate factors that are most likely excluded during fractionation including phase of cell
cycle, and tumor oxygenation may play a role in tumor recurrence.

6.1.3 GPMs for Enhanced Clearance and Improved
Pharmacokinetics
A major limitation for nanoparticle technologies is their poor elimination profiles,
especially for particles larger than 6 nm, which is believed to be the size cut off for
successful renal clearance. Large sized particles are retained primarily in organ systems
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that are particularly high in macrophages such as the liver, spleen, bones, lymph nodes,
and skin. For gold, as these particles are not biodegradable, they remain there for
extended periods without significant reduction in gold content. In this thesis, our
approach was to form polymeric micelles with small AuNPs (0.9 and 5 nm) in their core.
We evaluated various organs for gold content up to three months, while regularly
measuring blood chemistries, weight changes, and monitoring for any signs of toxicity. In
contrast to many other documented studies, we saw a reduction over time in many organs
including the liver and the spleen. For both particle sizes, gold was detected in feces
suggesting the hepatobiliary pathway to be involved in particle excretion. Furthermore,
smaller AuNPs showed superior clearance to larger AuNPs with higher gold contents
measured in the feces during early time-points. Similarly, in the urine, gold was detected
only in mice administered 0.9 nm GPMs at very early time-points. Therefore, the use of
sub-nanometer particles within micelles can facilitate gold excretion via the liver in the
feces and kidneys at early time-points. It is important to note that very little or no gold
was detected in the feces or urine at three months showing that gold excretion reaches a
plateau at this timepoint. While AuNPs were not completely eliminated at the end of the
study, there was significant reduction of gold content in the RES compared to other
studies evaluating the biodistribution of AuNPs.

6.1.4 Targeted Iron Oxide Nanoparticle Oleosin Micelles
Thus far, both GPM and GSM particles used for our in vivo evaluations consisted
of a pegylated, hydrophilic corona and relied on passive targeting, i.e. nonspecific
accumulation within tumors through the EPR effect. Although some tumors may
experience high permeability, multiple passes through the circulation are needed for a
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substantial amount of nanoparticles to enter tumor tissue. Therefore, a critical criteria for
successful passive delivery is the design of nanoparticles with long in vivo circulation
times. Furthermore, passive targeting is non-specific relying heavily on high vascular
permeability and poor lymphatic drainage at the tumor site. In contrast, active targeting
arises from the direct interaction of targeting ligands with specific receptors on cancer
cells. While initially receptor targeted particles are also dependent on the EPR effect for
tumor penetration, there are several key advantages for targeted agents including higher
tumor retention, the ability to facilitate nanoparticle internalization for improved efficacy,
and improved tumor specificity. Our approach was to use a naturally occurring surfactant
protein oleosin to stabilize SPIO nanoparticles. These particles displayed high r2
relaxivity and showed cell specific targeting in cells overexpressing the Her2/neu
receptor. In addition, a major advantage of this platform compared to other targeted
particles is the ability to develop functionalized particles in a single step by blending in a
Her2 affibody-oleosin mutant.

6.2 Future Directions
6.2.1 Improving CT Sensitivity for Molecular Imaging
For molecular and tumor imaging, a fundamental limitation of using AuNPs as
CT contrast agents is the low sensitivity detection limit of X-rays compared to other
imaging modalities. Specifically, studies have shown that the detection limit of gold is
approximately 0.5 mg/ml. This is orders of magnitudes higher when compared to other
imaging modalities such as MRI and PET. In order to overcome the sensitivity limitations
of CT, highly concentrated doses need to be administered. In addition, although AuNPs
attenuate X-rays better than conventionally used iodinated contrast agents, the cost of
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using gold is a huge obstacle for their clinical utilization. However, recent improvements
in CT technology such as multicolor spectral CT have shown that molecular imaging
using CT may be possible.5 This technique enables the simultaneous detection of multiple
elements by distributing incident X-rays into various energy bins enabling significantly
lower concentrations of AuNPs to be administered. Another imaging strategy to improve
contrast is to use dual energy X-ray imaging that increases the signal intensity of imaging
agents by the removal of the soft-tissue signal variation in the background. This is
obtained by subtracting the images obtained at two energy levels that flank the k-edge of
the contrast material.

6.2.2 Fractionated Studies Using GPMs and GSMs
Although there are some scenarios during which a single radiation dose exceeds 2
Gy (high grade gliomas),6 most conventional radiation therapy treatment regimens are
generally divided into multiple sessions with doses usually not exceeding 1.8 – 2 Gy. To
our

knowledge,

there

are

currently

no

documented

studies

examining

the

radiosensitization effects of AuNPs that are administered during fractionated radiation
therapy. Therefore, it would be valuable to compare the benefits AuNPs with subtherapeutic doses of radiation therapy.
The administration of radiation to blood vessels has been shown to increase
endothelial permeability.6 This strategy could be adapted to our studies such that subtherapeutic doses of radiation are applied to tumor volumes in order to disrupt tumor
vasculature thereby increasing nanoparticle penetration for subsequent radiation therapy.
AuNPs can either be injected prior to or right after the first few fractions of radiation
therapy. The advantage of administering AuNPs prior to the initiation of fractionated
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radiation therapy is that they can provide tumor contrast for assisting image guided and
enhanced radiation therapy. However, the application of AuNPs after the first fraction of
radiation would increase nanoparticle tumor accumulation, thereby increasing AuNPs
mediated radiosensitization during subsequent fractions.
Lastly, most studies including our own demonstrate improved dose enhancement
and radiosensitization in the less clinically relevant kilovoltage energy ranges. While a
handful of studies have shown some improvement in the radiation enhancement effects at
megavoltage energies, the exact mechanisms of sensitization are largely unknown.
Therefore, further studies need to be carried out at these energies in order to examine the
therapeutic benefits of AuNP mediated cytotoxicity.

6.2.3 In Vivo Use of GSMs for Evaluating Tumor
Physiology
Therapeutic response is an important subject in the management of cancer
patients. While some malignancies may be responsive to anticancer agents, a majority of
them will relapse increasing their resistance to first line therapies. These resistances are
governed by mutations in cancer cells that can alter their phenotype and expression
profiles. Moreover, some regions of tumors may be poorly visible on imaging or have
limited access through the blood supply for successful distribution of agents. As a result,
therapies are often costly, time consuming, and unsuccessful with huge burdens on
patients.
Through MR imaging, we found a direct correlation between extent of tumor
contrast and response to radiation therapy. While the most likely explanation for this
effect is due to the increased accumulation of nanoparticles, there are also other potential
causes. Since there is heterogeneity in the vascular supply and permeability of blood
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vessels supplying tumors, one must consider this to be a key barrier that limits the
successful delivery of intravenously administered agents to tumor cells. In fact, we
observed this in our animal studies with some tumors showing more nanoparticle
accumulation than others. Increased tumor permeability to particles can also mean
increased tumor oxygenation. As mentioned in the introduction section, hypoxia is a
significant contributor to tumor radioresistance. With this in mind, tumors exhibiting
substantial nanoparticle accumulation may experience some free radical generation from
the presence of oxygen in addition to photoelectrons generated from nearby
nanoparticles. Therefore the use of MR imaging, particularly nanoparticle mediated
contrast enhancement, can provide some insight on tumor vascularization, permeability,
oxygenation, and the likelihood to be responsive to specific therapies. This approach can
be extended to other forms of cancer therapy to provide information of drug
accumulation at tumor sites.

6.2.4 Improved Clearance Using Novel AuNPs
Since a micelle nanoplatform can carry a payload of small AuNPs, it can
significantly increase the particle size to prolong blood circulation and avoid renal
clearance. We have already seen that using smaller AuNPs can help enhance total body
excretion. However despite using sub-nanometer AuNPs, there are still a number of
improvements to be made using this nanoparticle formulation since gold within the
organs was not completely eliminated, and levels of gold in both urine and feces were
essentially undetectable at later time point. Although, this study has shown significant
clearance of AuNPs over 3 months, the hydrophobic coating present on the surface of the
nanoparticles may limit their complete removal. An alternative strategy would be to
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develop sub-nanometer AuNPs that transition from hydrophobic to hydrophilic. Initially,
these particles would be hydrophobic enabling the successful encapsulation of gold into
the hydrophobic core of the micelle. However, as these cells are internalized, and
experience a low pH environment within lysosomes, the biodegradable coating will be
hydrolyzed exposing the hydrophobic AuNPs. These AuNPs will become water-soluble
within acidic lysosomes. Once dispersed, their small size will render the individual
AuNPs susceptible to excretion by glomerular filtration and/or more readily degraded by
lysosomal enzymes. Alternatively, nanoformulations can be developed that can
incorporate hydrophilic AuNPs directly. Previous studies have shown that AuNPs can be
assembled into clusters using weakly adsorbing biodegradable triblock copolymers.7
Once the polymer is degraded, the nanclusters can deaggregate into individual AuNPs to
facilitate clearance.

6.2.5 In Vivo Targeting of Iron Oxide Oleosin Micelles
While we have successfully demonstrated cell specific targeting of iron micelles
to cancer cells in vitro, a more thorough biological investigation is warranted in vivo.
Since the protein oleosin is easily modifiable, alterations in the surface charge and
appending specific stealth ligand (CD47) to the particles could engineer nanoparticles to
be less immunogenic and nontoxic while maintaining long circulation times.8 The amino
acid sequence of the oleosin protein can also by modified such that particle formation and
stability are improved. Further modifications to the nanoparticle surface could improve
targeting. For example, the density of targeting ligand on the surface of the nanoparticle
is a major determinant of cell specific binding.9 Therefore, optimizations of ligand
density will likely improve nanoparticle targeting capabilities. Linkers between oleosin
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and the ligand can also be introduced to reduce the steric hindrance of targeting agents
and maximize ligand receptor interactions.

6.3 Concluding Remarks
During the past decades, advancements in the field of radiation therapy have
revolutionized the process of cancer treatment. New technologies that enable accurate
tumor segmentation, dose specific deliveries, and specific tumoricidal agents have
contributed significantly to maximizing therapeutic doses only to intended tissues. In the
future, we envision a nanoplatform that can be used to actively target cancer cells via
ligand-receptor mediated interactions, provide tumor specific contrast for image guided
radiation therapy and prognostic information, and that is effectively cleared from both
systemic circulation as well as the reiculoendothelial system. Further improvements to
increase tumor specific targeting and biological clearance would inevitably facilitate the
translatability of nanodevices to the clinic.
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